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ABSTRACT 
 
Uveitis is the fourth most common cause of blindness among the working age group in 
developed countries. The aim of this research is to examine the influence of diabetes 
mellitus, cataract surgery, and retinal vasculitis on the visual outcome and prognosis of 
eyes with uveitis. The studied cohort included 1169 patients with uveitis attending 
Moorfields Eye Hospital between January 2012 and December 2013. 
The first study divided uveitis cases with diabetes into two groups; the first group included 
99 eyes with diabetes diagnosed prior to uveitis. The second group included 96 eyes with 
uveitis later diagnosed with diabetes. Within the first group, 28.2% had vision loss mainly 
from maculopathy with the risk of vision loss 4.6 times higher when compared to the 
control group of non-diabetic uveitis group. The diagnosis of diabetes in the second group 
was associated with a drop in the mean vision over the year post diagnosis. The mean dose 
of corticosteroid was lower post diagnosis (15 mg versus 10 mg, p=0.03), and relapses were 
significantly less often treated with systemic corticosteroid alone (70.2% vs. 55.6% of the 
relapses, p=0.003). 
The second study included 236 eyes with retinal vasculitis (121 ischaemic, 115 non- 
ischaemic) which was compared to non-vasculitis control group (1022 eyes). Macular 
ischaemia increased the risk of vision loss in vasculitis by 4.4 times. Retinal vasculitis had 
twice the risk of macular oedema compared to non-vasculitis. Macular oedema and 
ischaemia increased risk of vision loss in ischaemic vasculitis while corticosteroids reduce 
the risk by 30%. Retinal ischaemia involving ≥ 2 quadrants was associated with increased 
risk of NV formation.  
The third study included 228 uveitic eyes undergone cataract surgery and was compared to 
a control group of 300 phakic eyes with uveitis. The vision continued to improve from the 
baseline first postoperative week. However, risk of vision loss and CMO were twice more 
in the pseudophakic group compared to the control. The rate of uveitis relapse and rate of 
using high dose of corticosteroids was significantly lower postoperatively versus 
preoperatively.  
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1 CHAPTER ONE: INTRODUCTION 
1.1 General introduction 
The prevalence of uveitis is estimated at 38 cases per 100,000 people and can vary based on 
the age group with the prevalence of adult uveitis 93 per 100,000 while the prevalence of 
uveitis in children is about 30 cases per 100,000 (1,2). The annual incidence of uveitis 
ranges from 4.3 to 6.9 per 100,000 in children, compared with 26 to 102 per 100,000 in 
adults (3,4). Uveitis is more prevalent in younger people with a mean age of less than 40 
years at the onset of their first symptoms (5). 
Uveitis is a potentially blinding condition (6), account for 5–20% of legal blindness in both 
the United States and Europe (7,8), and considered the fourth most common cause of 
blindness among the working age group in the developed world (9).  The most common 
cause of visual loss in uveitis is cystoid macular oedema (CMO) and cataract, with one 
study documenting visual loss due to CMO or cataract in 64.5% of uveitis patients (10).   
Management of macular oedema and active uveitis may require initially a high dose of 
systemic glucocorticoids and for prolong duration. Glucocorticoids may induce diabetes 
mellitus (DM) as well as worsen glycaemic control in patients with pre-existing diabetes 
(11–13).  There is a considerably high prevalence of DM world wide, including UK with 
2.6 million people diagnosed with DM  in 2009, and an estimated doubling of diabetes 
prevalence by 2025 (14). Meanwhile, little is known regarding the synergistic effect of DM 
and uveitis on the visual outcome and the control of uveitis relapses.  The presence of 
uncontrolled hyperglycaemia may require reducing the dose of systemic corticosteroids or 
the use of other alternative treatments such as local corticosteroid injections; however, the 
effect of these modifications on the control of uveitis is not clear. Approach of uveitis 
management and its outcome post DM needs to be addressed. 
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Performing cataract surgery for this large cohort of uveitis patients carries a lot of risks, 
both during surgery as a result of limited access secondary to posterior synechiae, and after 
surgery due to high risk of postoperative inflammatory response. Most studies on cataract 
removal among uveitic eyes showed an initial good visual outcome with reduced risk of 
intraocular inflammation and postoperative macular oedema following the wide use of 
preoperative corticosteroid prophylaxis. However, little is known regarding the long term 
effect of cataract removal on the frequency and severity of uveitis compared to the time 
prior to the surgery and whether ongoing chronic or recurrent inflammation may sabotage 
the initially good visual result obtained post cataract surgery. While both CMO and cataract 
are potentially reversible causes of visual loss, ischaemic retinal vasculitis can lead to 
permanent loss of vision, either due to macular ischaemia(15,16), or through inducing 
retinal neovascularisation (NV) with subsequent complications such as vitreous 
haemorrhage and traction resulting in retinal detachment (17). 
1.2 Aims and objectives 
 
 Examine the influence of diabetes mellitus on the management and visual outcome 
in patients with uveitis. 
 Address the effect of cataract surgery on the visual outcome and course of uveitis. 
 Study the pattern, management and visual outcome of patients with ischaemic 
retinal vasculitis. 
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1.3 Background and literature review 
1.3.1 Uveitis 
1.3.1.1 Definition and classification 
Uveitis refers to the inflammation of the uveal tract (iris, ciliary body, and choroid) within 
the eye (Figure 1.1). However, adjacent structures such as the retina, optic nerve, vitreous, 
and sclera may also be affected, grouping them all together as intraocular inflammatory 
diseases. 
 
 
Figure 1.1 Diagram showing the structure of the eye(18) 
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1.3.1.1.1 Anatomical classification 
At present, the most widely used classification of uveitis is the Standard Uveitis 
Nomenclature (SUN) devised by the International Uveitis Study Group (IUSG) in 1987, 
based on the anatomical location of the inflammation (19,20). The anatomic classification 
system allows the description of the physical location of the uveitis. However, the cause of 
uveitis is not addressed in this classification, nor does it describe various masquerade 
syndromes that may be malignant in origin and similar to uveitis in presentation.  Based on 
this classification, uveitis can be grouped into four anatomic forms: anterior uveitis (AU), 
intermediate uveitis (IU), posterior uveitis (PU), and panuveitis (PANU) (Table 1.1) 
Table 1.1 The SUN working group anatomic classification of uveitis (19,20) 
Type Primary site of inflammation Includes 
Anterior 
uveitis 
Anterior chamber Iritis, Iridocyclitis, Anterior cyclitis 
Intermediate 
uveitis 
Vitreous Pars planitis, Posterior cyclitis, Hyalitis 
Posterior 
uveitis 
Retina or choroid 
Focal, multifocal, or diffuse choroiditis 
Chorioretinitis, Retinochoroiditis, Retinitis 
Neuroretinitis 
Panuveitis 
Anterior chamber, vitreous, and 
retina or choroid  
 
 
1.3.1.1.2 Clinical classification 
In 2008, the IUSG designed a simplified, clinical classification system based on 
aetiological criteria. The aim of this classification was to assist in the diagnosis and 
treatment of uveitis cases. The IUSG clinical classification of uveitis include the 
following(21):  
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Infectious (bacterial, viral, fungal, parasitic). Examples are herpes simplex virus (HSV), 
varicella zoster virus (VZV), syphilis, cytomegalovirus (CMV), human immune deficiency 
virus (HIV), toxoplasma gondii and onchocerciasis.  
Non-infectious Known systemic association- Examples are sarcoidosis, Behcet’s disease 
(BD), juvenile idiopathic arthritis (JIA), multiple sclerosis (MS), systemic lupus 
erythematosis (SLE), granulomatosis with polyangitis (GPA), Vogt-Koyanagi-Harada 
(VKH) syndrome, histocompatibility leukocyte antigen (HLA)-B27 related conditions  
No known systemic association (inflammation confined to the eye) – Examples are 
Birdshot chorioretinopathy (BSCR), sympathetic ophthalmitis, Fuchs’ Heterochromic 
iridocyclitis (FHC), idiopathic IU, and Posner–Schlossman syndrome. 
 Masquerade: Neoplastic and non neoplastic. 
1.3.1.2 Epidemiology 
The prevalence of uveitis is estimated at 38 cases per 100,000 people (1,2). This can vary 
based on the age group with the prevalence of adult uveitis 93 per 100,000 while the 
prevalence of uveitis in children is about 30 cases per 100,000.The annual incidence of 
uveitis ranges from 4.3 to 6.9 per 100,000 in children, compared with 26 to 102 per 
100,000 in adults (3,4). It is more prevalent in younger people with a mean age of less than 
40 years at the onset of their first symptoms (5,22). 
According to the World Health Organization (WHO), 285 million people were estimated to 
be visually impaired; of these, 39 million suffered from blindness, with uveitis as an 
underlying cause in approximately 10% of the cases (23). Uveitis also accounts for 10% of 
blindness cases among the working age group in the United States and Europe (24,25).  
The pattern of uveitis can vary according to the geographic location, which can be related 
to many factors such as environmental and genetic predisposing factors.  
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HLA-B27 AU is the most common identifiable cause of AU. It can either be limited to 
ocular involvement or, in 49- 84 % of cases, is associated with seronegative 
spondyloarthropathies, including ankylosing spondylitis (AS), reactive arthritis, psoriatic 
arthritis and arthritis associated with inflammatory bowel disease) (26). HLA-B27 
associated AU is significantly more common in western countries (6-29% of AU) compare 
to Japan (6-13% of AU), Korea (1% AU) and India (2% of AU cases) (27). BD is a 
dominant cause of uveitis in Japan and in the Mediterranean region (28). Onchocerciasis is 
a leading cause of uveitis in Africa, such as Sierra Leone (29,30). Presumed ocular 
histoplasmosis syndrome (POHS) is mainly found within certain areas in North America, 
mainly Ohio and Mississippi River valleys (31). Some causes of uveitis are more prevalent 
among specific ethnic groups such as BSCR, which is strongly correlated with the HLA-
A29 class I type, mainly predominant among Caucasian ethnicity. BSCR accounts for 
about 8% of PU cases in U.S. (32) while very rare or absent in epidemiological reports of 
uveitis in China (33). VKH has a great predilection for dark-skinned populations, such as 
Asian, Middle East, Hispanic and Native Americans. With a prevalence of 7%, VKH was 
the second most common cause of uveitis after sarcoidosis in a multicentre study in Japan 
(28). In paediatric age group, JIA is the most common systemic association of paediatric 
uveitis (34), with the prevalence of uveitis among JIA patient varies from 11.6% (35) to 
30% (36).  
Idiopathic AU, BD, and VKH syndrome are among the most common entities of uveitis in 
China with very rare incidences of ocular toxoplasmosis, POHS, and BSCR (33). This is 
unlike other countries like Tunisia, where ocular toxoplasmosis is among the most common 
causes of uveitis, together with BD, HSV infection and VKH disease (37). The Manchester 
Uveitis Clinic study in UK on 3000 new cases of uveitis between 1991 and 2013 found AU 
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to be the most common type of uveitis (46% AU, 11% IU, 21.8% PU and 21% PANU) and 
FHC to be the most common diagnosis in their cohort (11.5%) followed by sarcoidosis-
related uveitis (9.7%), idiopathic IU (7.9%), idiopathic acute AU (7.0%), and 
toxoplasmosis (6.9%) (38).   
1.3.1.3 Immunopathology of uveitis 
The initial trigger for the immune reaction leading to uveitis is not always known. In some 
cases there is an exogenous stimulus, such as viral or bacterial infection, that may directly 
or indirectly trigger inflammation. Other cases can be triggered by an endogenous molecule 
within the eye that became exposed under certain circumstances to the immune system and 
thus induces inflammation. Furthermore, there are possible environmental and genetic 
factors that may lead to variations in the inter-individual and population liability and 
manifestations of the ocular inflammation. The role of hereditary factors has been 
supported through the association of some forms of uveitis with the presence of identified 
HLAs. Examples are the association between idiopathic IU and HLA-DR2 and HLA-
DR15(39),  ocular BD with HLA-B51/B5(40), VKH with HLA-DR4/DRB104 (41), BSCR 
with HLA-A2901 and HLA-A2902 (42). 
The CD4+ T-lymphocyte is pre-eminent in the development of uveitis as observed in 
experimental autoimmune uveitis where eye-specific antigens, such as retinal S-antigen or 
intraretinal binding protein, are introduced at a site remote from the eye to induce a tissue-
specific immune response (43). Stimulated T-lymphocyte produces cytokines; T-helper cell 
1 (Th1) response lead to the release of interferon-gamma (IFN-γ), interleukin-2 (IL-2), IL6, 
IL8, IL12, IL18 and tumour necrosis factor alpha (TNFα) which activates macrophages and 
cell mediated immunity, while T helper cell 2 (Th2) released IL-4, -5, -10, and -13 that 
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leads to stimulation of B lymphocytes, maturation of plasma cell, immunoglobulin–E (IgE) 
formation and eosinophil activation (44).  Most of these cytokines have been involved in 
the immunopathology of variable causes of non-infectious IU and PU (45).   
In BD, both Th1 and Th2 cells are involved (46) with CD8+ T cells observed to be the 
predominant intraocular infiltrating cells in active ocular BD(47). High levels of IL8, IL12, 
TNFα had been correlated with ocular BD activity(48)  including new onset of PU(49). In 
cases of SO, the CD4+ helper T-lymphocytes that dominates the early stage of the disease 
is replaced with CD8+ T cytotoxic T-lymphocyte which dominates the later course of the 
disease(50). B cells are identified in 5-15% of choroidal infiltrates (51). Ocular VKH 
disease show infiltration of T-lymphocytes with IL-2 receptors and an increased CD4:CD8 
ratio, as compared to peripheral blood. In its late stage, VKH is characterised by choroidal 
infiltration with CD8+ T-lymphocyte, B lymphocytes, and plasma cells (52). More recent 
study suggests that decreased IL-27 expression in peripheral blood mononuclear cells may 
result in a higher Th17 differentiation in active VKH patients (53).  Th17 cells, expanded 
by IL-2 and inhibited by IFN-γ, has been found in high levels at the peripheral blood in 
patients with active uveitis and scleritis (54). The role of Th17 in BSCR has also been 
enforced through the detection of significantly higher intraocular levels of IL-17 together 
with IL-1β and TNFα compared to their concurrent serum levels (55). This Th-1 cell 
mediated inflammation in VKH is possibly triggered through CMV infection which 
stimulates an inflammatory response that cross-reacts with molecularly similar melanocyte 
peptides, including tyrosinase, in the uvea, skin, inner ear, and central nervous system (56).  
It is still unclear why certain individuals are more vulnerable to experiencing uveitis. It is 
known that many pathogens and their molecules can have similarities with the host 
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structure and the immune reaction against these molecules can cross-react with host 
structures, causing tissue damage and disease. Infection, tissue damage, superantigen 
stimulation, or inappropriate activation of CD4+ T lymphocytes can lead to loss of 
tolerance to self, allowing autoreactive T and B lymphocytes to become active (57). 
1.3.1.4 Clinical features 
Uveitis can have a variable course; either an acute uveitis with sudden onset and limited 
duration; recurrent when repeated episodes followed by periods of inactivity without 
treatment for at least three months; or chronic uveitis when it persists and relapses in less 
than three months after discontinuing treatment. Patients with insidious-onset uveitis do not 
have symptoms until the development of complications such as poor vision, this is 
especially true among children with JIA associated uveitis who can exhibit no symptoms 
despite the presence of severe intraocular inflammation (34) wheareas patients with HLA-
B27 associated uveitis are symptomatic even in the presence of mild inflammation. 
Symptoms of uveitis include pain and photophobia secondary to ciliary and iris sphincter 
muscle spasm, redness, and tearing, as well as floaters and blurred vision secondary to the 
inflammatory cells opacities and fibrin deposition in the anterior vitreous. Blurred vision 
can also be secondary to other manifestations of intraocular inflammation such as corneal 
oedema, corneal band keratopathy, cataract, and CMO. 
Keratic precipitates (KPs) are inflammatory cellular deposits on the corneal endothelium, 
especially at the lower 1/3 of the cornea except for FHC, which has a diffuse stellate KPs, 
and herpetic uveitis. The presence of large KPs with greasy appearance, or “mutton fat” 
KPs differentiate the uveitis as granulomatous compared to nongranulomatous uveitis with 
no or fine KPs (58).  The aqueous fluid is infiltrated with leukocyte cells that are graded 
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based on the inflammatory cell count within a defined set from grade “0” to grade “4”. 
Meanwhile, the presence of proteinaceous materials in anterior chamber results in “flare” 
with variable grades ranging from “0+” to “4+” according to SUN classification system, 
reflecting the severity of the AU(19). Other signs of inflammation include band keratopathy 
which is secondary to calcium salt deposition on the coreal surface commonly observed 
with chronic uveitis such as JIA associated uveitis. Hypopyon, representing excessive 
leukocyte infiltration within the aqueous mainly seen in BD, syphilis and HLA-B27 
associated uveitis (59). Signs observed within the iris include iris nodules, associated with 
granulmoatous uveitis such as sarcoidosis, and iris atrophy, which can be diffuse as in FHC 
or segmental as in herpetic uveitis (58).  
IU is characterised by inflammation in the pars plana area of the ciliary body together with 
the vitreous base and peripheral retina. Symptoms include blurred vision and floaters while 
the main findings consist of variable degrees of vitreous inflammatory cells and haze with 
aggregation of lymphocyte cells in the inferior vitreous forming “snowballs” or a more 
dense aggregations known as a “snowbank”. Additional findings include retinal vasculitis, 
and CMO(60). Complications of IU include secondary glaucoma, cataract, posterior 
vitreous detachment, vitreous haemorrhage, and tractional retinal detachment. Around 67-
72% of patients with IU have positive HLA-DR, especially HLA-DR15, which is also 
associated with MS (45). MS can be observed in 17 % of patients with IU, while 27 % of 
patients with MS patient can present with IU (61).  
The inflammation in cases with PU is mainly confined to the the retina and choroid in the 
form of retinitis, focal or multifocal choroiditis, retinichoroiditis, chorioretinitis, with or 
without an associated retinal vasculitis and neuroretinitis. The choroidal lesions represent 
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focal defects in Bruch membrane may facilitate the development of choroidal neovascular 
membrane (CNVM), a major risk factor for visual loss in these cases (62).   
1.3.1.5 Laboratory investigations in uveitis  
In the presence of a wide range of laboratory tests, both general and specific for a defined 
set of pathology, it is important to plan and order for the appropriate tests directed by the 
patient’s general history and the symptoms associated with his presentation with uveitis 
together with the clinical examination findings. 
1.3.1.5.1 Routine blood investigations 
These investigations are usually recommended for uveitis patients regardless of the 
suspected underlying disease that might be associated with the uveitis. Total blood count 
(TBC) and erythrocyte sedimentation rate (ESR) may not be specific enough in defining the 
underlying condition with uveitis but it can provide some clues that can direct us toward 
additional, more specific tests. Lymphocytosis can be observed in the presence of bacterial 
infection such as TB, while lymphopenia can suggest an underlying viral infection or 
malignancy. The presence of eosinophilia can be associated with parasitic infections and 
has also been observed in patients with Sarcoidosis. Peripheral blood smear is needed to 
exclude the presence or leukemia or other forms of myeloblastic malignancies. Abnormal 
renal function test can suggests tubulointerstitial nephritis and uveitis (TINU) syndrome. 
Renal and Liver function tests, together with TBC are important not only for diagnostic 
purposes but also as a baseline investigation and for monitoring patients treated with 
systemic corticosteroids and mmunomodulatory therapy (IMT). Elevated C-reactive protein 
may not be considered a specific test but it can indicate an active inflammatory process that 
may guide toward performing more disease specific tests accordingly. 
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1.3.1.5.2 Disease specific laboratory investigations 
Serum angiotensin converting enzyme (ACE) and serum lysozyme can be secreted from the 
macrophages within the sarcoid granuloma, making an elevated ACE above its normal 
levels highly suggestive of sarcoidosis but not pathognomonic considering that it can be 
elevated secondary to variable other conditions. In addition, the interpretation of high ACE 
in paediatric age group can be difficult as they tend to have high ACE level in the absence 
of underlying sarcoidosis. A recent study of 83 patients with biopsy proven sarcoidosis 
associated uveitis demonstrated an elevated ACE (>62 IU/L) in 61.7% of cases while 
elevated lysozyme levels (>16.7 mg/L) were observed in 83.9% of cases (63). 
The first International Workshop on Ocular Sarcoidosis in Tokyo (58) identified seven 
clinical signs suggestive of ocular sarcoidosis; 1) bilateral ocular involvement 2) mutton-fat 
KPs and/or  iris nodules, 3) trabecular meshwork nodule and/or tent-shaped peripheral 
anterior synechiae, 4) vitreous opacities (snowballs), 5) multiple chorioretinal lesions, 6) 
nodular or segmental periphlebitis (± candle wax drippings) and/or macroaneurysm, 7) 
optic disc nodule/granuloma and/or solitary choroidal nodule. The diagnosis of sarcoidosis 
is supported by a group of laboratory findings such as (1) negative tuberculin skin test in a 
Bacillus Calmette-Guerin (BCG) vaccinated patient or in a patient having had a positive 
tuberculin skin test previously, (2) elevated serum ACE levels and/or elevated serum 
lysozyme, (3) bilateral hilar lymphadenopathy on chest X-ray (4) abnormal liver enzyme 
tests, and (5) chest computed tomography scan in patients with a negative chest x-ray 
result. Among the paediatric age group with granulomatous uveitis, one should exclude 
Blau syndrome (Familial juvenile systemic granulomatosis), an autosomal dominant 
disorder characterise by skin rash, polyarthritis and granulomatous AU resembling 
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sarcoidosis which can only be differentiated through positive family history and genetic 
mutation affecting the CARD15/NOD2 gene on chromosome 16q12 (64). 
Interferon gamma release assays had been found to be less sensitive but more specific than 
tuberculin skin test in the identification of TB associated uveitis as it is less likely to cross 
react with previous BCG vaccination.(65) In syphilis associated uveitis, the veneral disease 
research laboratory tests utilised based on the reaction of non specific antibodies produced 
by Treponoma pallidum against cardiolipin. Other tests like fluorescent treponomal 
antibody absorption test and microhemagglutination Treponoma pallidum test are also used 
to detect antibodies against Treponoma pallidum which confirm the diagnosis of syphilis 
and also monitor disease response to treatment based on change in antibody titer. 
Rheumatoid factor (RF) and antinuclear antibody (ANA) are also performed in patients with 
possible JIA associated uveitis and other underlying connective tissue diseases associated 
with uveitis. While most of the HLA tests are not required in the investigation process of 
uveitis due to lack of specificity, HLA-B27 as well as HLA-A29 are of value in 
determining the presence of underlying seronegative arthritis associated uveitis as well as 
BSCR, respectively. In patients presenting with vasculitis, the presence of high titers of 
antinuclear cytoplasmic antibodies (ANCA) and anticardiolipin antibodies can raise the 
suspicion of underlying collagen vascular diseases such as SLE. 
Although the diagnosis of most cases of toxoplasmosis chorioretinitis is established through 
clinical assessment, laboratory tests may still be needed for cases with atypical 
presentation. An acute Toxoplasma gondii infection is associated with positive IgM and 
IgG antibodies. IgM usually appears in the first week post infection, reaching its peak at 
one month before it disappears by nine months (66). 
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Aqueous sample (0.1 ml) can be obtained from anterior chamber papracentesis to help in 
the diagnosis of the causative microorganisms in cases of possible infectious uveitis and 
endophthalmitis. It has the advantage of being quick, and can be carried out in outpatient 
setting and is of use when there are fears that the vitreous biopsy cannot be performed for 
any reason. However, this procedure has higher chance of yielding false-negative results 
compare to vitreous biopsy. Samples from aqueous or vitreous can be sent for 
microbiologic assessment of bacterial, fungal or acid fast bacilli under microscopic 
examination, or for performing culture and sensitivity tests. Polymerase chain reaction 
(PCR) and enzyme-linked immunosorbent assay (ELISA) tests for suspected 
microorganisms can also be performed to detect viral infections such as HSV, CMV and 
VZV infections. The samples can also be sent for cytological assessment in cases with 
suspected ocular lymphoma.  
1.3.1.6 Ancillary tests in uveitis 
1.3.1.6.1 Ultrasound biomicroscopy 
Ultrasound biomicroscopy used for ocular examination differs from the conventional 
ultrasound in that we use a high frequency waves (35 – 100MHz), allowing for greater 
microscopic resolutions of the anterior chamber and ciliary body together with vitreous 
structures, peripheral retinal and sclera (67). Ultrasound is also of importance in uveitis 
complicated with hypotony to assess ocular structure and exclude the presence of choroidal 
effusion.  
In eyes with acute AU, ultrasound biomicroscopy in one study had shown a large number 
of cells in the anterior and posterior chamber, and oedema and exudates at the iris and 
ciliary body, especially within two weeks of acute AU onset, which almost resolve six 
weeks from onset of acute AU after initiating steroid therapy (68). The same investigation 
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is of value in eyes with IU as it can detect the vitreous cells or condensations associated 
with vitritis in addition to other underlying structural abnormalities that occasionally 
missed on clinical examination (69). It can also exclude the presence of vitreoretinal 
adhesions and tractional retinal detachment that can occur in association with uveitis, more 
commonly in ischaemic retinal vasculitis. Tltrasound biomicroscopy is also of importance 
in assessing the posterior sclera thickness in patients with scleritis or VKH and for 
excluding significant subretinal fluid or serous retinal detachment. In eyes with disc 
swelling suspected to be secondary to optic neuritis, ultrasound is performed to exclude 
optic disc drusen or other abnormalities associated with swollen disc. In the presence of 
significant media opacity such as cataract that limits the fundus view, ocular ultrasound 
would be useful as a diagnostic tool, especially prior to cataract surgery to exclude any 
underlying complications that may affect the prognosis such as retinal detachment.  
1.3.1.6.2 Fundus photography  
Fundus colour images help in viewing and baseline documentation of the abnormalities 
observed within the fundus on clinical examination, and is useful in monitoring the 
progression or resolution of the uveitis manifestations within the retina and choroid such as 
epiretinal membrane (ERM), retinitis, choroiditis and occlusive retinal vasculitis (70). 
Fundus fluorescein angiography (FFA) has been widely used as an essential investigation 
tool for the diagnosis and monitoring of uveitis cases through identifying any perfusion, 
permeability and proliferation abnormality. FFA can show evidence of active inflammation 
within the eyes such as the presence of vascular leakage or occlusion or leaking NV 
associated with vasculitis. Active retinochoroiditis can be associated with focal or diffuse 
hyperfluoresence. The status of the macula can also be assessed with FFA, which can show 
parafoveal hyperfluorescence, including the characteristic “petalloid” pattern secondary to 
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CMO. A localised area of leakage with an increasing intensity suggestive of CNVM, or of 
increasing pooling of dye as seen in steroid induced central serous chorioretinopathy. FFA 
is also useful in assessing any break in the foveal avascular zone circle or an increase in its 
diameter, which suggest the presence of macular ischaemia. Optic disc fluorescein leakage 
can either be localised from NV at disc or diffuse “hot disc” suggestive of neuritis or VKH 
but can also be observed with any form of severe IU and PANU. The small molecules of 
free unbound fluorescein dye normally can’t pass through blood-retinal-barrier (BRB) but 
can leak out from even minimally damaged BRB secondary to inflamed retinal vessels or 
retina which makes it very useful in the diagnosis of retinitis and retinal vasculitis. 
However, the limited ability of activated fluorescein molecule under the retinal pigment 
epithelium (RPE) layer to emit light through the melanin, xanthenes, and haemoglobin 
pigments makes it of limited use in the diagnosis of choroidal pathologies or in the 
presence of severe preretinal or intraretinal haemorrhages, for such cases, indocyanine 
green (ICG) angiography can aid in the diagnosis. 
ICG angiography is based on the emission of fluorescence waves within the infrared 
wavelength that can be detected through the RPE which allows for the evaluation of 
choroidal structure. The value of ICG angiography in the management of chorioretinal 
disease was assessed through a group of retinal expertise in 2003 who reviewed 376 articles 
out of which 92 were eventually included. In addition to highly recommending ICG to 
identify polypoidal choroidal vasculopathy and other forms of CNVM, they also 
recommended ICG with some enthusiasm to identify chronic central serous retinopathy, 
MEWDS, vasculitis, AMPEE, VKH and BSCR. Meanwhile, they didn’t find ICG useful in 
adding clinical information for the diagnosis and management of BD or sarcoidosis related 
uveitis (71).  
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Ultra-widefield images have been increasingly used in uveitis, such as the Optos fundus 
camera (Optos, Dunfermline, Scotland, UK) which can capture up to 200-degrees of the 
ocular fundus in a single photograph, thus reveals a wider area of the fundus and more 
peripheral view than the standard 30- to 50-degree fundus images. A study compared the 
wide field images obtained from Optos FFA to a 9-field montage images in eyes with 
uveitis demonstrated superiority of the wide-field FFA in capturing the retinal vascular 
pathology, in both the periphery and the posterior pole (72). 
Campbell et al suggested that the use of ultrawide-field images can eventually alter the 
management plan for uveitis for those made based on clinical examination and standard 
imaging even though the wide-field imaging was not superior over standard examination 
and imaging when it comes to detecting disease activity (73). 
1.3.1.6.3 Optical coherence tomography (OCT) 
Optical coherence tomography (OCT) is a non-invasive, noncontact, transpupillary imaging 
method that can analyse the retina and choroid in cross-sections with 8 to 10μm resolution 
(74). Three pattern of CMO in uveitis has been described; diffuse macular oedema seen in 
54.8% eyes and presents as sponge-like thickening of the retina with low-reflectivity; 
clearly defined intra-retinal cystic spaces seen in 25%; and finally the serous retinal 
detachment seen in 5.9% of cases with fluid accumulation between RPE and neurosensory 
retina (75). 
While FFA is very useful in detecting leakage associated with active uveitis or CMO, OCT 
allows for more quantifiable measurement of macular thickness and associated changes 
such as intraretinal or subretinal fluid, ERM, pigmented epithelial detachment and RPE 
atrophy. The Multicenter Uveitis Steroid Treatment (MUST) trial group compared the 
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effectiveness of FFA versus OCT in the diagnosis of CMO among 479 eyes with uveitis.  
They found that both OCT and FFA offered only moderate agreement when it comes to the 
diagnosis of CMO. OCT was superior to FFA when it comes to providing more usable 
information regarding the CMO characteristics (90% versus 77%, respectively). However, 
OCT had a limitation of failing to detect macular leakage required to make modifications to 
the uveitis treatment , for which case FFA is recommended in addition to OCT (76). 
1.3.1.7 Management of uveitis 
The approach in uveitis management can vary depending upon the anatomical location and 
aetiology of uveitis, severity of the inflammation, and the associated complications. In most 
cases, the treatment of non-infectious uveitis is initiated with the use of corticosteroid 
therapy administered topically, through local injection or systematically, aiming to rapidly 
control inflammation. In cases where corticosteroid therapy cannot be tapered to low level 
without having a uveitis relapse, alternative or second line agents should be considered to 
reduce the risk of prolonged corticosteroid use (77). Figure 1.2 illustrates a proposed 
therapeutic algorithm for managing non-infectious uveitis. 
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Figure 1.2  Proposed therapeutic algorithm for managing non-infectious uveitis 
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1.3.1.7.1 Corticosteroids 
 
Corticosteroids are steroid hormones naturally secreted from adrenal gland cortex of 
humans and involved in the carbohydrates and protein metabolism as well as controlling 
electrolyte levels and body immune reaction against inflammation and stress. In the eye, 
steroids acts on inflammation control through inducing phospholipase-A2 inhibitory 
proteins which eventually reduce the production of inflammatory mediators such as IL-6 
and prostaglandins (78). Furthermore, corticosteroids used in the management of CMO 
through reducing vascular and BRB permeability and breakdown through stabilising the 
RPE tight junctions (79) and reducing vascular endothelial growth factor (VEGF) level 
(80). For the purpose of uveitis management, corticosteroids have been used widely 
through variable routes of administration; either topically, as periocular or intraocular 
injections, or systemically. 
1.3.1.7.1.1 Topical corticosteroids 
Topical corticosteroids remain the primary treatment for non-infectious AU as it can 
penetrate the cornea to concentrate mainly within the anterior chamber. Commonly used 
preparations for managing AU include dexamethasone 0.1% and prednisolone 1% eye 
drops. Methylprednisolone 1% eye drops had been shown equal efficacy in treating AU 
compared to prednisolone 1% drops (81). Another randomised study found Rimexolone 1% 
to be as effective as prednisolone acetate 1% in the management of AU and with no 
difference in the risk of increased intraocular pressure (IOP) between the two drops (82). 
Topical drops are initiated at frequent intervals depending on the degree of active 
inflammation and are then tapered down gradually, aiming to either stop once inflammation 
control has been achieved, or reduced to ≤ 3 drops per day as the latter has been shown to 
be associated with the minimum risk of side effects, especially cataract formation (83,84). 
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Another adverse effect includes steroid-induced glaucoma, possibly through the 
accumulation of extracellular matrices in the trabecular meshwork, resulting in increased 
resistance to aqueous outflow in the trabecular meshwork and leading to increased IOP 
(85). Other complications include increased risk of secondary ocular infection and corneal 
toxicity associated with the preservatives that are present in some steroid drops 
formulation.  
1.3.1.7.1.2 Systemic corticosteroids 
Systemic corticosteroids are preferred route of administration when the uveitis extends 
beyond the anterior chamber bilaterally, and in the presence of relative contraindications to 
the use of periocular or intraocular corticosteroid injections(86). Prednisone is the most 
commonly used oral corticosteroid, with initial dose ranges from 0.5 to 1.5 mg/kg/day then 
tapered down until stopped or kept at a maintenance level as low as 7.5mg /day or less. 
High-dose intravenous corticosteroids have been used successfully in the management of 
acute and severe uveitis episodes (87). However, it doesn’t show superiority in determining 
the vision outcome nor on the development of complications when compared to per oral 
route of administration (88). This can be significant considering the cost of hospital 
admission and the need of medical experts to administer corticosteroids intravenously when 
it is not required with the use of steroid tablets. Side effects associated with systemic 
corticosteroids include ocular complications such as cataract, increased IOP and central 
serous retinopathy, while systemic complications include systemic hypertension, 
gastrointestinal disturbance, altered mood, elevated blood sugars, hypokalaemia, 
leukocytosis, myopathy, osteoporosis and Cushingoid changes (moon facies, weight gain, 
and increased acne). Prolonged use of systemic corticosteroids should be avoided in all 
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patients, especially in children in whom corticosteroid-induced growth retardation is a 
significant risk of this therapy (89).  
Patients on systemic corticosteroids require regular checking of their blood pressure and 
blood glucose levels, at least once every 3 months. Bone mineral density evaluations, blood 
cholesterol and lipids should also be monitored on a regular basis (86). The fracture risk 
assessment tool have to revise the 10-year probability of fracture by a 15% for individuals 
on corticosteroids daily dose of 7.5mg or more (90). Calcium and vitamin D 
supplementation is widely recommended for these cases to prevent mineral bone density 
loss in patients at high risk of osteoporosis (91). 
1.3.1.7.1.3 Periocular corticosteroids 
Periocular injections of corticosteroids such as triamcinolone acetonide (TA) and 
methylprednisolone  can be performed through variable techniques; into the 
subconjunctival space, into the subTenon space, into the orbital floor through 
transcutaneous or transconjunctival approach, or into the retrobulbar space (92).  This 
method is especially preferred in the management of CMO when it is unilateral or there is a 
relative contraindication against the use of systemic corticosteroid, or it maybe used as an 
adjuvant treatment with other systemic therapy.  A single injection of periocular TA has 
been reported to resolve CMO in 53% of eyes within one month post injection and 22% did 
so with more than one injection of TA (93). A major limitation though is the high risk of 
cataract formation and increased IOP. In a large study cohort involved 1192 eyes that 
received ≥1 periocular injection found about 72% of the eyes achieved complete uveitis 
control within 6 months follow up and half of the eyes achieved an improvement in vision 
to 6/9 or better.  In the same study, the incidence of increased IOP ≥30 mmHg was 15% 
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within one year post injection while the incidence of visually significant cataract formation 
was 20% of the cases (94).  
1.3.1.7.1.4 Intraocular corticosteroids 
Triamcinolone acetonide (TA), a water- insoluble crystalline steroid in a suspension form, 
can be injected into the vitreous at a therapeutic dose of typically 2 or 4 mg. The 
preservative-free TA approved by the U.S. food and drug administration (FDA) to treat 
ocular inflammatory diseases includes Trivaris® and Triesence®. On the other hand, 
Kenalog-40® is the most common form used for off-label intravitreal injection. The 
intravitreal half-life of TA is approximately 18 days with a therapeutic activity that lasts for 
approximately 3 months post injection (95). 
Intravitreal injection of TA (IVTA) was first used in human eyes in the late 1990s, since 
then it has been commonly used as initial or supplementary therapy for uveitis and its 
associated CMO (96). IVTA have been used in the management of CMO among variable 
causes of non-infectious uveitis such as BD (97), VKH (98), serpiginous choroiditis (99) 
and AS (100). A study compared IVTA injection to subTenon TA and intravitreal 
bevacizumab in treating uveitic CMO found all three groups achieved the best 
improvement in VA and reduction in central foveal thickness at 4 weeks in all groups then 
gradually subsided until 12 weeks. The IVTA injection was associated with a longer period 
of effectiveness (30 weeks) compared to intravitreal bevacizumab (16 weeks) and posterior 
subTenon TA (12 weeks) (101).  In the paediatric age group, a study of 16 eyes with uveitis 
receiving IVTA has shown a clinically significant improvement in VA among 56% of  
cases that lasted up to 15 months post injection (102). 
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The use of IVTA injection can be limited due to its complications, mainly the high risk of 
increasing IOP and cataract formation. An increase in IOP > 10mmHg has been reported to 
occur in 43% of eyes following IVTA, especially in patients <40 years of age (96). The risk 
of cataract development requiring surgery can vary based on published studies but one 
study reported an incidence of 29% of uveitic eyes at an average of two years (12-34 
months) post IVTA injection compared to only 5% of eyes that received placebo injection 
(103). Other rare adverse events include pseudoendophthalmitis secondary to the 
preservatives in off-label TA (Kenalog®) and endophthalmitis. A systematic review of 
literature from 1966 to 2004 estimated the prevalence of all forms of endophthalmitis post 
IVTA injection to be 1.4% (0.6% were bacterial endophthalmitis) (104). Another two 
reports found the incidence of endophthalmitis post IVTA injection ranging from none (97) 
to 0.21% (105), respectively. IVTA should be avoided in cases where the possibility of 
infectious uveitis hasn’t been excluded, an example is toxoplasmosis chorioretinitis that can 
present with fulminant chorioretinitis following IVTA (106).  
Dexamethasone intravitreal implant (Ozurdex®, Allergan, Inc., Irvine, CA), known 
previously as Posurdex, is a biodegradable device that is inserted into the vitreous using a 
23-gauge needle device preloaded with the implant. The implant itself contains a 
therapeutic dose of 0.7 mg preservative-free dexamethasone.  
Ozurdex has been approved in 2010 by the FDA for the treatment of non-infectious 
intermediate and posterior uveitis (107) based on reports of the Dexamethasone drug 
delivery system (DDS) phase II study group on 41 eyes with chronic CMO secondary to 
uveitis or Irvine-Gass syndrome. Three months after receiving dexamethasone implant, 
there was a significant improvement in visual acuity by at least 15 letters in 53.8 % of eyes 
on 0.7 mg implant compared to 16.7% of eyes on 0.35mg implant and only 7% in the 
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control group. Improvement in CMO was also observed in 58% of eyes on 0.7 mg implant 
compared with 8% in the control group (108). Repeated Ozurdex implantation had also 
shown an accumulated effect  in a cohort of 38 eyes with uveitis with a relapse rate of 69% 
following first intravitreal implant and 48% following second implant(109). Ozurdex 
implant is also of benefit in improving vision and managing CMO among the paediatric age 
group with non-infectious uveitis (110). 
The risk of increased IOP and cataract progression can be seen in eyes with Ozurdex 
implant but less frequent compared to those observed secondary to IVTA and Retisert 
implant. In eyes with 0.7 mg dexamethasone implant, increased IOP requiring 
antiglaucoma drops has been reported in 23% (111) to 38% (108) of cases. Cataract 
formation has been observed in 15% of the eyes within six months post 0.7 mg 
dexamethasone implant (111). Ozurdex implant should be avoided in aphakic eyes and eyes 
with compromised posterior capsule due to the high risk of implant migration into the 
anterior chamber resulting in corneal decompensation and requiring implant removal and 
occasionally penetrating keratoplasty (112).  
Fluocinolone acetonide is one of the most potent and selective glucocorticoids with no 
mineralocorticoid effect and has been available for intravitreal implantation in the form of 
Retisert® and Iluvien®.  Retisert implant consists of a tablet containing 0.59 mg of active 
ingredient and needs to be implanted surgically through a sclerotomy incision made at the 
level of pars plana. Once implanted, its effectiveness can last for about 2.5 years (30 
months). 
The MUST trial is an ongoing prospective study set up to compare the visual acuity 
outcome in patients with non-infectious intermediate posterior or panuveitis randomised to 
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receive either systemic immunosuppressant or Retisert insertion, in both eyes if necessary 
and withdrawal of systemic medication. The two year results of the MUST trial 
demonstrated that the visual outcome following Retisert implant was not significantly 
different when compared to those on systemic anti-inflammatory medications. The Retisert 
implant group had better control of uveitis activity when compared to the group on 
systemic therapy with an incidence of active uveitis in 12% versus 29%, respectively. The 
group on Retisert implant, however, had a higher risk of cataract surgery (80%), treatment 
for elevated IOP (61%) and glaucoma (17%) within 2 years follow up period (113). 
A study comparing Ozurdex to Retisert implant found no superiority of one over the other 
in terms of uveitis control and vision improvement. However, Retisert implant had higher 
rates of cataract progression compared to Ozurdex (100% versus 50%), as well as more 
need for glaucoma medications, laser, and surgery (114). 
1.3.1.7.2 Antimetabolites  
1.3.1.7.2.1 Methotrexate (MTX) 
MTX is a folic acid analogue that inhibits dihydrofolate reductase enzyme, leading to 
inhibition of DNA replication and the proliferation of rapidly dividing immune cells (115). 
MTX has been used in the management of uveitis secondary to JIA, sarcoidosis, and 
idiopathic panuveitis (86). It is typically administered in the form of tablets or subcutaneous 
injections at a dose between 7.5 and a maximum of 25 mg per week and requires 3 to 6 
weeks before reaching its full therapeutic effect. The main serious side effect is reversible 
hepatotoxicity thus patient on MTX requires regular monitoring of liver function test (77). 
 The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) involved 384 patients 
with non-infectious uveitis from 4 tertiary ocular inflammation clinics in the United States. 
The study reported suppression of ocular inflammation with the use of MTX in 66% of 
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cases within one year; in addition, 58% of the cases had successfully stopped or reduced 
their systemic steroids to 10 mg/day or less. MTX was ineffective in controlling 
inflammation in 13% of the cases while the side effects resulted in discontinuation of the 
medication in 16% of cases (116). These side effects reported in the same study ranged 
from gastrointestinal upset (3%), bone marrow suppression (2.6%), elevated liver enzyme 
(2.3%), malaise (2.1%), allergy (1.6%), mouth ulcers (1.3%), to less common side effects 
such as infection,, hair loss and cirrhosis of liver (each <1%). No increased risk of 
neoplasia has been demonstrated with long-term use (116). 
1.3.1.7.2.2 Azathioprine (AZA)  
AZA is used in inflammation control through its ability to prevent protein synthesis in 
lymphoid cells through interfering with purine incorporation into DNA, resulting in 
synthesis of nonfunctional DNA sequences. Other mechanisms of action include selective 
T-cell inhibition, decreased development of monocyte precursors, and natural killer cell 
suppression leading to reduced cytotoxic inflammatory reactions (115,117). AZA is usually 
prescribed at an initial dose of 1–3 mg/kg/day orally and then adjusted afterwards 
according to the side effects and clinical response, which can take up to 4-12 weeks to 
occure. AZA is particularly effective in the management of uveitis secondary to JIA and IU 
(115).  
The SITE study group reported inflammation control with the use of AZA in 69% of 
patients with uveitis within 6 months with uveitis while achieving steroid sparing effect in 
32% and 47% of patients by 6 months and 12 months, respectively (118). Side effects of 
AZA include gastrointestinal upset (25%), bone marrow suppression, and reversible 
hepatotoxicity (<2%) (119).  
46 
 
1.3.1.7.2.3 Mycophenolate mofetil (MMF) 
MMF is a selective monophosphate dehydrogenase inhibitor. Usual dose for managing 
uveitis is 2-3 grams divided over two daily doses. In the SITE study, 236 patients (397 
eyes) with ocular inflammation treated with MMF monotherapy. Complete control of 
inflammation over at least 28 days was achieved within 6 months in 53% of patients and 
within 1 year in 73% of patients. Steroid sparing effect was achieved in 41% and 55% of 
patients within 6 months and 1 year, respectively. MMF had to be discontinued in 12% of 
cases within a year because of side effects (120). The most common side effects of MMF 
include gastrointestinal symptoms (31%) as well as myalgias, fatigue, headache and bone 
marrow suppression (119). The latter had been associated with discontinuation of MMF in 
1.7% of patients while gastrointestinal symptoms lead to discontinuation of MMF in 2.5% 
of patients reported in the SITE study (120). 
1.3.1.7.3 Alkylating agents  
1.3.1.7.3.1 Cyclophosphamide  
Cyclophosphamide is a cytotoxic drug targeting lymphocytes but with a high toxic profile 
that limits its use to managing severe ocular inflammation that is resistant to other IMT 
medications.  The drug is of particular use in controlling inflammation secondary to GPA, 
SLE, polyarteritis nodosa, peripheral ulcerative keratitis, and necrotising scleritis (86). The 
SITE Cohort Study group on cyclophosphamide reported complete control of inflammation 
in 50% and 81% of patients within 6 months and 12 months treatment, respectively. Steroid 
sparing effect was achieved in 30% and 61% of patients by 6 months and 12 months, 
respectively.  The ability to discontinue the medication due to inflammation remission was 
achieved in 63% of patients on cyclophosphamide, which is a higher rate achieved when 
compared to other IMT.  Side effects of cyclophosphamide lead to discontinuation of 
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medication in 33.5% of patients within one year (121). Regular follow up of total blood 
count should be performed and the cyclophosphamide should be stopped when white blood 
cell counts fall below 2500 cells per µl. The risk of haemorrhagic cystitis and bladder 
cancer are major risks associated with cyclophosphamide and thus should only be 
considered when the benefits are believed to outweigh the risks when used for short 
duration to control active ocular inflammation (115).  
1.3.1.7.3.2 Chlorambucil 
Chlorambucil has a similar mechanism of action to cyclophosphamide in preventing 
inflammation through DNA synthesis in rapidly dividing cells. Initially started at an oral 
dose of 0.1 mg/kg/day that can changed based on clinical response and development of side 
effect to a maximum dose of 6 to12 mg/day (77). One study looked at the effectiveness of 
chlorambucil in 44 patients with refractory uveitis secondary to BD, and observed 
inflammation control in 66% of patients(122). Another review found uveitis control in 68% 
out of 28 patients with refractory uveitis secondary to BD, JIA, pars planitis, SO, idiopathic 
uveitis, Crohn’s disease, and HLA-B27 associated uveitis (123). Side effects include bone 
marrow suppression, which can progress to irreversible aplastic anaemia, cutaneous 
malignancy, and haematological malignancy (119). Chlorambucil is not as effective as 
cyclophosphamide when it comes to controlling uveitis and thus makes it less favourable 
choice by ophthalmologists when decision is made to initiate alkylating agents for uveitis 
control (115).  
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1.3.1.7.4 Calcineurin inhibitors  
1.3.1.7.4.1 Cyclosporine (CSA) 
CSA and tacrolimus are termed calcineurin inhibitors due to their ability to bind to the 
protein cyclophilin in T lymphocytes leading to calcineurin inhibition. The latter is 
responsible for activating the transcription of IL-2 under normal condition as well as 
inhibiting the production of TNFα, IFNγ, IL-3, and IL-4 and therefore leads to suppression 
of T-cell function (124). CSA dose ranges from 2.5 mg/kg/day to a maximum dose of 
7.5 mg/kg/day, given over two equally divided doses. CSA has been effective in the 
management non-infectious uveitis (86). One study on the use of CSA for managing ocular 
BD found it to be successful in stabilising or improving the vision in 69% of 104 eyes with 
BD with no uveitis relapse in over 50% of the eyes over one year follow-up period (125). 
The SITE study observed CSA to be successful as steroid-sparing agent (control 
inflammation with prednisone ≤10 mg/day) in 22% by six months and 36% within one year 
(126). Toxicity secondary to CSA is a major limitation that can lead to discontinuation of 
therapy within one year in 10% of the population, especially in patients over 55 years of 
age where the risk of stopping the medication due to side effects such as nephrotoxicity and 
hypertension is three times more than the younger age group (126). 
1.3.1.7.4.2 Tacrolimus  
With a mechanism of action similar to that of CSA and with a lower profile of drug 
toxicity, tacrolimus has been used for managing uveitis (127). Tacrolimus is usually 
administered orally at a dose of 0.05 mg/kg/day. Tacrolimus when used as a second line 
medication has shown steroid sparing effect following its use for 14 months in uveitis eyes 
while maintaining low incidence of nephrotoxicity and hypertension (128). However, there 
is still limited data regarding the effectiveness of tacrolimus in managing variable forms of 
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non-infectious uveitis. In addition, its effectiveness in comparison to other IMT therapies 
has yet to be understood. 
1.3.1.7.5 Tumour necrosis factor inhibitors 
Anti-TNFα such as infliximab, adalimumab, or etanercept have been implemented as off-
labelled drugs in the management of uveitis cases resistant to other local or systemic 
immuneosuppressant medications (129). Underlying infections should be excluded and all 
patients should be screened for latent TB prior to starting treatment and they may require 
Hepatitis B vaccination if they are at risk of infection (130).  Anti-TNFα are excluded in 
patients with severe heart failure and used with caution in those with mild heart disease. 
Blood tests such as TBC and liver function test should be performed at baseline and 
afterward at regular intervals (130). Another risk associated with the use of Anti-TNFα is 
central nervous system demyelination which has been observed in 0.05 to 0.2% of patients 
and should be avoided in cases suspected to have MS (131). Additional side effects include 
secondary infection, especially TB and fungal infections, thromboembolism, drug-induced 
lupus-type reaction, and possibly malignancy (132). 
1.3.1.7.5.1 Infliximab (Remicade®)  
Infliximab is a chimeric IgG monoclonal antibody that binds to TNFα and inhibits its 
biological function.  It has been licensed for the control of systemic manifestations of 
variable autoimmune diseases such as JIA, ulcerative colitis, AS and psoriasis. Infliximab 
is administered intravenously at a dose of 3–5 mg/kg given at weeks 0, 2, 6 and then every 
8 weeks, or as early as every 4-6 weeks, at 5–10 mg/kg and can be given for 2 years once 
disease remission is achieved (133).  Infliximab has been successfully used to treat difficult 
cases of uveitis associated with BD (134), JIA (135), BSCR (136), AS, sarcoidosis, and 
Crohn’s disease (137).  
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Adalimumab is a humanised monoclonal IgG antibody against TNFα given subcutaneously 
at a usual dose of 40mg every two weeks. It is similar to infliximab on the aspect of 
inflammation control and side effects, with less reaction against adalimumab administration 
owing to its fully humananised nature.  Adalimumab had also been observed to 
successfully reduce the rate of AU flare up by 51% in patients with AS (138).  
Etanercept acts as TNFα and TNFβ antagonist through acting as a fusion protein of a 
human Fc molecule and two p75 TNF receptors. And while there were initial reports 
suggesting its effectiveness in controlling uveitis, a small cohort, randomized double 
masked, study found no apparent difference between JIA patients treated with etanercept 
from placebo in controlling AU (139). 
1.3.1.7.6 Anti-CD 20 monoclonal antibody 
Rituximab (RTX), a chimeric monoclonal antibody against CD20+ antigen on B-cells, has 
been used in the treatment of non-Hodgkin’s lymphoma and rheumatoid arthritis. Studies 
did suggest using it as a treatment option in managing severe, sight threatening uveitis 
secondary to JIA as well as other forms of non-infectious uveitis that are recalcitrant to 
other conventional IMT or TNFα antagonists (140).  The treatment dose for managing 
uveitis varies but has been used at a dose of 1,000mg given twice at 2 week interval (141). 
1.3.1.8 Uveitis complications and causes of vision loss 
The WHO defines blindness as the best corrected vision in the better eye of less than 3/60 
or a visual field ≤10°, whereas severe visual impairment is defined as the best corrected 
visual acuity in the better eye of 3/60 or more, but less than 6/60 or a visual field ≤20°. 
Legal blindness can be defined in certain countries as the level of blindness that makes a 
person eligible for social support and financial benefits (23). 
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Uveitis is a potentially blinding condition accounting for 5–20% of legal blindness in both 
the United States and Europe (7,8,22). The risk of visual loss can vary based on the type 
and cause of uveitis and age group. PU has been the most common anatomical type of 
uveitis associated with visual loss, followed by anterior uveitis. Among all cases of uveitis, 
reports of complications have been as high as 41%, with 19% of cases having resulted in 
blindness (142).  
Among children with JIA related uveitis, at least 20% develop severe vision-compromising 
complications, such as cataracts, band keratopathy, posterior synechiae, hypotony, and 
glaucoma (143,144). Studying 75 patients with JIA over a median follow-up of three years 
found the rate of vision loss ≤6/12 or worse was 0.1 per eye year and rate of vision loss 
≤6/60 was 0.08 per eye year (83). Another study of patients with JIA associated uveitis 
found the incidence of any ocular complication to be 0.33 per eye-year (EY) with the rates 
of moderate vision loss 0.10/EY and severe vision loss 0.08/EY. The study also found 
posterior synechiae, active anterior chamber inflammation, and abnormal intraocular 
pressure (IOP) at presentation associated with increased incidence of vision loss (83). Poor 
prognostic factors for visual outcome among children with JIA related uveitis include male 
gender, anterior chamber flare > or = 1+, positive antinuclear antibody (ANA) and uveitis 
onset preceding the development of arthritis symptoms (145,146). 
1.3.1.8.1 Potentially reversible causes 
Cataract and CMO are the most common cause of visual loss in uveitis. One study found 
CMO and cataract, either alone or in combination, to be responsible for visual loss ≤6/18 in 
64.5% of the patients with uveitis(10). Rothova et al, investigating causes of visual loss in 
582 patients with intraocular inflammation, found CMO to be the most common cause of 
decreased vision (26%) followed by cataract (19%) (6). The incidence of cataract in uveitis 
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can vary according to the anatomical and aetiological type of uveitis, severity of 
inflammation, use of topical or local steroid therapy, and duration of uveitis with a reported 
average of 7.5 years from time of uveitis diagnosis until the eye requires cataract surgery 
(147). Cataract formation, especially in the form of  posterior subcapsular opacity, is very 
common in cases of FHC, with an incidence of 50%  (17-75%). (148,149) 
CMO is caused by cystic accumulation of intra-retinal fluid in the outer plexiform and inner 
nuclear layers of the retina due to breakdown of the BRB (150). The incidence of clinical 
CMO varies from 1-2% (151), while angiographic CMO has an incidence range of 9-
19%(152,153). In an attempt to study the impact of CMO on visual outcome using data 
from 529 patients (842 eyes), one third of the patients had history of CMO among which 
44% resulted in VA ≤ 6/18, making it one of the major causes of visual loss in uveitis 
(154). CMO is more commonly observed in cases with IU (25-70%) but can also occur in 
AU (20-26%), PU (20%) and PANU (35%) (155). 
The incidence of ERM, known also as cellophane maculopathy or macular pucker, can vary 
based on the aetiology and duration of uveitis. ERM has been reported in 30% of cases with 
pars planitis (156), 17% of patients with ocular BD (157). In a recent study on 1799 eyes 
with uveitis, ERM was the third most common cause of moderate vision loss after chronic 
CMO and macular scarring, occurring in1.39% of cases with uveitis while ERM caused 
severe vision loss in 0.1% of the eyes (147).  Vitrectomy with ERM peel in eyes with 
uveitis has been available as a management option in cases associated with significant 
vision loss but the visual outcome postsurgery is guarded.  
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1.3.1.8.2 Irreversible causes 
Irreversible causes of visual loss can occur to a lesser extent compared to cataract and 
CMO, but can have dramatic consequences on the quality of life among uveitis patients. 
Among 220 patients with uveitis, vision loss ≥ 6/18 was attributed to macular pathology 
(scarring, atrophy, hole) in 7.7% of the cases; other causes include glaucoma (5%), optic 
neuropathy (5%), and retinal detachment (3.6%) (10). Ocular hypotony may results in 
maculopathy, choroidal effusion, optic nerve swelling, irregular astigmatism and eventually 
phthisis bulbi (158).  
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1.3.2 Diabetes mellitus  
1.3.2.1 Definition and classification 
Diabetes mellitus (DM) is a group of diseases associated with various metabolic disorders 
characterised by hyperglycaemia as a result of defect in insulin secretion, function or both. 
The chronic hyperglycaemia of diabetes results in multi-organ damage, dysfunction, and 
failure, mainly affecting the eyes, kidneys, nerves, heart, and blood vessels. DM has been 
generally divided based on its aetiology into the following types (Table 1.2) (159,160). 
Table 1.2 Aetiological classification of diabetes mellitus (159,160) 
I. Type 1 DM 
 A. Autoimmune 
 B. Idiopathic 
II. Type 2 DM 
III. DM due to other specific mechanisms or diseases  
 A. Those in which specific mutations have been identified as a cause of genetic susceptibility 
  (1) Genetic abnormalities of pancreatic β-cell function 
  (2) Genetic abnormalities of insulin action 
 B. Those associated with other diseases or conditions 
  (1) Diseases of exocrine pancreas 
  (2) Endocrine diseases 
  (3) Liver disease 
  (4) Drug- or chemical-induced 
  (5) Infections 
  (6) Rare forms of immune-mediated diabetes 
  (7) Various genetic syndromes often associated with diabetes 
IV. Gestational diabetes mellitus 
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1.3.2.1.1 Type 1 diabetes  
This type accounts for only 5–10% of those with diabetes, known previously as insulin-
dependent diabetes, or juvenile-onset diabetes, caused by cell mediated autoimmune 
destruction of pancreatic β-cells. Type 1 diabetes can be either autoimmune mediated, 
characterised by the presence of auto-antibodies against islet antigens and pancreatic β-cell 
destruction, or idiopathic where patients reach an insulin-dependent status without 
identifiable auto-antibodies and in the absence of an underlying cause. Typically it presents 
early during childhood or adolescence with ketoacidosis as the first manifestation of the 
disease. Others may have moderate increase in the fasting hyperglycaemia that increase in 
severity in the presence of stressful condition such as infection.  
1.3.2.1.2 Type 2 diabetes  
Type 2 DM accounts for around 90–95% of those with diabetes, previously known as non–
insulin-dependent diabetes, or adult-onset diabetes, including those who have insulin 
resistance and relative insulin deficiency.  Obesity is commonly seen among type 2 DM 
which can increase insulin resistance and induce more hyperglycaemia. Ketoacidosis is 
rarely seen in this type of diabetes when compared with type 1 DM. However, patients with 
type 2 DM are at increased risk of developing macrovascular and microvascular 
complications (159). Risk factors for the onset of this type of diabetes include age, obesity, 
lack of physical activity, history of gestational DM, hypertension and hyperlipidemia (161–
163).  
1.3.2.2 Epidemiology 
DM is one of the world's greatest health challenges and its prevalence appears to be 
increasing. In the UK some 2.6 million people had diabetes in 2009 with a prevalence of 
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4%, among which 85% of the cases are type 2 DM (14).  Among patients with type 2 
diabetes in the United Kingdom Prospective Diabetes Study (UKPDS), 37% had 
retinopathy (164); 9% neuropathy; and 7.3% nephropathy at the time of diagnosis (165). 
1.3.2.3 Clinical features and complications 
 Patient may present initially with symptoms related to hyperglycaemia such as polyurea, 
polydipsia, weight loss, polyphagia, and blurred vision. Some patients may present with 
life-threatening complications of hyperglycaemia including ketoacidosis or the nonketotic 
hyperosmolar syndrome. Long-term complications of diabetes include microvascular 
complications such as diabetic retinopathy with high risk of visual loss(166) and 
macrovascular complications such as atherosclerotic cardiovascular, peripheral vascular 
and cerebrovascular disease (167). Other complications include nephropathy resulting in 
renal failure (168); peripheral neuropathy with risk of foot ulcers, amputations, and Charcot 
joints (169); and autonomic neuropathy causing gastrointestinal, genitourinary (170), and 
sexual dysfunction (171). 
1.3.2.4 Diagnosis 
Diagnosis of DM has advanced but the basis for all has been a timed glucose sample such 
as a fasting sample, casual sample independent of prandial status, or, a sample taken two 
hours following a standardised oral glucose load. Currently, DM is diagnosed based on the 
recommendations made by the Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus in 2003 (172). Accordingly, diagnosis of DM is made when fasting 
plasma glucose is ≥126 mg/dl (7.0 mmol/L) while normal value is defined as <110 mg/dL 
(6.1 mmol/L) and impaired fasting glucose test is for those with fasting glucose measured 
between 6.1-6.9 mmol/L. Another more recent report by the same committee agreed on 
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recommending the use of  haemoglobin A1C (HbA1c ) in the diagnosed of DM when it is 
>6.5% (173). Also, random blood glucose levels of ≥200 mg/dL (11.1 mmol/L) should be 
considered suspicious for the presence of diabetes, especially when associated with 
classical symptoms of DM.  For those with impaired fasting glucose test, the WHO 
recommended performing oral glucose tolerance test for diagnosing DM and the test is 
abnormal when plasma glucose measures ≥200 mg/dL (11.1 mmol/L) two hours following 
the administration of 75 g oral glucose (174).  
1.3.2.5 Management 
The main aim in managing patients with DM is to eliminate symptoms and to prevent or 
delay the development of complications. The risk of diabetic retinopathy and nephropathy 
can be reduced through good glycaemic control and by maintaining normal blood pressure. 
Cardiovascular and cerebrovascular complications can be reduced through treating 
hyperlipidemia and hypertension if exists, as well as smoking cessation and the use of 
aspirin. According to NICE guidelines for diabetes control, it is recommended for patients 
with DM to agree with their healthcare professional on a documented personalised HbA1c 
targer, usually between 48 mmol/mol and 58 mmol/mol (6.5% and 7.5%) (175). 
The first step in managing a patient with DM involves life style intervention such as diet 
modification, activity composition, glucose self-monitoring, and structured patient 
education with emphasis on cessation of smoking (176,177). There is still a need to initiate 
a glucose lowering agent, typically Metformin, at the initial management of those patients. 
In case of failure to achieve HbA1c < 7% or if high dose of Metformin cannot be tolerated, 
a second medication may be added, either insulin or a sulfonylurea (178,179). In type 1 
DM, insulin replacement is the main line of management (180–182) while for type 2 DM, 
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glucose-lowering agents have been used for providing glycaemic control, whether a single 
agent or combination of medication. Common glucose lowering agents used include 
biguanide (metformin) (183), sulfonylureas (e.g. glibenclamide, gliclazide, glimepiride, and 
glipizide) (184), and glinides (185). The choice of glucose-lowering agents used to achieve 
diabetes control must be tailored for each patient, based on its capacity to reduce HbA1c 
with a consideration to medication side effects, ease of use, and patient compliance.  
1.3.2.6 Diabetic retinopathy 
1.3.2.6.1 Definition and classification  
Diabetic retinopathy (DR) is an important neurovascular complication of diabetes that may 
develop into sight threatening disease with devastating visual impairment (166). The 
spectrum of DR can range from mild and moderate non-proliferative diabetic retinopathy 
(NPDR), or background DR to pre-proliferative or severe-NPDR that can advance further 
into proliferative diabetic retinopathy (PDR).  
According to the Early Treatment Diabetic Retinopathy Study (ETDRS) definitions of 
retinal lesions (186), one of the earliest features of background DR is formation of 
microaneurysms, which are the consequence of localised capillary closure with swelling of 
the adjacent patent capillaries or weakness in the capillary wall. Leakage from the 
microaneurysms results in the formation of dot haemorrhage and exudates (Figure 1.3). 
Blot haemorrhages occur as a consequence of capillary closure and deep retinal infarction 
and are localised mainly in the outer plexiform layer of the retina, unlike flame shape 
haemorrhages which localise superficially within the nerve fiber layer of the retina. Cotton 
wool spots, a non specific feature of DR, occurs secondary to obliteration of axoplasmic 
flow within the axons of the retinal nerve fiber layer (186).  
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Pre-proliferative DR is characterised by the formation of intraretinal microvascular 
anomalies (IRMA), which are tortuous microvascular abnormalities in the area of retinal 
capillary occlusion, representing dilated capillary remnants following capillary network 
closure between arterioles and venules. Venous beading represents focal areas of 
endothelial cell proliferation that failed to progress to new vessel formation seen in veins 
running through areas of extensive capillary closure (186). 
 
Figure 1.3 Diagram of the retina illustrating some of the changes associated with 
diabetic retinopathy 
 
The proliferative DR represents the stage where extensive capillary occlusion trigger 
angiogenesis and new vessel formation at the disc (NVD) or elsewhere in the retina (NVE), 
typically at the interface between perfused and ischaemic retina. These NV grow between 
the inner surface of the retina and the posterior hyaloid face of the vitreous gel leading to 
scar formation which can contract leading to elevation of the new vessels and bleeding with 
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either preretinal or subhyaloid haemorrhage, or into the vitreous gel itself resulting in 
vitreous haemorrhage (VH). The same scars secondary to NV formation can contract and 
pull the vitreous away from the retina and occasionally are complicated with tractional 
retinal detachment. Extensive retinal ischaemia may also lead to iris neovascularisation 
(NVI) resulting in neovascular glaucoma. Diabetic papillopathy may occur in diabetic 
patients independent of the DR status. It is associated with reduced visual acuity without 
causing severe vision loss, and would require to be differentiated from ischaemic optic 
neuropathy and NVD (186). 
Diabetic maculopathy could be in the form of focal or diffuse diabetic macular oedema 
(DMO) that can progress into clinically significant macular oedema (CSMO), or macular 
ischaemia, or a mixture of all of these. The DMO could be focal, when the retinal 
thickening and exudates is secondary to leakage from isolated or clusters of 
microaneurysm, or diffuse oedema secondary to widespread leakage from retinal 
capillaries. DMO may also occur secondary to RPE dysfunction and ischaemia, which 
damage the outer BRB and result in accumulation of exudative fluid (extracellular oedema) 
or secondary to hypoxia causing fluid accumulation within retinal cells (intracellular 
oedema). 
Table 1.3 gives the English and  nternational clinical classification of DR and CSMO 
adopted by the Royal College of Ophthalmologists and the American Academy of 
Ophthalmology based on the ETDRS definitions of retinal lesions (187,188). In the UK, the 
National Screening Committee (NSC) have used this classification in the Diabetic Eye 
Screening Programme which provides annual screening with digital fundus photography to 
all diabetic patients age 12 years or older. Once a potentially sight-threatening retinopathy 
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is suspected, a referral is made to a tertiary eye clinic for further assessment and 
management according to a specified time frame (189). 
Table 1.3 The English Diabetic Eye Screening Programme grading classification 
(189,190) 
NSC* Term Retinal features  
R0 No retinopathy 
No retinal changes 
Isolated cotton wool spots in the absence of any 
microaneurysm or haemorrhage 
R1 
Background* 
(Mild-Moderate NPDR) ** 
Haemorrhages & microaneurysms , venous 
loop, any exudates, any number of cotton wool 
spots 
R2 
Pre-proliferative* 
(Severe NPDR ) ** 
 
Any of the following: 
Multiple intraretinal haemorrhages  
Definite venous beading in two or more 
quadrants 
Prominent  intraretinal microvascular 
abnormalities (IRMA)   
R3 proliferative retinopathy 
R3a ( Active PDR)  
NVD 
NVE 
Vitreous/pre retinal haemorrhage 
Pre retinal fibrosis +/- tractional retinal 
detachment  
R3s  (Stable post-treatment) 
Evidence of peripheral retinal laser treatment 
and stable retina from photograph taken at or 
shortly after discharge from the hospital eye 
service 
M0 No maculopathy No maculopathy 
M1 Diabetic Maculopathy 
Clinically significant macular oedema (CSMO) 
is diagnosed in the presence of one of the 
following: 
Retinal oedema within 500 µm (one third of a 
disc diameter) of the fovea 
Hard exudates within 500 µm of the fovea  
Retinal oedema that is one disc diameter (1500 
µm) or larger, any part of which is within one 
disc diameter of the fovea. 
P0 No photocoagulation No photocoagulation 
P1 
Previous 
photocoagulation  
(focal/grid to macula or peripheral scatter) 
U Unclassifiable  An image set that is inadequate for grading 
* UK Diabetic Eye Screening Program   ** American Academy of Ophthalmology classification. 
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1.3.2.6.2 Epidemiology 
Internationally, there are around 93 million people with DR, 17 million with proliferative 
diabetic retinopathy, 21 million with diabetic macular oedema and 28 million with vision-
threatening diabetic retinopathy globally (191). The overall prevalence of retinopathy in 
diabetes is 38%, and 85-90% of all diabetic patients have some manifestations of 
retinopathy after 25 years of DM (166). But the Wisconsin epidemiological study of DR 
(WESDR) has documented a higher rate in those with earlier age of onset of type I 
diabetes, approaching 98% after 15 years of disease (192).  
 
1.3.2.6.3 Risk factors 
The duration of diabetes is one of the most important risk factors for the development of 
retinopathy. Other risk factors, such as poor metabolic control, hypertension, high blood 
cholesterol, nephropathy, age, sex, smoking, and genetic disposition are other factors that 
may play a role in the development of DR but the exact mechanism is not fully understood 
(193). 
1.3.2.6.4 Pathophysiology of diabetic retinopathy 
1.3.2.6.4.1 Histological changes in early stages of diabetic retinopathy 
The pathogenesis behind the development of DR has been attributed to many factors. A 
persistent increase in blood glucose levels shunts excess glucose into the aldose reductase 
pathway in certain tissues, which converts sugars into alcohol (eg, glucose into sorbitol, 
galactose to dulcitol). Intramural pericytes of retinal capillaries seem to be affected by this 
increased level of sorbitol, eventually leading to the loss of its ability to auto-regulate 
retinal capillaries. Loss of function of pericytes results in weakness and eventual out-
pouching of capillary walls (microaneurysms). In addition, capillary occlusion and 
degeneration represent reduced retinal perfusion. Possible mechanisms leading to the 
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degeneration of retinal capillaries in diabetes include vascular lumen obliteration by 
leukocytes or platelets, capillary cells apoptosis secondary to biochemical abnormalities, or 
secondary to products generated by other cells such as neurons or glial cells. 
1.3.2.6.4.2 Increased vascular permeability and Late stage diabetic retinopathy 
Increased permeability of capillary vessels results in leakage of fluid and proteinaceous 
material, which clinically appears as retinal thickening and exudates. The swelling and 
exudation may involve the macula leading to macular oedema and a reduction in central 
vision.  As the disease progresses, thickening in the capillary artery basement membrane 
occur causing capillary occlusion and poor retinal perfusion. Infarction of the nerve fibre 
layer leads to the formation of cotton-wool spots with associated stasis in axoplasmic flow. 
Further increases in retinal ischaemia trigger the production of vasoproliferative factors that 
stimulate new vessel formation. These new blood vessels initially are associated with a 
small amount of fibroglial tissue formation. However, as the density of the neovascular 
frond increases, so does the degree of fibrous tissue formation. In later stages, the vessels 
may regress leaving only networks of avascular fibrous tissue adherent to both the retina 
and the posterior hyaloid face. As the vitreous contracts, it may exert tractional forces on 
the retina via these fibroglial connections, with a subsequent formation of retinal tear and 
detachment. 
1.3.2.6.4.3 Neurodegenerative changes in diabetic retinopathy 
Loss of ganglion cells has been detected in diabetic rats(194,195) and humans (196).  The 
loss of neuronal cells can be found at the early months from the onset of diabetes and can 
precede the development of vascular changes but whether it play a role in its development 
is still under investigation (196).  
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1.3.2.6.4.4 Role of inflammation in diabetic retinopathy 
There is more evidence now supporting the role of inflammatory cells, cytokines and other 
inflammatory products in the development of DR (197–199). An animal study showed 
retinal capillary occlusions by leukocytes, mainly monocytes, endothelial cell damage, 
extravascular macrophage accumulation, and areas of NV at the sites of extravascular 
leukocytes accumulation (200). The possible role of inflammation in the development of 
capillary degeneration and early diabetic retinopathy is demonstrated in Figure 1.4. The 
high glucose result in the release of advanced gycation end products (AGEs), AGEs, 
together with other factors such as oxidative stress and aldose reductase result in the release 
of nuclear factor kappa beta (NF-κB). The latter is a transcription factor that regulates many 
genes involved in inflammatory and immune responses, proliferation and apoptosis. NF-κB 
was found to be activated in retinal endothelial cells or pericytes when subjected to high 
glucose levels (201,202). NF-κB increases expression of intracellular adhesion molecules 
(ICAM) in the endothelium of retinal vessels of animals and humans. The ICAM interact 
with the CD18 adhesion molecule on monocytes and neutrophils, resulting in increase in 
leukocyte aggregation within retinal blood vessels in diabetes (203). Furthermore, NF-κB 
activation leads to the expression of cyclooxygenase (COX). COX-2 rather than COX-1 is 
mainly involved in the production of prostaglandin-E2 (PGE2) and VEGF in the retina of 
diabetic rats (204,205). VEGF is produced by many retinal cells, such as ganglion cells, 
Müller cells, and pericytes in response to retinal hypoxia and COM-2 production in patients 
with diabetes. VEGF has an important role in retinal NV and increased vascular 
permeability (206). Other growth factors that play a role in the pathogenesis of DR include 
insulin-like growth factors I and II (207), transforming growth factor β (208), and high ratio 
of VEGF to pigment epithelium-derived factor (PEDF) (209,210). Cytokines also play a 
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role in the early development of DR. A study on a group of cytokines (IL-1,4,2,6,10; TNF, 
IFNγ) found the cytokines related to Th-1 group, namely IL-2 and IFNγ, to be present at 
high levels in the retina of experimental diabetic rats (211). Other studies were also able to 
detect elevated levels of IL-8 and IL-6 in the vitreous and aqueous humor of patients with 
DM  (212,213). More recently, high concentration of IL-12 have also been detected in the 
aqueous humor of patients with non-treated DR compared with healthy control group in the 
absence of similar difference in the serum level of IL-12 between both groups, suggesting 
an increase in the production and/or secretion of IL-12 in the eyes of patients with DR 
(214). 
  
  
  
     
 
   
 
 
1.3.2.6.5 Management of diabetic retinopathy 
1.3.2.6.5.1 Management of modifiable risk factors 
An important aspect in managing DR includes proper glycaemic control which helps in 
reducing the incidence of DR and its progression (215). Guidelines  for establishing goals 
for diabetes control were set mainly by the Diabetes Control and Complications Trial 
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Figure 1.4 Role of inflammation in the development of capillary degeneration and early 
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(DCCT) for type 1 DM (216), and the UKPDS for type 2 DM (217,218).  The goal is to 
maintain blood glucose at near-normal levels (fasting glucose level of 5.0 to 7.2 mmol/L 
and HbA1c levels between 48-58mmol/mol (6.5-7.5%), together with maintaining normal 
blood pressure and serum lipid. Aggressive glucose lowering may not be advised in some 
cases with established cardiovascular events and among older age group(219). Meanwhile, 
tight glucose control had a better effect in reducing the risk of microvascular complications, 
including diabetic retinopathy, with less effect on preventing macrovascular complications 
(220,221).  In case of type 1 diabetes, the DCCT research showed that each 1% decrease in 
HbA1c reduces the risk of DR by 39% (222). In type 2 DM, the UKPDS found a 25% 
reduction in the risk of microvascular complications for every 1% decline in HbA1c (223). 
While the blood pressure control has a little influence in altering the course of DR among 
normotensive patients, it can be of importance in reducing visual loss secondary to DR 
among hypertensive patients with diabetes. The UKPDS showed that each 10 mmHg 
decrease in systolic blood pressure reduces the risk of microvascular complications by 
13%, independent of glycaemic control (224). The benefit of blood pressure treatment in 
normotensive diabetic patients is less clear. The effect of controlling blood lipid levels in 
reducing the risk of retinopathy is supported by the finding of the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study which demonstrate reduced risk of DR 
progression by about a 40% over 4 years following the use of lipid therapy with fenofibrate 
and simvastatin (225). Similarly, the Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) study showed a significant effect of fenofibrate in reducing the need for 
laser photocoagulation (226). In both the FIELD and ACCORD-Eye studies, no 
relationship was found between the lipid effects of fenofibrate and the appearance or 
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progression of DR. Thus, the beneficial effects of fenofibrate on DR are unrelated to 
quantitative change in serum lipid level.  
1.3.2.6.5.2 Retinal laser photocoagulation 
The main principle of applying retinal laser photocoagulation in DR is to induce thermal 
destruction of RPE cells and its adjacent photoreceptor, thus reducing the production of 
VEGF and its angiogenesis effect and regression of the NV (227). The retina contain three 
main pigmented substances with variable light wavelengths’ absorbtion capacity; these 
include the xanthophylls (420-500 nm) within the neurosensory layer, melanin (400-1000 
nm) within the RPE cells and choroidal melanocytes, and hemoglobin (450 to 550 nm) 
within red blood cells within the blood vessels or within areas of blood leakage (228). The 
melanin and haemoglobin both can absorb the green (495-570 nm) and yellow (570-590 
nm) laser wavelengths, making them ideal for use in photocoagulation of macular 
disorders. The green wavelength laser can be produced by argon laser (514.5 nm), Krypton 
laser (530.9 nm) diode and PASCAL frequency-doubled Yttrium Aluminum Garnet (YAG) 
laser (532nm), while the yellow wavelength, which has the advantage of using less power 
and better absorbtion by the haemoglobin, can be provided by krypton laser (568 nm) as 
well as dye and diode laser (577 nm). So far there has been no proven superiority of yellow 
focal/grid laser treatment over the traditional green laser therapy in managing CSMO (228). 
The more recent laser technologies include subthreshold diode-laser micropulse technology 
works within the infrared spectrum of light (810nm) and is designed to deliver repeated 
laser shots for about 0.1-0.3 seconds separated by intervals of 1.7 to 1.9 seconds, allowing 
for heat dissipation and hence prevent collateral damage and localise the photothermal 
effect to the targeted RPE with little intraretinal damage or ophthalmologically visible 
scarring during or after treatment. A recent randomised trial found a better improvement in 
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visual acuity in eyes treated with the high density micropulse laser (0.25LogMAR) 
compare to modified ETDRS laser (0.08LogMAR) and no improvement with the normal 
density micropulse laser (0.03LogMAR) (229). 
Panretinal photocoagulation (PRP) can be carried out in a single or multiple sessions of 
laser application, starting initially with about 2000 burns of 500 μm spot size, or more with 
smaller burn size. Retreatment can be performed if necessary within one to three months of 
initial laser treatment. Macular laser photocoagulation reduces central macular thickness 
and improves the vision in eyes with CSMO as shown in the ETDRS study where macular 
laser therapy reduced the risk of moderate vision loss from 24% to 12% over 3 years follow 
up period (230). The laser application in the ETDRS study was performed as follows; 1) 
Focal treatment of microaneuysms and other sites of focal leakage with a 50 -100μm spot 
size to obtain definite whitening around the area of leakage. 2) Diffuse leakage and areas of 
capillary closure (that were not contiguous with the foveal avascular zone) within two discs 
diameters of the centre were treated in a grid fashion using spot sizes of 50 - 200μm, a 
space of 1 burn width apart. 3) Lesions within 500μm of fovea were not treated initially but 
treatment was allowed to within 300μm of the fovea on repeated sessions, as needed (230). 
The long term efficacy of macular laser therapy has also been studied through the diabetic 
retinopathy clinical trial research network (DRCR.net) which compared the IVTA therapy 
against traditional laser therapy in the management of CSMO (231). In the DRCR trial 
group, a modified ETDRS focal green laser treatment was performed as follows: 1) All 
leaking microaneurysms 500 to 3000μm from fovea treated directly with 50μm spot size, 
duration 0.05 - 0.1s. 2) Direct whitening of the micronaneurysm was not required, but a 
greyish reaction beneath the microaneurysm was needed. Grid treatment was performed to 
areas of retinal thickening.  3) Grid was performed from 500 to 3000μm superiorly and 
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inferiorly and to 3500μm temporally. The spots were 2 burn widths apart and no burns were 
performed within 500μm of the disc.  Possible complications that can be associated with 
macular grid laser therapy include paracentral scotoma and colour vision impairment, 
accidental foveal photocoagulation, subfoveal fibrosis, hard exudates, and CNVM at area of 
laser scar (232). 
1.3.2.6.5.3 Intravitreal anti-VEGF therapy 
While initially the focal/grid laser photocoagulation used to be the main standard of care in 
managing DMO, the use of repeated intravitreal injection of anti-VEGF has the potential to 
revolutionise the treatment strategy for DMO and can provide additional benefit over the 
use of focal/grid laser treatment in reducing central retinal thickness and improving vision 
(233). The latest guidelines from the National Institute for health and Clinical Excellence 
(NICE) recommend the use of ranibizumab in treating visual impairment secondary to 
DMO with central retinal thickness of 400μm or more at the start of the treatment. For 
those who currently receiving ranibizumab for treating visual impairment due to DMO and 
didn’t meet the above criteria, the NICE still recommend them to continue with the 
treatment until it is stopped according to clinical response (234). The Safety and Efficacy of 
Ranibizumab in Diabetic Macular Edema (RESOLVE) trial found a significant 
improvement in vision by a mean of 10 letters and gained ≥10 letters in 60% of eyes treated 
with repeated ranibizumab of the cases compare to the sham group (235). In the 
Ranibizumab Monotherapy or Combined With Laser vs Laser Monotherapy for Diabetic 
Macular Edema (RESTORE) trial, 345 eyes with DMO were randomised into receiving 
either ranibizumab alone, ranibizumab with macular laser therapy, or laser therapy alone. 
By one year, there was an improvement in vision by about six letters in both groups 
receiving ranibizumab compare to an average of one letter gained in eyes treated with laser 
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alone (236). An extension of the RESTORE study observed the outcome of the three 
treatment groups for a further two years. By the third year of follow-up, eyes treated with 
ranibizumab were able to maintain the gain they had in their vision over the first year, 
while the group with previous laser treatment managed to further gain vision from baseline 
from a mean of 2.3 letters gain at the first year to six letters gain by the third year of follow-
up (237). 
Despite the advantages of ranibizumab intravitreal injection in managing DMO, it can still 
be insufficient alone as an ultimate treatment option. This was observed in the RISE 
(Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center 
Involvement Secondary to Diabetes Mellitus) and RIDE (Ranibizumab Injection in 
Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to 
Diabetes Mellitus) trials which found 30.4% and 43.2% of patients received 0.3 or 0.5 mg 
intravitreal ranibizumab still failed to have improvement in vision after 3 years of treatment 
(238). Also the DRCR.net study, failure to gain ≥10 letters was observed after 3 years 
follow up period in 57.6% of patients treated with combined ranibizumab and prompt laser 
group and in 44.2% of patients on ranibizumab and deferred laser (≥24 weeks) group and 
there was vision loss of ≥15 letters in 6% and 3%, respectively (239). For this reason, 
further development of treatment strategies is still required when managing cases with 
DMO.  
While ranibizumab is the main anti-VEGF licensed for use in eyes with DMO, other anti-
VEGF therapies have also been used as an off-label treatment in selected cases. 
Bevacizumab has a similar mechanism of action to ranibizumab but is much cheaper and 
has shown potential benefit in managing DMO as well as in managing vasoproliferative 
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complications associated with proliferative DR. The prospective randomised BOLT trial of 
intravitreal bevacizumab or laser therapy in the management of DMO compared these two 
treatment methods over two years. Patients within the bevacizumab group gained ≥10 
letters in 49% of cases and gained ≥15 letters in 32% of cases compare to 7% and 4% of the 
laser group, respectively (240,241).  
Pegaptanib is another anti-VEGF that has been used in the management of DMO when 
given at a dose of 0.3mg intravitreal injection given every six weeks. A multicentre 
randomised trial found 36.8% of the patients from the pegaptanib group experienced an 
improvement in vision by ≥10 letters over two years follow-up compared to only 19.7% 
from the sham group (242).  
Aflibercept is administered as a single 2mg intravitreal injection that can be given every 
month for five consecuative months then every two months onward up to one year before 
the interval is changed based on clinical response. Aflibercept has been recently 
recommended by the NICE guidelines as a treatment option for eyes with DMO and central 
retinal thickness of 400μm or more at start of treatment (243).  The initial report from the 
da Vinci multicentre study compared the use of intravitreal aflibercept given in four 
different doses and/or interval periods in comparison to macular laser photocoagulation 
(244). Over the first year, the maximum improvement in vision by ≥15 letters was observed 
in eyes receiving 2mg intravitreal aflibercept every 4 weeks (45%) compared to other 
treatment protocols and compared to those received macular laser treatment (11.4%) (244). 
A more recent randomised phase 3 trial comparing intravitreal aflibercept to macular laser 
therapy among 872 patients found a significant superiority of aflibercept given in 2mg dose 
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every 4 weeks or every 8 weeks (following 5 initial monthly doses) in comparison to the 
macular laser therapy over a one year follow-up period (245).  
The Protocol-T multicentre study by the DRCR network compared the effect of all three 
anti-VEGF intravitreal injection; aflibercept, bevacizumab, ranibizumab in managing 
DMO. Patients were randomized to receive one of these therapies every 4 weeks. After one 
year, aflibercept group had an overall better vision outcome, with the mean visual acuity 
letter score improving by 13.3, vs. 9.7 with bevacizumab and 11.2 with ranibizumab, and 
this was mainly observed in eyes with worse visual acuity at baseline (246).  
1.3.2.6.5.4 Intravitreal steroids 
Intravitreal injection of steroids has been used in the management of CSMO aiming to 
reduce capillary permeability and intraretinal fluid accumulation, together with controlling 
cytokine formation and inflammatory mediated reaction. Intravitreal dexamethasone, 
fluocinolone acetonide and TA have been licensed for the management DMO. Managing 
DMO with focal/grid laser treatment has been shown to be more effective when compared 
to the use of IVTA as suggested by the results of the DRCR.net group randomised trial on 
eyes with DMO. In this study, there was initial improvement in the visual outcome among 
eyes treated with 4mg IVTA compared to both the 1mg IVTA and the focal/grid laser 
groups. However, no significant difference in the visual outcome existed between the three 
groups after one year follow-up. However, by the end of two years follow-up the focal/grid 
laser photocoagulation group had a better visual outcome and fewer side effect profile 
when compared to those receiving IVTA (247). 
The dexamethazone implant (Ozurdex®) has shown effectiveness in managing DMO as 
shown in the outcomes of Dexamethasone DDS Phase II Study which found an 
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improvement in vision by ≥10 letters in about one third of eyes following the 
administration of 0.7 mg dexamethasone implant. This was also associated with a 
significant reduction in the central retinal thickness and FFA leakage, making the 
dexamethasone implant a recommended treatment option in managing persistent DMO 
(248). The safety and efficacy of dexamethasone implant in combination with laser 
focal/grid photocoagulation was addressed in the PLACID study.  Within the first nine 
months of the study, there was a significant improvement in vision among eyes receiving 
the combined dexamethasone implant and laser therapy compared to the group receiving 
laser therapy alone, although this advantage became less apparent by the end of the one 
year follow-up period (249). The efficacy and long term safety of dexamethasone implant 
was further studied through the MEAD group who conducted a randomised, multicentre, 
phase III clinical trial including 1048 patients with DMO divided into three groups to 
receive either 0.7 mg implant, 0.35 mg implant, or sham procedure. After 3 years of follow-
up, a significant proportion of patients on 0.7mg (22%) and 0.35mg (18.4%) implants did 
achieve 15 letters improvement compared to the sham group (12%). The average reduction 
in central retinal thickness was considerably greater in eyes that received dexamethasone 
implant compared to the sham group. By the end of the follow-up period, adverse effects in 
the form of cataract formation was observed in about 68% of eyes with the 0.7mg 
dexamethasone implant compared to 64% in the 0.35mg group and 20.4% for the sham 
group. Only two patients (0.6%) with the 0.7mg dexamethasone implant required 
trabeculectomy for managing glaucoma (250). Based on these results, the NICE guidelines 
in UK recommend the use of dexamethasone intravitreal implant as a treatment option for 
managing DMO only if the oedema does not respond to non-corticosteroid therapy, or such 
treatment is unsuitable, and that the implant is to be used only in pseudophakic eyes (251). 
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Fluocinolone acetonide intravitreal implant (Iluvien) is a non-erodible implant which 
contains fluocinolone acetonide at a dose of 190 µg and can be injected into the vitreous 
using a preloaded needle device. Once in the vitreous, the medication is released at a rate of 
0.2 µg /day and continues to be released at a steady rate for up to 36 months post injection. 
Its effectiveness over at least 3 years post injection had been examined by the Fluocinolone 
Acetonide in Diabetic Macular Edema (FAME) study group which found 28% of patients 
with DMO successfully gained ≥15 letters compared to only 19% of patients on sham 
intervention. Cataract is the main side effect associated with fluocinolone acetonide 
implant, with almost all phakic patients developing cataract by the end of the FAME study 
period. Meanwhile, increased IOP and secondary glaucoma is an additional risk factor, with 
4.8% of the patients requiring glaucoma surgery by the third year following fluocinolone 
acetonide intravitreal injection (252).  The effectiveness of the implant is even more 
prominent in eyes with chronic DMO (duration of diagnosis ≥3 years) who failed to 
respond to at least one session of macular laser therapy. The FAME study showed that 
patients with chronic DMO had a greater percentage with improved vision by ≥15 letters 
while on 0.2 µg /day of intravitreal fluocinolone acetonide compare to the sham group 
(34% versus 13.4%), whereas no significant difference was observed between patients with 
non chronic DMO receiving the implant compare to the sham group (22.3% versus 
27.8%).(253) The findings of the FAME clinical trials and other related research formed 
the base for the UK NICE guidelines which recommended the use of fluocinolone 
acetonide intravitreal implant as a treatment option for managing chronic DMO only if they 
showed insufficient response to other available therapy and that the implant is to be used 
only in psedophakic eyes (254). However, a recent study from the FAME group found the 
long term outcomes were not worse in eyes with DMO that had cataract surgery after 
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receiving 0.2 µg/day of fluocinolone acetonide implant compared to pseudophakic eyes 
receiving the implant (255).  
1.3.3 Retinal vasculitis 
1.3.3.1 Blood retinal barrier and the blood supply of the retina  
The retina is composed of the outer pigmented layer, the retinal pigmented epithelium 
(RPE), and an inner neurosensory layer. The latter is subdivided further into nine layers 
arranged from the inside out as follows; internal limiting membrane,  nerve fibre layer, 
ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer 
nuclear layer, external limiting membrane and photoreceptor layer. The posterior pole of 
the retina is vulnerable to develop oedema due to a high cell count, increased metabolic 
activity, shifting of Henle’s fibre layer away from central fovea, thin and loose connection 
of inner connecting fibres in the outer plexiform layer leaving a large reservoir for the 
accumulation of extravascular fluid, and finally the central avascular zone creating a 
watershed arrangement between the choroidal and retinal circulation, thus decreasing 
resorption of extracellular fluid. On the other hand, variable mechanisms prevent an 
accumulation of extracellular intraretinal fluid and proteins in the retina; these include 
osmotic forces, hydrostatic forces, capillary permeability and tissue compliance. These 
mechanisms provide a balance between the rate of capillary filtration and the rate of fluid 
removal from the extracellular retinal tissue.  To maintain this physiological balance, an 
intact BRB formed by intercellular junctions is required to separate blood from surrounding 
retinal tissues, and to regulate the transfer of ions, cells and protein, in addition to leukocyte 
extravasation during inflammation. In the inner retinal circulation, the inner BRB is formed 
by tight junctions (zonulae occludentes). Intercellular communication is realised by 
adherens junctions (zonulae adherentes) and gap junctions (maculae communicantes), 
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joining the endothelium of retinal capillaries.  In the outer retinal circulation, the tight 
junctions between the RPE cells maintain the outer BRB as well as adherent junctions and 
desmosomes (maculae adherentes). Movement of fluid from the vitreous into the subretinal 
space is limited by the external limiting membrane, formed by the zonulae adherents 
between photoreceptors and Müller cells. But, this junction is less tight than the zonulae 
occludentes of the RPE and retinal capillaries. As a consequence, they can only partially 
limit the movement of large molecules such as fluoresceinated albumin from subretinal 
space to the vitreous cavity and vice versa. On the other hand, the internal limiting 
membrane may have no significant role in preventing water movement but may keep large 
molecules such as proteins in the retina, maintaining osmotic movements. Any pathological 
conditions leading to a breakdown of the BRB can result in the retention of proteins within 
the retinal tissue, leading to water retention by osmosis and the development of DMO 
(256). 
The central retinal artery is the first branch of the ophthalmic artery entering the eye 
through the lamina cribrosa. Soon after entering the globe, it splits into four branches, 
superior and inferior nasal and temporal branches, each supplying one quadrant of the 
retina. Sometimes, a cilioretinal artery, branching from the ciliary circulation, supplies part 
of the inner retina between optic nerve and the centre of the macula.  At the tissue level, the 
inner two third of the retina is supplied by two layers of capillaries, one superficial in the 
ganglion and nerve fiber layer, and one deeper in the inner nuclear layer. The outer one 
third of the retina beyond the inner nuclear layer is avascular and receives its oxygen and 
nutrition from the choriocapillaries made of a fenestrated capillary system of the choroidal 
arteries that branch from the ciliary arteries, supplying 95% of the oxygen used in the 
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fundus.  Blood collected from the capillaries accumulates within a branch retinal vein that 
ends in the central retinal vein (257). 
1.3.3.2 Definition and Clinical presentation of retinal vasculitis 
The definition of retinal vasculitis has been a controversial topic. The SUN working group 
in 2004 considered the eye to have retinal vasculitis in the presence of  perivascular 
sheathing and vascular leakage or occlusion on FFA as evidence of retinal vascular 
disease(19).  Clinically, patients with retinal vasculitis may be asymptomatic or present 
with blurred vision and floaters associated with IU, PU and PANU.  Reduced visual acuity 
in retinal vasculitis might occur due to combined factors including severe vitritis, optic 
neuritis, ERM and CMO. In one study, vascular sheathing was observed in 85% of the eyes 
with vasculitis in the absence of cotton wool spots and intraretinal haemorrhage. Combined 
vascular sheathing and intraretinal haemorrhage occurred in 11% of cases while vascular 
sheathing combined with cotton wool spots were only observed in 4% of cases. The same 
study found ERM to be more common in association with cotton wool spots and 
intraretinal haemorrhage compared to those with vascular sheathing (258). In eyes with 
retinal ischaemia, vision loss can also occur secondary to macular ischaemia or due to the 
complications of NV such as vitreous haemorrhage, tractional retinal detachment and 
neovascular glaucoma. 
1.3.3.3 Pathophysiology   
Based on histological studies, vascular changes in uveitis are characterised by perivascular 
infiltration of lymphocytes resulting in perivasculitis rather than a true vasculitis of the 
vessel wall (259,260). Cell-mediated immunity also plays a role in the pathology of retinal 
vasculitis, with CD4+ T cells documented within and around the retinal vessels. The 
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pathogenesis of ischaemia in retinal vasculitis is not clear but is suggested to be either 
thrombotic or obliterative secondary to the infiltration of inflammatory cells. Thrombotic 
vascular changes can occur due to local endothelial injury or increased prothrombin activity 
as observed in BD (261). The retina has a uniquely high metabolic demand for oxygen that 
is normally met by a highly efficient vascular supply. Insufficiency of the retinal circulation 
causes neuroretinal dysfunction and degeneration. Focal retinal ischaemia results in 
selective damage to specific subpopulations of retinal neurons and can result in cellular 
death by apoptosis or necrosis with dysfunction and degeneration of the inner retina and 
eventually visual loss. Retinal vascular obstruction can also promote the production of 
VEGF (Figure 1.5) which increases vascular permeability and results in macular oedema 
and induce new vessels formation (262). These fragile new vessels bleed easily resulting in 
VH, fibrovascular proliferation and subsequent tractional retinal detachment. 
1.3.3.4 Classification and aetiology of retinal vasculitis 
Retinal vasculitis is a sight-threatening inflammatory condition, occurring in approximately 
one in every eight eyes with uveitis (263). Based on the aetiology, retinal vasculitis may be 
classified as either idiopathic or secondary to infection, neoplasia or a systemic 
inflammatory disease (264,265).  Retinal vasculitis can be classified either as idiopathic, 
when there is no associated systemic disease, or secondary vasculitis in the presence of 
other systemic conditions, the most common being BD, collagen vascular disease  and 
systemic granulomatous diseases (sarcoidosis and TB).(266) 
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Figure 1.5 Diagram showing the pathophysiology of vascular leakage and 
neovascularisation secondary to retinal ischaemia. VEGF = vascular endothelial 
growth factor. 
 
In a cohort study involving 1390 patients with uveitis, 15% had retinal vasculitis as part of 
their uveitic manifestations (263). Secondary vasculitis can also be subdivided into 
infectious and non-infectious vasculitis. Infectious retinal vasculitis is commonly unilateral 
characterised by intraocular inflammation associated with arteritis and retinal infiltrates as 
seen in herpes related retinitis. Direct infection of retinal vessels has only been reported in 
cases of CMV and Bartonella infection (267,268). Other infectious causes of vasculitis 
include TB related uveitis, syphilis, Lyme disease, and human T-cell lymphotropic virus 
type-1 (265). Retinal vasculitis can also be classified based on the vessel involved, whether 
arteries, veins, capillaries or all. A study including 1,254 eyes with uveitis, 85 (6.8%) were 
associated with retinal vasculitis; among these, 58.8% involved both arteries and veins, 
36.5%  were periphlebitis while only 4.7% had isolated periarteritis (266). In another study 
by Ali et al on 101 eye with vasculitis, the inflammation mainly involved retinal veins in 
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43% while arterial involvement were seen in only 2% and the remaining cases had mixed 
arterial and venous involvement (258). Common diseases presenting with periphlebitis 
include pars planitis, sarcoidosis, MS, and idiopathic retinal vasculitis. Both retinal arteries 
and veins can be involved in BD  but there is more chance of it involving the veins 
compared to the arteries (265). The third classification of vasculitis divides cases based on 
the FFA findings into ischaemic and non-ischaemic vasculitis (Table 1.4) (265,269).    
Table 1.4 Cause of retinal vasculitis according to the type of vessels involved and 
association with retinal ischaemia 
 
Mainly involve arteries Mainly involve veins 
Associated with retinal 
ischaemia 
Infectious 
disorders 
Acute retinal necrosis 
Toxoplasmosis 
Cat scratch disease 
West Nile virus 
 
Tuberculous 
hypersensitivity  
Syphilis 
CMV 
HIV 
Rift Valley fever virus 
HTLV-1 
Tuberculous 
hypersensitivity  
West Nile virus 
 
 
 
 
Non-
infectious  
disorders 
SLE 
APHA 
Takayasu’s disease 
IRVAN 
GPA 
Churg-Strauss syndrome 
Crohn’s disease 
Polyarteritis nodosa 
Susac syndrome 
Dermatomyositis 
 
 
Behçet’s disease 
Sarcoidosis 
Multiple sclerosis 
Birdshot chorioretinopathy 
APMPPE  
Parsplanitis 
HLAB27 associated 
uveitis 
 
Behçet’s disease 
Sarcoidosis 
Multiple sclerosis 
SLE 
APS 
Takayasu’s disease 
IRVAN 
GPA 
Dermatomyositis 
Churg-Strauss syndrome 
Crohn’s disease 
Polyarteritis nodosa 
Susac syndrome 
Idiopathic retinal vasculitis 
SLE= Systemic Lopus erythematosus, APHA = Antiphospholipid Antibody syndrome, IRVAN= Idiopathic retinal vasculitis, arteriolar 
macro aneurysms and neuroretinitis, CMV= Cytomegalovirus, HIV= Human immunodeficiency virus , HTLV-1= human T-cell 
lymphoma virus type 1, APMPPE =Acute posterior multifocal placoid pigment epitheliopathy . GPA= granulomatosis with polyangiitis. 
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1.3.3.4.1  Behçet's Disease 
BD is a chronic, relapsing multi-systemic inflammation of the blood vessels of all sizes 
characterised by oral and genital mucous ulcerations, skin lesions, and uveitis (270). BD 
affects young patients aged between 20 and 40 years with more prevalence in male gender 
within the Eastern Mediterranean region and in female gender within Northern 
Europe(271). The incidence of ocular involvement in BD is high that can reach up to 80% 
of patients with BD (272) and thus ocular involvement had been one of the key features 
within the scoring system that guide toward the diagnosis of BD (273). Uveitis is often the 
dominant manifestation of this disease and occurs mainly in the form of chronic, episodic 
PANU that is characteristically bilateral and associated with hypopyon affecting 20 % of 
patients. Other ocular manifestations include PU, retinal vasculitis, retinal vein or artery 
occlusions with sight threatening complications such as optic neuritis, macular ischaemia 
and NV formation (274).  
Retinal vasculitis in ocular BD most commonly manifests as vitritis with diffuse vascular 
leakage on FFA due to inflammatory hyperpermeability. This may be accompanied by 
capillary nonperfusion secondary to occlusive vasculitis resulting in NV. Both retinal 
arteries and veins can be involved in BD though venous involvement is more common 
(265). BRVO with intraretinal hemorrhages and CMO are frequently seen and these are 
often central in the retina with a high risk of significant visual loss (Figure 1.6). BRVO and 
ischaemic retinal vasculitis have been reported as the first presentation of ocular BD in 28% 
and 21%, respectively, while central vein (4%) and artery (1%) occlusions are less common 
presentations (275). Macular ischaemia, a predictor of poor visual outcome, has also been 
reported in cases with BD. In a recent retrospective study of 120 eyes of patients with BD, 
macular ischaemia was seen in one eye (0.8%) at initial visit, while three eyes (2.5%) 
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developed ischaemia during a mean follow up period of 22 months (276). NV is a serious 
complication observed by one study in 4% of 1567 eyes with Behçet's uveitis (157), and a 
multicentre study reported an incidence rate of 0.12 to 0.17 per person per year (277). NV 
in BD can be secondary to inflammation and regress in response to IMT therapy or present 
as an early complication of Behçet’s uveitis even in the absence of retinal ischaemia (278). 
 
Figure 1.6 Fundus photographs of branch retinal vein occlusion secondary to Behçet's 
disease.  
(A, B) Colour images of the right eye showing vascular sheathing (white long arrow), 
exudates ( black star) and intraretinal haemorrhages (black arrow). (C) Fluorescein 
angiography demonstrates multiple areas of hypofluorescence (white arrow) 
corresponding to areas of retinal haemorrhage and (D) upper retinal quadrant 
hypoperfusion secondary to vasoocclusion (white star). 
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1.3.3.4.2 Sarcoidosis 
Sarcoidosis is a chronic granulomatous disease affecting multiple organs, with ocular 
involvement in 25-60% of patients, mainly manifesting as uveitis (30–70%) and 
conjunctival nodules (40%) (279,280). The anterior chamber is most commonly affected, 
with up to 66 % of patients with ocular sarcoidosis presenting with iridocyclitis while the 
posterior chamber is involved in 25 % of cases (281). Retinal vasculitis in the form of 
multifocal periphlebitis has been reported in 37% of patients with ocular sarcoidosis (266). 
Retinal periphlebitis is a common ocular manifestation and was considered  by the first 
International Workshop on Ocular Sarcoidosis as one of seven clinical signs that comprise 
the diagnosis of ocular sarcoidosis (282). Although ocular sarcoidosis is typically 
associated with non-obstructive vasculitis, ischaemic retinal vasculitis has rarely been 
reported in patients with sarcoidosis. Typical features of the involved vessels include 
segmental cuffing or extensive sheathing and perivenous exudates, known as “candle wax 
drippings” associated with vasculitis on FFA that mainly involves midperipheral retinal 
veins. Additional vascular features include the presence of macroaneurysms, peripheral 
vessel closure and NV (Figure 1.7) (269,283). 
The exact underlying pathology of retinal vasculitis in these cases is not clear. One case 
report documented the presence of non-caseating granulomas around retinal blood vessels 
following a post-mortem examination of a patient with known idiopathic ischaemic retinal 
vasculitis. Even though such histological finding was suggestive of ocular sarcoidosis, there 
was no similar findings in the blood vessels elsewhere and no features of systemic 
sarcoidosis (15). 
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Figure 1.7 Fundus imaging of retinal vasculitis secondary to sarcoidosis  
(A) Perivenous exudates, “candle wax drippings” (Black arrow).  (B) Fundus fluorescein 
angiography of an eye with ischaemic vasculitis secondary to sarcoidosis shows leakage at 
macula secondary to macular oedema (white arrow), (C) peripheral retinal hypoperfusion 
with focal area of fluorescein leakage corresponding to new vessel formation (black star). (D) 
Five months following treatment with corticosteroids and laser photocoagulation shows 
regression of the neovascularisation (white star).  
 
1.3.3.4.3 Presumed tuberculous retinal vasculitis 
Ischaemic retinal vasculitis may be secondary to tuberculous infection (TB) or as a result of 
a hypersensitivity reaction to tuberculoprotein. In a clinical review of 21 patients with 
presumed ocular TB infection, occlusive retinal vasculitis was the commonest presentation 
affecting 12 patients, of which eight (38%) had underlying active systemic TB (284). In 
another study on 73 eyes (51 patients) with presumed TB uveitis, the authors found retinal 
periphlebitis in 35% of eyes involved. This was complicated by NV in 29% (half seen on 
presentation), VH in 11% and retinal detachment in 3% of eyes (285). Possible mechanisms 
resulting in venous occlusion include disc oedema secondary to tuberculous inflammation 
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or obliteration of the vessels by a hypersensitivity reaction to M. tuberculosis. In these 
cases, occlusive periphlebitis can affect the retina in multiple quadrants and is associated 
with thick exudates around the retinal veins and retinal haemorrhages. As a consequence to 
retinal ischaemia, NV, VH, tractional retinal detachment, rubeosis iridis, and neovascular 
glaucoma can occur (269). CRVO has also been reported (286,287) and may be associated 
with retinal vasculitis, chorioretinitis and retinal ischaemia. In one case, the inflammation 
resolved gradually following the initiation of anti-TB therapy, while intravitreal 
bevacizumab therapy given one month after presentation had little effect with VH occurring 
five months after the injection (287). Active or healed patches of focal choroiditis along the 
retinal veins can be suggestive of presumed TB vasculitis (288) (Figure 1.8).   
 
Figure 1.8 Fundus images of tuberculosis associated occlusive retinal vasculitis.  
(A) Fundus fluorescein angiography shows retinal nonperfusion together with small area of 
hypofluorescence corresponding to chorioretinal lesions along the retinal blood vessels 
(arrow) (B) A colour image showing vascular sheathing and fibrovascular tuft. (C)Fluorescein 
angiography showing leakage at the disc secondary to neovascularisation at disc (black arrow) 
and (D) peripheral capillary drop-out (star) and dye leakage from new vessels elsewhere 
(black arrow). 
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1.3.3.4.4 Systemic lupus erythematosus  
The incidence of retinopathy in patients with SLE ranges from 3% to 29% (289–291) 
depending on the studied population and associated risk factors for SLE retinopathy such as 
the presence of anticardiolipin antibodies, central nervous system involvement, serum 
creatinine level, and SLE activity (289,292). Retinal vasculopathy and associated vascular 
occlusion is a sight threatening manifestation of SLE retinopathy, reported to cause severe 
visual loss in 55% of patients (293). The main factor affecting visual outcome in these 
cases is the occurrence of NV with or without VH, reported in about 40% of the cases 
(290), as well as an increased risk of developing retinal vein occlusion (294). 
Vasoocclusive retinopathy can be the primary manifestation that leads to the diagnosis of 
SLE (295). The exact pathogenesis of vascular occlusion is not clear, but there have been 
proposed theories on the role of immune-complex deposition and complement activation 
with fibrinoid degeneration of the vascular wall as factors contributing to the vascular 
damage seen in these cases (296,297). Occlusive retinal vasculopathy involving the retinal 
arterioles may present with cotton-wool spots, predominantly in the posterior pole, 
representing retinal micro-infarctions. On FFA (Figure 1.9), vascular occlusion can 
manifest as widespread arteriolar or branch retinal artery occlusion (BRAO) with severe 
retinal ischaemia and NV (290). Larger retinal vessels may be occluded leading to retinal 
and optic disc infarction that may also result in NV (298). Central retinal artery occlusion 
(CRAO) and central retinal vein occlusion (CRVO), while very rarely seen in other causes 
of retinal vasculitis, have been reported secondary to SLE (299–301). In one report 
involving 71 patients with SLE and retinal vasculopathy, three (6.3%) of the patients had 
either CRAO, CRVO or ischaemic optic neuropathy (266). 
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Figure 1.9 Fundus photographs of SLE associated occlusive retinal vasculitis.  
(A) Colour images demonstrating vascular sheathing (arrows). (B) Fluorescein 
angiography shows multiple areas of capillary drop-out at the retinal midperiphery 
with leakage from retinal neovascularisation (arrows).  
 
1.3.3.4.5 Antiphospholipid syndrome 
Antiphospholipid syndrome (APS) is an autoimmune disease characterised by the presence 
of vascular thrombosis, recurrent miscarriage and antiphospholipid antibodies (IgG 
anticardiolipin, lupus anticoagulant, and anti-B2 glycoprotein-I antibody) (302). 
Anticardiolipin antibody is associated with a higher incidence of occlusive vasculitis in the 
eye (303) and was reported to be present in 22.5% of patients with retinal vasoocclusive 
events in the absence of conventional risk factors for thrombosis (304). APS can be 
associated with ocular manifestations, occurring in up to 80% of cases and can commonly 
result in retinal vasoocclusion independent of the presence of SLE (305). APS can result in 
unilateral and bilateral arterial, venous and cilioretinal artery occlusion (306–308). On rare 
occasions, nonarteritic anterior ischaemic optic neuropathy has also been reported 
(309,310). It is not uncommon for patients to initially present with only ocular findings 
before the diagnosis of APS is established. Therefore, it is reasonable to exclude this 
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condition in younger patients presenting with occlusive vasculitis in the absence of known 
systemic risk factors (311).  
1.3.3.4.6 Multiple sclerosis 
The risk of uveitis in patients with MS is ten times higher compared to the general 
population, commonly in the form of intermediate uveitis (312). However, the presence of 
peripheral periphlebitis was described in the early case reports of MS related uveitis 
(313,314). A review of 1254 uveitis case records at a tertiary eye centre found 14 (1.3%) to 
be MS related uveitis, with more than half of the cases associated with vasculitis (61). 
Periphlebitis has been suggested to be a risk factor for the development of neurological 
manifestations of MS, including optic neuritis (156,315).  
Many theories have been proposed to explain the pathophysiological correlation between 
MS and the presence of periphlebitis (316). In an autopsy series of 93 eyes from patients 
with an established diagnosis of MS, seven showed segmental perivenular infiltrates of 
lymphocytes and plasma cells (317), lymphocyte and plasma cells were also concomitantly 
observed around retinal and central nervous system veins in two patients with MS, leading 
to the conclusion that periphlebitis is an early event that may lead to plaque formation in 
the brain (318). While periphlebitis has been reported in 20% of eyes (319), occlusive 
vasculitis and NV are rare complications in MS related uveitis (320–324). In a case series 
of 16 patients with MS related uveitis, eight suffered from ischaemic retinal vasculitis with 
NV requiring SLP, while three eyes had unresolved VH secondary to NV requiring 
vitrectomy (323). Peripheral retinal ischaemia can be severe and had been reported to cause 
bilateral rubeosis iridis and neovascular glaucoma. While the rubeotic vessels regressed 
following treatment with oral corticosteroids and SLP, one eye required trabeculectomy to 
manage the glaucoma. No steroid sparing drugs were required in this case (325). Although 
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the presence of VH in uveitis can be highly suspicious of ocular BD or sarcoidosis, the 
presence of MS may also need to be excluded in patients with IU that develop VH. In a 
series of 25 patients with MS related IU, six (24%) had periphlebitis associated with retinal 
ischaemia and VH and four had NV on angiography. VH occurred at an average of five 
years following onset of uveitis, while it was the initial presenting manifestation in two 
patients (320).  The visual prognosis of MS related uveitis is generally good (61); however, 
in those with occlusive vasculitis and NV the visual prognosis may vary. In one report, two 
of six patients with retinal ischaemia and VH had a final vision of 20/80 five years after 
onset of VH (320). 
1.3.3.4.7 Other causes of occlusive retinal vasculitis 
Idiopathic retinal vasculitis, arteriolar macro aneurysms and neuroretinitis (IRVAN) is 
characterised by recurrent multiple branch retinal arterial occlusions of unknown cause in 
one or both eyes of healthy middle-aged patients with no associated ocular or systemic 
aetiology. An important cause of visual loss in IRVAN is chronic CMO with hard exudate 
accumulation in the fovea. Vision loss also occurs secondary to peripheral capillary non-
perfusion leading to NV and tractional retinal detachment (326). 
West Nile virus infection has been associated with chorioretinitis as its most common 
ocular finding; whereas occlusive retinal vasculitis is an uncommon finding reported to date 
in eight cases. Findings include perivascular sheathing, microaneurysms, cotton wool spots, 
intraretinal haemorrhages and NV with or without macular ischaemia. Interestingly, six of 
these cases with established West Nile virus infection also suffered from DM (327,328). 
Progressive outer retinal necrosis, a viral retinitis most commonly caused by VZV, can 
rarely be associated with occlusive vasculitis. In a recent report, a 45 years old HIV 
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infected patient on highly active antiretroviral therapy presented with bilateral progressive 
retinal necrosis and was treated with combined systemic and intravitreal ganciclovir 
therapy, which was repeated a week later. Despite all the management efforts, he 
progressed to occlusive vasculitis and CRVO within a week after the second intravitreal 
injection. Even following the application of PRP, which acts poorly on necrotic retina, the 
condition progressed with the occurrence of VH and eventually retinal detachment (329). 
Haemorrhagic occlusive retinal vasculitis is rare but potentially aggressive form of retinal 
vasculitis, predominantly phlebitis, occuring after uncomplicated cataract surgery 
associated with prophylactic intracameral injection of antibiotics. While the exact 
mechanism is not clear, it is believed to be caused by delayed immune reaction against the 
antibiotics Intraocular injection of aminoglycosides (amikacin and gentamycin) were 
reported to be associated with severe intraocular inflammation 1-3 days post surgery 
together with macular ischaemia (330,331). A case series of 11 eyes were reported with a 
diagnosis of haemorrhagic occlusive retinal vasculitis, all occurred following intracameral 
vancomycin injection in uncomplicated cataract surgery. Treatment involved topical and 
systemic corticosteroids together with PRP and anti-VEGF intravitreal injection. In 
addition, four cases received antiviral medications, four received intravitreal antibiotics, 
and four underwent vitrectomy.  Despite all the treatments, eight of the 11 eyes had a final 
visual acuity worse than 6/60 (332). Crohn's disease has been reported to be associated with 
ischaemic retinal vasculitis, NV (333), NV glaucoma (334) and CRAO (335).  
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1.3.3.5 Treatment 
1.3.3.5.1 Systemic immunosuppressants  
Severe retinal vasculitis requires adequate inflammation control using corticosteroids and, 
in non-infectious vasculitis, may need the addition of IMT (336). IMT of choice include 
MMF, MTX and Cyclosporine A. The latter has shown to be effective in providing long-
term inflammatory control but can be associated with renal toxicity (337). Meanwhile, 
AZA in BD with retinal vasculitis may not be very effective in producing complete 
resolution and relapse prevention during corticosteroid tapering(338). In SLE vasculopathy, 
systemic corticosteroids and IMT, such as cyclophosphamide and MMF, are established 
treatments that can reduce vasculopathy and resolve cotton wool spots (339), though there 
is little evidence supporting their role in preventing the progression of retinal vasoocclusion 
(290). In presumed TB vasculitis, commencing systemic anti-TB therapy is useful in 
controlling the inflammation by suppressing the active TB focus, which causes immune 
activation and triggers uveitis. In addition, adjunctive use of systemic corticosteroid therapy 
may be required in the management of these cases to prevent damage to ocular tissues 
especially from delayed hypersensitivity.  
1.3.3.5.2 Biologics 
Anti TNFα drugs such as infliximab and adalimumab have been used successfully in the 
management of sight threatening retinal vasculitis. In severe ocular BD, anti-TNFα can be 
considered as first-line IMT (133) or used in cases refractory to other IMT to reduce the 
risk of severe visual loss and promote long term remission of uveitis(275,340,341). BD 
vasculitis with NVD has been reported to regress, recurrent VH resolve, and vision improve 
following extended treatment with infliximab (342,343).  Anti- TNFα is used successfully 
in treating refractive cases of  sarcoidosis with retinal vasculitis, especially infliximab 
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(137,344) and adalimumab (345,346). Clinical reports on the use of infliximab to control 
ischaemic retinal vasculitis secondary to sarcoidosis have shown good results, especially in 
cases where ocular symptoms manifest despite the use of IMT (347). Meanwhile, 
etanercept is not only less effective in managing sarcoidosis, it is also reported to induce 
sarcoid IU and PANU (348,349). It should be noted that anti-TNF, often used in the 
management of severe non-infectious uveitis, should be avoided in treating MS related 
uveitis as it may precipitate or exacerbate nerve demyelination and worsen the neurological 
manifestations of this disease (350). Infliximab used in patients with IRVAN was very 
successful in inducing dramatic resolution of ocular inflammation, reduction of retinal 
exudation, improving nerve leakage and vision improvement after the first dose of 
infliximab therapy. However, it was not useful in preventing NV formation which occurred 
months later requiring laser therapy(351). The use of rituximab, a chimeric monoclonal 
antibody against CD20+ B cells, demonstrated some benefit in treating severe cases of SLE 
in uncontrolled studies but failed to prove superiority against placebo groups in a 
randomised controlled trial (352). Rituximab combined with cyclophosphamide infusions 
was shown to result in rapid resolution of retinal vasoocclusion in a paediatric group of 
SLE patients when used early in the course of the disease (353). 
Interferon alfa (INFα) therapies have been used in selected conditions to control 
inflammation. In ocular BD, INFα-2a therapy was reported to provide long lasting 
remission in up to 55% of cases even after discontinuation of therapy (354). In a 
retrospective study, INFα-2a was effective in controlling retinal vasculitis in 36/38 eyes 
with BD, and in 18/22 eyes with other causes of retinal vasculitis (355). INFα-2a may also 
result in reperfusion of vasoocclusion (356) and induce NVD regression among BD 
vasculitis even in the absence of concomitant SLP (357).  In a retrospective review, five 
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patients with BD and unilateral ischaemic NVD received SLP; three had resolution of NVD 
following laser treatment while the other two patients responded only following additional 
treatment with INF-α-2a therapy (278). 
The role of INFβ, an established treatment for MS, needs to be further studied to examine 
its effectiveness in controlling MS with retinal vasculitis. In a small retrospective study of 
13 patients with MS related uveitis, ten of which were associated with retinal vasculitis, 
showed promising results with improvement of visual acuity in 71% of the eyes while a 
corticosteroid sparing effect was achieved in all cases (358). 
1.3.3.5.3 Retinal laser photocoagulation and intravitreal anti-VEGF 
SLP is the main approach in managing NV that form secondary to occlusive vasculitis. In 
patients with presumed TB vasculitis, SLP was found to be very effective in inducing 
involution of NV. In a case series of 21 eyes with presumed TB vasculitis that received 
SLP for NV, there was no recurrence of VH or NV formation within a mean follow up 
period of 18 months (285). In BD, SLP is useful in inducing regression of NV and 
preventing further complications such as NV glaucoma (359). In patients with IRVAN, 
SLP has been recommended in the presence of retinal ischaemia before or shortly after the 
formation of NV regardless of the extent of vascular closure in order to prevent its 
progression and maintain good visual outcome (360). Another study suggested using SLP 
only in eyes with retinal ischaemia involving more than two quadrants (361). In addition to 
SLP, other treatment options for IRVAN include macular grid laser, vitrectomy and anti-
TNFα agents with a smaller role for corticosteroids (351,362). 
The primary treatment of retinal NV among patients with SLE and APS vasculopathy 
involves the use of SLP to the ischaemic area with or without intravitreal anti-VEGF agents 
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(308). Unlike cases with presumed TB vasculitis, SLP is less effective in causing regression 
of NV in SLE and APS vasculopathy. In a systematic review of literature, SLP was 
performed on 22 eyes, causing regression of the NV and stabilisation of vision in only 54% 
of the cases (290). Thus, it is not uncommon to see NV formation with subsequent VH and 
vitreoretinal traction even after retinal laser application (295). In the absence of randomised 
clinical trials, it is difficult to assess the role of SLP alone in controlling NV due to the 
concomitant use of IMT in most cases.  Intravitreal bevacizumab can be used in eyes with 
recurrent or persistent NV following SLP. A reported case of SLE with NVE that 
progressed despite the use of IMT and fill-in laser, did respond to one  intravitreal injection 
of bevacizumab resulting in NVE regression with no new bleeding over three months 
follow up (363). However, bevacizumab itself can reduce retinal perfusion and worsen 
retinal ischaemia and therefore should be administered concomitantly with SLP. In a report 
of two patients with SLE, one received bevacizumab combined with SLP that resulted in 
halting the progression of the vascular occlusion with regression of the NVD. The second 
patient, who did not have laser, had progression of retinal ischaemia with secondary NVE 
within a month of injecting bevacizumab (364).  In rare cases, intravitreal bevacizumab was 
reported to aggravate capillary nonperfusion within a day following injection despite 
previous administration of SLP (365).   
Based on the treatment options described above, a proposed treatment pathway or protocol 
for managing retinal vasculitis is illustrated in Figure 1.10 
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Figure 1.10 Proposed therapeutic algorithm for managing retinal vasculitis 
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1.3.4 Cataract surgery in uveitis 
1.3.4.1 Management of cataract in eyes with uveitis 
The decision and timing of cataract surgery is subject to many factors including the visual 
potential, uveitis activity, associated ocular comorbidity, and the risk of amblyopia among 
paediatric age group with cataract. The main indications for cataract surgery in eyes with 
uveitis is to achieve a better visual outcome, or as part of managing the uveitis secondary to 
leakage of lens proteins (phacoantigenic uveitis). Cataract surgery is also required to obtain 
a better fundus view necessary in managing certain retinal pathologies such as assessment 
of fundus disorders e.g. diabetic retinopathy or glaucomatous optic neuropathy, or for 
performing vitreoretinal surgeries or applying retinal laser therapy (366).  
1.3.4.1.1 Preoperative management  
Preoperative assessment is essential to decide on the visual potential of the eye if cataract 
surgery is to be performed and whether any associated complications may have an impact 
on the visual outcome postoperatively. The macular and optic nerve structure and function 
should be assessed prior to surgery to exclude the presence of any coexisting complications 
that may jeopardise the outcome of surgery, such as the presence of macular scar or 
atrophy, macular ischaemia, and chronic CMO; as well as the presence of pre-existing optic 
neuropathy or atrophy. In cases where there is poor view of the fundus secondary to a dens 
cataract, B-scan ultrasonography is essential to exclude the presence of retinal detachment 
as a complication of uveitis.  
Preoperative inflammation control is essential in preventing complications associated with 
cataract surgery in uveitis with most of the literature recommending the eye be quiescent 
for a minimum of three months prior to surgical intervention. In certain situations, such as 
previous history of CMO or severe panuveitis, prophylactic anti-inflammatory medication 
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is required to be initiated 7-14 days prior to surgery. The most common prophylactic 
therapy is in the form of systemic prednisolone given for adults at a dose of 40mg once a 
day, or 0.5 to 1mg/kg, for two weeks until the day of surgery. Alternatively, preoperative 
periocular or intraocular steroids, such as IVTA, can be given preoperatively (367). Case 
reports exists which describe the successful use of dexamethasone intravitreal implants 
(Ozurdex®) preoperatively as a prophylactic measure in JIA related uveitis with the eye 
continuing to be quiescent over the 10 month follow-up period (368). 
1.3.4.1.2 Intraoperative management  
Since the beginning of the new millennium, phacoemulsification with in-the-bag 
intraocular lens (IOL) implantation has become the preferred surgical procedure for 
cataract removal in most people with uveitis (369).  Cataract surgery in uveitic eyes can be 
difficult due to limited access secondary to the possible presence of band keratopathy, 
posterior synechiae, miotic pupil, and pupillary fibrinous membranes over the lens. A poor 
view may require managing the corneal band karatopathy first before advancing with the 
cataract surgery, either through phototherapeutic keratectomy or chemical chelation with 
ethylenediaminetetraacetic acid. Efforts may also be needed to release the 
adhesions/synechiae and expand the pupil size through variable approaches such as the use 
of viscoelastics and iris hooks (367). In some cases with IU or FHC associated with 
significant vitritis, cataract removal is combined with pars plana vitrectomy which helps 
not only to improve vision and reducing floaters, but also to reduce the postoperative 
inflammation and the incidence of postsurgical CMO (370). 
In addition to anterior capsulotomy and lens aspiration within the sac, cataract removal with 
IOL implantation in children with uveitis often requires an additional step of posterior 
capsulotomy combined with anterior vitrectomy to minimise the chance of posterior 
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capsular opacity (PCO) and fibrinous deposition over the IOL (371). In the presence of 
concomitant glaucoma and cataract, it is recommended to avoid combined glaucoma and 
cataract surgery due to the high risk of bleb failure in these cases, and thus it is better to 
remove the cataract first prior to planning for glaucoma surgery (372). 
The choice of optimum IOL associated with minimal postoperative adverse effect has been 
addressed in several studies. Acrylic IOLs in some studies show superiority over other 
types of IOL materials, such as silicon lenses, and was associated with the lowest level of 
postoperative uveitis and lowest rate of PCO within the first 6 months of follow up 
postoperatively (369). However, a recent review paper found no enough evidence that 
acrylic lenses may perform better than silicon lenses (373). The anterior chamber IOL in a 
recent study was not associated with a significant increase in the incidence of intraoperative 
and postoperative complications among uveitic eyes over five years follow up period when 
compared to a control group without uveitis. However, the uveitis flare-up attributed to the 
IOL and the risk of ERM formation were indeed more in uveitic eyes with anterior chamber 
IOL compare to non uveitic eyes with same lens type (374).  When  another study made a 
comparison to posterior chamber IOL in uveitic eyes, the anterior chamber IOL did not 
have a significant difference in the risk of long-term complications and can still be 
associated with a significant improvement in the visual acuity over 3 years follow up period 
postoperatively (375). 
Overall,  uveitic eyes undergoing cataract surgery with IOL implantation have a better 
visual outcome than eyes with no IOL placement as the latter appeared in a systematic 
review to only achieve 6/12 vision or better in 23% of cases (376). In some cases of chronic 
AU, mainly children with JIA associated uveitis, the decision to insert an IOL can be 
controversial. IOL insertion in these cases may be associated with variable postoperative 
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complications such as fibrin deposition and synechiae, pupillary membrane formation, 
hypotony, and secondary lens opacity, with some cases requiring IOL explantation. 
However, several more recent studies have demonstrated no significant worsening of 
uveitis outcome post cataract removal and IOL implantation among cases with JIA 
associated uveitis. One study examined the long term outcome of 48 eyes in children with 
JIA associated uveitis over 16 years follow up period and found no significant difference in 
the incidence of postoperative complications such as elevated IOL, glaucoma, and CMO 
between pseudophakic eyes and aphakic ones. Moreover, the pseudophakic group 
experience a better visual outcome over seven years follow-up compared to the aphakic 
eyes, with no incidence of phthisis or hypotony (377). 
1.3.4.1.3 Postoperative management  
Postoperatively, local and systemic steroids are tapered gradually based on the degree of 
postoperative inflammation. In eyes with flare up of uveitis postoperatively, adequate 
administration of topical steroids and mydriatic eye drops should be initiated. Systemic or 
periocular/intraocular steroid injection can be administered in the presence of severe uveitis 
not responding to topical drops or in the presence of postoperative CMO.  Other 
postoperative complications require management accordingly such as PCO and elevated 
IOP. 
1.3.4.2 Complications of cataract surgery in uveitis 
Prior to the era of using systemic corticosteroids to control inflammation, cataract surgery 
in uveitic eyes was inevitably associated with significant preoperative and postoperative 
complications that could sometimes progress to permanent vision loss (378,379). The 
incidence of complications associated with cataract surgery in uveitic eyes has reduced over 
the past years, mainly due to the improved ability to control inflammation preoperatively 
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and the recent developments in implementing new systemic and local anti-inflammatory 
therapies, as well as the rapid evolution in microsurgical techniques over the past few years 
(372).  
Complications of cataract surgery in uveitis include retained cortical and nuclear lens 
matter, hyphaema, severe or persistent postoperative inflammation, CMO, elevated IOP, 
pupillary membrane, PCO, hypotony and endophthalmitis. A recent study looked at the 
outcome of phacoemulsification in uveitic eyes with more than three years follow up 
period. Intraoperative complications included posterior capsule rupture (1.7%) whereas 
long term complications postoperatively include CMO in 10.2% with an incidence rate of 
0.02 per EY which was highly related to the presence of chronic postoperative 
inflammation and also in those with more than one postoperative relapse per year. PCO 
occurred in 27% with an incidence rate of 0.07 per EY with no significant association with 
the presence of chronic postoperative inflammation. Elevated IOP more than 21mmHg 
observed in 10.2% of cases with an incidence of 0.04 per EY. Hyoptony on the other hand 
was related to the presence of chronic inflammation postoperatively and mainly confined to 
eyes with AU, occurring in 5.1% of cases and an incidence of 0.02 per EY (380).  Cataract 
surgery in uveitic eyes can also increase risk of hypotony by seven fold, especially in 
aphakic eyes. Even with phacoemulsification, which carries a lower risk of hypotony, there 
is five fold increased risk when performed on uveitic eyes (381). The incidence of 
hyphaema in FHC post cataract surgery can vary from 3.6% to 76%, with recent reports 
showing a reduced incidence mainly following the use of improved microsurgical 
techniques (372). The incidence of PCO following cataract surgery in FHC has been 
reported to occur in 14.6% of eyes within a mean follow up period of 17 months after 
surgery (148). Meanwhile, the most significant sight threatening complication of cataract 
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surgery in FHC cases is glaucoma, reported in 3 to 35% of cases, with almost 2/3 of cases 
eventually requiring glaucoma surgery (382).  Cataract surgery in general is associated with 
a small risk of endophthalmitis, about 1 in 1000 cases, and an overall incidence rate of 
0.12%, leading to permanent vision loss in most of the cases (383). The risk of 
postoperative endophthalmitis that can be reduced with the use of intraoperative 
prophylactic intracameral injection of antibiotics, such as cefuroxime (1 mg/0.1 ml) (384).  
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2 CHAPTER TWO: GENERAL METHODOLOGY  
2.1 Patients and setting 
The initial stage of the research involved reviewing hospital case notes of all patients with 
uveitis who attended the uveitis clinic of a single consultant (S.L.) at Moorfields Eye 
Hospital, London, United Kingdom, between January 2012 and December 2013. The study 
received institutional review board approval (ethical approval for data collection: 
LIGS10201, visual loss in uveitis; Clinical Trials registry no., NCT01983488). Collected 
data from these case-notes were eventually entered into a Microsoft Access database 
designed to be used as a general database for uveitis patients (Figure 2.1). This eventually 
led to the collection of 1169 patients with uveitis. From this collected cohort of uveitis 
patients, eyes from diabetic patients, retinal vasculitis and those underwent cataract 
surgeries who met the inclusion criteria were selected for three separate studies and were 
further analysed as discussed in the methodology of chapter 3, 4 and 5. 
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Figure 2.1 Screenshot of the uveitis database entered through Microsoft Access 
datasheet entry system 
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2.2 Uveitis clinical and demographic data  
Patient demographic data such as gender and age at time of uveitis diagnosis were 
documented.  Uveitis was classified based on the SUN Working Group classification of 
uveitis as AU (inflammation confined to the anterior segment), IU (inflammatory cells 
observed in the anterior vitreous and commonly associated with snowballs or snowbanks), 
PU (inflammation mainly affecting the retina and/or choroid), and PANU (inflammation is 
diffuse involving the anterior chamber, vitreous and retina or choroid (19).  In addition, the 
aetiology of uveitis if known was recorded including infectious and non-infectious 
aetiology together with any localised ocular pathology or systemic diseases associated with 
uveitis development. Other data of interest were the first and last clinic visit date and 
changes in the clinical data over the follow up period. Uveitis management approach was 
recorded including the use of topical, periocular and intraocular injections as well as the use 
of systemic prednisolone and IMT therapy. Additional data included the use of laser 
therapy and the type and timing of surgical management of uveitis complications e.g. 
cataract surgery, aqueous shunt and vitrectomy. 
All patients had their best corrected visual acuity (BCVA) measured separately in each eye 
during the clinic visits. This was done using an illuminated Snellen chart at a distance of six 
metres. The BCVA was obtained from measuring the vision while looking through a 
pinhole or with patient’s glasses prescription and the result was recorded in Snellen acuity 
format. For eyes that were unable to see the top line at a distance of six metres, they were 
brought up closer to the chart by one metre a time. If there was still no view at one metre, 
then ability to view finger counting, hand movement, or light perception were assessed at a 
distance of 1 meter. For the purpose of continuous or longitudinal data analysis, the BCVA 
measurements were converted from Snellen acuity into the negative value of the decadal 
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logarithm of the minimal angle of resolution (LogMAR) (385). For visual acuity of 
counting fingers or worse, the following conversion was used: counting fingers = 2.0 
LogMAR, hand motion = 2.3 LogMAR, light perception = 2.6 LogMAR, and no light 
perception = 2.9 LogMAR.(386,387)  Vision loss was defined as final BCVA of ≤ 6/15 
(<0.3 LogMAR) or loss of > 2 snellen lines in eyes with baseline BCVA of 6/24 or better. 
Vision loss were described as either moderate vision loss (MVL) in eyes with BCVA 
between 6/15 and 6/36 or severe vision loss (SVL) in eyes with BCVA ≤ 6/60 according to 
the SUN working group criteria (19). 
Patients attending the clinic had a full ophthalmological examination including slit-lamp 
examination, funduscopy using indirect ophthalmoscopy after pupil dilation and IOP check 
using Goldman applanation tonometry. Ancillary tests were requested as appropriate to the 
history and the clinical examination such as OCT using Topcon 3D OCT (Topcon, Inc) 
(Error! Reference source not found. ) or Heidelberg Spectralis (SD-OCT; Spectralis, 
Heidelberg Engineering GmbH) (Figure 2.3), FFA and ICG taken through the digital retinal 
camera system either as 30-50 degree images (Topcon TRC 50IX; Topcon Medical 
Systems Inc, Paramus, NJ) or as ultra-widefield images (Optos PLC, Dunfermline, 
Scotland) (Figure 1.9), as well as performing orbital B-Scan ultrasound, 
electrophysiological and laboratory tests.  
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Figure 2.2 Normal Topcon 3D Optical Coherence Tomography (OCT) scan (Topcon, 
Inc) showing retinal layers from inside out: inner limiting membrane (ILM), nerve 
fiber layer (NFL), ganglion cell layer (GCL), inner nuclear layer (INL), inner 
plexiform layer (IPL), outer nuclear layer (ONL), outer plexiform layer (OPL), 
external limiting membrane (ELM), photoreceptor inner segment (IS) and 
photoreceptor outer segment (OS) and their IS/OS junction, and the retinal pigment 
epithelium layer (RPE). 
 
Figure 2.3 Normal eye on Heidelberg Spectralis Optical Coherence Tomography 
(OCT) scan (SD-OCT; Spectralis, Heidelberg Engineering GmbH) showing retinal 
layers from inside out: inner limiting membrane (ILM), nerve fiber layer (NFL), 
ganglion cell layer (GCL), inner nuclear layer (INL), inner plexiform layer (IPL), 
outer nuclear layer (ONL), outer plexiform layer (OPL), external limiting membrane 
(ELM), photoreceptor inner segment (IS) and photoreceptor outer segment (OS) and 
their IS/OS junction, and the retinal pigment epithelium layer (RPE). 
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Retinal vasculitis was defined in accordance with the SUN working group description 
which considered the eye to have retinal vasculitis in the presence of  perivascular 
sheathing and vascular leakage or occlusion on FFA as evidence of retinal vascular disease 
(Figure 2.4) (19).  The presence of retinal vasculitis complications in the form of NVD, 
NVE, NVI, CMO and macular ischaemia were also recorded.  
Depending on the location of the obstruction, RVOs can be divided into CRVO and BRVO. 
In BRVO, the obstruction is located in one of the branches of the central vein, affecting 
only part of the posterior pole or peripheral retina (Figure 2.5). In CRVO, it is located in the 
central vein, at the level of the optic nerve, so most of the retina is affected. Both BRVO 
and CRVO are considered ischaemic if more than 10 disc areas of capillary nonperfusion 
was observed on FFA (388).  
Uveitis complications and causes of vision loss were recorded, including loss of corneal 
and vitreous clarity, cataract formation, CMO, RPE atrophy, CNVM and macular scarring, 
macular ischaemia, ERM formation, retinal detachment, optic neuropathy, glaucoma as 
well as hypotony and phthisis.  
Cataract formation was based on documented lens opacity on clinical examination 
associated with at least two Snellen lines drop in vision. The type of cataract was classified 
as either nuclear, cortical or posterior subcapsular cataract (389). 
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Figure 2.4 Clinical signs associated with vasculitis as observed on colour fundus images and 
fluoresceine angiography. A) Neovascularisation (black arrow). B) Fundus fluoresceine 
angiography showing hyperfluoresecence representing neovascularisation (white arrow) at 
the border of nonperfusion area representing capillary occlusion (star). C) Fundus 
fluoresceine angiography shows active vasculitis with dye leakage over the course of inflamed 
retinal vessels (white arrow). D) Active vasculitis with area of retinal haemorrhage (white 
arrow) and perivascular sheathing and exudates (black arrow). 
 
 
Figure 2.5 Branch retinal vein occlusion in the right eye of a patient with idiopathic 
retinal vasculitis. The colour fundus image (Left) shows perivascular sheething and 
exudates (black arrow) together with preretinal haemorrhage (white arrow). The 
fundus fluorescein angiography (Right) shows area of hypofluorescence secondary to 
overlying retinal haemorrhage (white arrow) as well as areas of hypoperfusion (star). 
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CMO documentation was mainly based on the OCT findings of increased central retinal 
thickness and/or presence of low-reflective intraretinal spaces defined and separated by 
high-reflective retinal tissue (390). In cases where the OCT was not available, we relied on 
case notes documentation of macular oedema based on fundus examination or if available 
the FFA evidence of parafoveal hyperfluoresence (19). (Figure 2.6) 
Macular ischaemia was defined based on FFA findings of an increased foveal avascular 
zone (FAZ) ≥ 1,000 µm at its widest diameter, or broken perifoveal capillary rings at the 
borders of the FAZ (186) (Figure 2.7).  
ERM are presented on clinical examination as retinal folds or wrinkling of the internal 
retinal surface secondary to proliferation of abnormal tissues on the surface of the macula 
or posterior pole (Figure 2.8).  
Glaucoma was considered present in uveitic eyes as per the SUN group criteria that 
depends on the presence of glaucomatous optic disc damage or showed glaucomatous 
visual field loss(19). For this research, the incidence of elevated IOP >30mmHg were 
documented as it was believed to be the level above which would require the initiation of 
antiglaucoma therapy even in the absence of glaucomatous optic disc damage. While 
steroid responder were defined as cases with elevated IOP by10mmHg or more following 
the administration of corticosteroid therapy (19).   
Ocular hypotony was defined as IOP <5mmHg and can be associated with choroidal 
effusion, optic nerve swelling, irregular astigmatism and eventually phthisis bulbi (158). 
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Figure 2.6 Cystoid macular oedema in a uveitic eye diagnosed using spectralis optical 
coherence tomography scan (above) and fundus fluorescein angiography (below).  
The scan shows loss of normal foveal configuration and increase retinal thickness 
secondary to multiple large intraretinal cysts (stars) and subretinal fluid (white 
arrow). The fundus fluorescein angiography showing cystic areas of 
hyperfluorescence around the fovea with a characteristic “flower- petalloid” pattern 
(black arrow).  
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Figure 2.7 Macular ischaemia in a patient with ischaemic retinal vasculitis as seen on 
fundus fluorescein angiography of the right eye which shows broken perifoveal 
capillary ring at the border of the foveal avascular zone (arrows). 
 
 
Figure 2.8 Epiretinal membrane (arrows) as seen on optical coherence tomography 
scan (Left) and on colour fundus image (Right) 
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For patients with DM, the prevalence of DR was recorded based on the ETDRS definitions 
and the classification adopted by the UK National Screening program as follows; (186) 
- Mild and moderate NPDR (background DR): Characterised by the presence of retinal 
haemorrhages, microaneurysms, venous loops, any exudates, any number of cotton 
wool spots. (Figure 2.9 A, B) 
- Severe NPDR (pre-proliferative): Characterised by the presence of IRMA in addition 
to venous beading and multiple intraretinal haemorrhages (Figure 2.9 C, D) 
- Proliferative DR: Characterised by the presence of retinal NV, typically at the interface 
between perfused and ischaemic retina, as well as at optic disc and iris (Figure 2.10), 
and can be associated with VH or preretinal haemorrhages with or without pre retinal 
fibrosis and retinal detachment.  
Diabetic maculopathy was also documented such as the presence of DMO and macular 
ischaemia. DMO was characterised by focal or diffuse retinal thickening and accumulation 
of exudates observed on clinical examination and confirmed through the FFA and OCT 
findings (Figure 2.11). DMO was differenciated from CMO secondary to uveitis in that the 
former is more diffuse and typically associated with intraretinal exudates and occur in the 
absence of inflammatory cells within the vitreous or anterior chamber. DMO was 
considered to be CSMO based on the ETDRS criteria which define it as either 1) retinal 
oedema within 500 µm (one third of a disc diameter) of the fovea, 2) hard exudates within 
500 µm of the fovea, or 3) retinal oedema that is one disc diameter (1500 µm) or larger, any 
part of which is within one disc diameter of the fovea (186). 
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Figure 2.9 Fundus images of eyes with nonproliferative diabetic retinopathy (NPDR).  
A) Colour fundus image shows moderated NPDR associated with macular exudates (black 
arrow) secondary to clinically significant macular oedema and B) Spectralis optical coherence 
tomography scan of the same eye shows intraretinal cysts (star) and exudates (white arrow) 
with increased macular thickness. C) Colour fundus image of an eye with severe NPDR 
associated with venous beeding (white arrow), cotton-wool spot (short black arrow) and 
macular exudates (long black arrow) D) Fundus fluorescein angiography of the same eye with 
hyperfluorescence at the macular area (white arrow). 
 
 
Figure 2.10 Right eye of a patient with proliferative diabetic retinopathy. A) Colour fundus 
image shows multiple intraretinal haemorrhages (black arrows) together with circinate 
exudates around the macular oedema (white arrow). B) Fundus fluorescein angiography of 
the same eye shows neovascularisation (black arrow) together with laser scars (white arrow) 
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Figure 2.11 The left eye fundus of a patient with proliferative diabetic retinipathy 
already treated with laser photocoagulation (black arrow) and clinical significant 
macular oedema. Upper image is a Topcon optical coherence tomography scan 
showing multiple intraretinal cysts (stars) as well as subretinal fluid (white arrow). 
The lower image is fundus fluorescein angiography showing diffuse area of 
hyperfluorescence over the macular area (white arrows) 
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2.3 Statistical analysis 
All the continuous data measured in the research were tested for normality of distribution 
through plotting of the data together with normality test using Shapiro-Wilk test which 
considered the data to be not normally distributed if the p value was <0.05. Baseline 
demographic and clinical parameters were described using mean and its standard error (SE) 
for continuous data and percentages for categorical data, except when lack of normality in 
distribution was observed for which case it was reported as median and interquantile range 
(IQR). Continuous data between two dependent groups were compared using dependent t-
test for normally distributing data, or Wilcoxin signed rank test for data which lack 
normality in distribution.  Chi-square test or Fisher’s exact test was used, as appropriate, to 
compare categorical variables among independent groups while using McNeemar test for 
similar analysis between dependent groups. Repeated measurements were analysed using a 
multivariate linear regression method to assess the mean difference (MD) in BCVA and 
corresponding 95% confidence intervals (C.I.) over the follow up period compared to the 
baseline measurement. This was performed using generalised estimating equation (GEE) 
methods to account for correlations between the eyes at multiple intervals (391).  
Kaplan-Meier survival analysis with Log-Rank (Mantel-Cox) test were applied together 
with survival curve graphs to compare the survival rates for the incidence of some uveitis 
outcomes such as vision loss, CMO and NV formation among studied subgroups. The 
hazard ratio (HR) and its corresponding 95% C.I for vision loss and uveitis complications 
were measured using Cox proportional hazards regression analysis.  
The incidence rate per eye per year (EY) and 95% C.I for uveitis relapse and use of topical 
and systemic corticosteroids were calculated using negative binominal regression with log 
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link model. The General Linear Model test was used to calculate the probability of 
Type II (Beta) error, or the power of the study, aiming to have a power level of 80% 
or more. Statistical analyses utilised the Statistical Package for the Social Sciences (SPSS) 
software, version 21 (SPSS®, Chicago, USA). The level of statistical significance was set at 
p<0.05.  
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3 CHAPTER THREE: THE INFLUENCE OF DIABETES 
MELLITUS ON THE VISUAL OUTCOME AND 
MANAGEMENT OF PATIENTS WITH UVEITIS  
3.1 Introduction 
DR is a well-known cause of newly acquired vision loss among the working age group 
between 20 to 74 years old, and accounts for approximately 12% of all cases of blindness in 
Western countries (392). In the UK, DR is the leading cause of blindness among the 
working age group with an estimate of 4,200 blind people in England due to DR and an 
annual 1,280 new cases each year (393). DR and diabetic maculopathy account for 6.3% of 
registered cases of blindness in the UK and is the third most common cause of blindness 
after degenerative macular changes (58.6%) and glaucoma (8.4%). It is also the second 
most common cause of partial sight impairment in UK, accounting for 7.6% of cases (394). 
One out of five patients with type 2 diabetes is diagnosed with DR within one year after 
diabetes diagnosis in UK general practices (395). 
Since 1868 when Noyes suggested that diabetes can cause iritis, many authors have 
subsequently presented various hypothesis that supported (396–398) or disputed (399,400) 
such an association. Few studies and case reviews have examined the association between 
DM and uveitis, focusing mainly on diabetes as a risk factor for the development of AU 
(25,401–404). Guy et al reported iritis in 30% of patients with type 1 DM associated with 
autonomic neuropathy, suggesting that an immunological mechanism may be involved in 
the development of uveitis as well as diabetic neuropathy (397). Another study of 340 
patients with AU found 6% to be associated with DM. This was more prevalent in patients 
with idiopathic AU, among which 12.5% had DM, compared to only 1.9% of AU patients 
with an underlying ocular diagnosis (405). Rothova et al while studying the association of 
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uveitis with systemic diseases in 865 patients with uveitis, found 29 (3.3%) to have DM; 20 
cases were idiopathic AU and nine cases were associated with an underlying aetiology 
(398). DM is associated with alteration in blood-aqueous barrier permeability, resulting in 
an increase in the aqueous protein concentration, or flare, in a degree parallel with the 
progression of the DR (406). 
The interaction between DM and uveitis can occur in two scenarios; either a patient known 
to have DM presents with uveitis, or a uveitic patient is subsequently diagnosed with DM, 
such as type 2 DM or steroid-induced DM. Oswal et al initially reported the clinical 
characteristics of 36 diabetic patients (48 eyes) that presented with their first episodes of 
uveitis (403). In this report, all of the cases were type 2 DM except for one case with type 1 
DM. The uveitis occurred after a mean period of 6.8 years from time of diagnosis with DM. 
Most of the uveitis cases were idiopathic and mainly in the form of AU (66%) followed by 
PANU (27%) and IU (6%). An underlying infectious disease was associated with the 
uveitis in 12.5% of the eyes, mainly toxoplasmosis, TB and syphilis associated uveitis 
(403). The same group of patients were further studied through another longitudinal 
retrospective research with a mean follow up period of 4.4 years. The study reported a final 
visual outcome of 6/18 or worse in 15.5% of the eyes, mainly secondary to cataract (37%), 
glaucoma (29%) and CMO (17%). In addition, DR was observed in 65.5% of the eyes, 
including 6 eyes with CSMO and nine eyes had PDR. Progression of DR to proliferative 
disease occurred in seven eyes over a mean of 4.4 years from onset of uveitis (407). 
While the role of DM in inducing or aggravating ocular inflammatory diseases is still 
controversial, the risk of uveitis therapy in inducing DM or jeopardising glycaemic control 
is a well known adverse effect, especially with the use of systemic corticosteroids.  
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Systemic corticosteroids have been widely used in the management of sight threatening 
uveitis, especially when topical or local corticosteroid use is ineffective or inapplicable and 
in the presence of severe ocular inflammation behind the lens and for managing associated 
complications such as CMO, optic neuritis or retinal vasculitis (86). However, systemic 
corticosteroids can be associated with variable adverse effects including hyperglycaemia 
and steroid induced DM (89).  Corticosteroids can induce DM through inducing 
gluconeogenesis as well as increasing peripheral insulin resistance (408). More recent in-
vitro studies suggested additional mechanisms, such as the inhibition of insulin secretion 
through increasing the expression of α-2 adrenergic receptors (409), decreased cAMP 
levels and pancreatic β-cell apoptosis through activating calcineurin phosphatase and 
corticosteroid receptors as well as reducing the secretion and the insulinotropic effects of 
the incretin glucagon-like peptide-1 (GLP-1) (410).  In addition to systemic corticosteroid 
therapy, some IMT therapy used in the management of uveitis can also have a diabetogenic 
effect. Calcineurin inhibitors such as CSA and tacrolimus are associated with increasing 
risk of hyperglycaemia or causing drug-induced DM through suppression of insulin 
secretion and transcriptional regulations in pancreatic β-cells (411). Meanwhile, other IMT 
such as MMF have not proven to carry similar diabetogenic effect (412). 
The incidence and risk factors of corticosteroid-induced hyperglycaemia have been 
addressed in the SITE  multicentre retrospective study on 2,073 patients with inflammatory 
eye diseases treated with oral corticosteroids (413).  Steroid induced hyperglycaemia 
requiring hypoglycaemic medications was observed in 25 patients (1.21%) on oral 
corticosteroids compare to 0.19% of patients who were not on similar treatment. The use of 
oral corticosteroid in the uveitis cohort was associated with four fold increase in risk of 
steroid-induced hyperglycaemia compared to those who did not receive oral corticosteroids. 
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The risk is even higher in patients with higher initial dose of corticosteroids of  >40mg per 
day compare to those on lower initial dose. Other risk factors for the development of steroid 
induced hyperglycaemia were older age and African-American race group.  Interestingly, 
62.7% of the uveitis patients on hypoglycaemic medications did subsequently manage to 
discontinue these medications within one year after starting them (413). The study though 
did not focus on the synergistic effect of IMT if used on the incidence of hyperglycaemia 
secondary to oral corticosteroids, nor did it address the effect of the newly acquired 
hyperglycaemia on the rate of uveitis activity or its influence, if any, on the management of 
uveitis relapse.  
Both macular oedema and secondary cataract are common causes of visual loss in uveitis 
(22,414) and DM (415,416). However, few studies have assessed the cumulative effect of 
uveitis and DM on visual outcome and uveitis management strategies. Furthermore, the rate 
of development of DR in the setting of uveitis is also another research question of interest.  
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3.2 Aims and objectives  
1) In uveitis eyes with newly diagnosed DM, the aim was to measure the average 
change in BCVA taken at time of diagnosis of diabetes and onward compared to 
the baseline (one year prior to diagnosis of diabetes) as well as the risk factors 
of vision loss if present. 
2) In the same group, another objective was to evaluate any change in the treatment 
strategy used to control active ocular inflammation and the effectiveness in 
treating uveitis relapses following the diagnosis of DM compared to the period 
preceding the DM diagnosis.  
3) In patients with DM presenting with newly diagnosed uveitis, the aim was to 
describe the clinical and demographic characteristics of these patients as well as 
risk factors for vision loss if present and the rate of uveitis complications 
compared to uveitis patients without diabetes. 
4) Examine the rate of developing diabetic retinopathy in the setting of combined 
DM and uveitis. 
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3.3 Subjects and method 
The study setting and ethical approval were previously described in Chapter 2.  Patients 
with DM were selected from the uveitis cohort and were divided into two groups based on 
the timing of DM diagnosis in relation to the uveitis onset.  
3.3.1 Group 1 (diabetic patients diagnosed with uveitis) 
Patients were included in this group if they had an established diagnosis of DM by the 
patient’s general health practitioner, prior to experiencing new onset of uveitis. A minimum 
of one-year follow-up visits post uveitis diagnosis was required as well. 
Patient demographic data were collected including gender, age at time of uveitis diagnosis 
and uveitis classification and its aetiology if known. The date of DM diagnosis and its 
duration prior to the diagnosis of uveitis were documented. The type of DM (type 1 and 
type 2) together with the use of hypoglycaemic medications at time of uveitis diagnosis and 
any alteration in the DM therapy by the final visit were recorded. The random blood 
glucose levels as well as systolic and diastolic blood pressure were collected if documented 
in the case notes at time of uveitis diagnosis and annually over the follow-up period. 
Diabetic patients were considered to have hypertension if they were on antihypertensive 
medications initiated by their general health care provider. The level of diabetes control 
was assessed according to the NICE guidelines which agree on a HBA1c target between 48 
to 58 mmol/mol (6.5% to 7.5%) (175). The DM in this study was considered poorly 
controlled if the patient had an abnormal HbA1c level >7.5% or had abnormally high 
random blood glucose levels ≥200 mg/dL (11.1 mmol/L) on more than one occasion 
observed during the follow-up time with uveitis. 
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The BCVA were measured at time of uveitis diagnosis and onward on an annual basis until 
last visit together with the incidence of vision loss if occurred.  
After the DM group with uveitis were collected, a control group of uveitis patients with no 
prior or subsequent diagnosis of DM were also collected and matched according to the 
uveitis aetiology and other demographic characteristics. 
3.3.2 Group 2 (Uveitis patients diagnosed with diabetes) 
The second group include uveitis patients presenting with newly diagnosed DM. Patients 
were included if they had uveitis followed by the diagnosis of type 2 DM, including drug-
induced DM, with at least one year follow up period before and after diabetes diagnosis. 
Patients were excluded if they were already on hypoglycaemic medication or had 
documented medical history with type 1 or type 2 DM before the diagnosis of uveitis.   
In group 2 patients with uveitis, the diagnosis of DM was mainly done through detecting 
elevated random blood glucose level during routine assessment of uveitis patients made 
prior to starting them on systemic corticosteroids or IMT or during follow-up visits while 
on these medications. In these patients, the blood glucose level was measured by the nurse 
using finger-stick testing and the clinic glucometer. Occasionally, the abnormal blood 
glucose levels were detected during preoperative assessment of uveitis patients undergoing 
ocular surgery. DM was suspected when the patient show abnormally high random blood 
glucose levels ≥200 mg/dL (11.1 mmol/L), or abnormal HbA1c > 6.5% (174).  In these 
cases, the ophthalmologist would refer the patient to the general practitioner who would 
confirm the diagnosis and manage them accordingly. Occasionally, uveitis patients were 
diagnosed with DM as part of regular monitoring by the patients’ general practitioners or 
other healthcare providers outside MEH.  The DM was considered steroid-induced if the 
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diagnosis of DM occurred within 12 months after starting them on systemic 
corticosteroids(413). 
Patient demographic data were collected including gender, age at time of uveitis diagnosis, 
age at time of DM diagnosis, uveitis classification and its aetiology if known. The random 
glucose levels as well as systolic and diastolic blood pressures were collected if 
documented at time of DM diagnosis and annually afterward.  
The BCVA measured at time of DM diagnosis and onward at an annual interval were 
compared to the BCVA at baseline (the year prior to the diagnosis of DM). The prevalence 
of vision loss (≥ 6/15) was recorded together with uveitis complications that occurred prior 
to DM diagnosis and afterward. 
 Strategies for uveitis treatment and successful control of relapses using local corticosteroid 
injections, systemic corticosteroids and IMT were compared pre and post diagnosis of 
diabetes. Successful relapse control was defined as reduction in anterior chamber cells and 
flare scores to ≤ 0.5+ and/ or an improvement in the vitritis haze score to < 1+ within three 
months of starting an intervention.(139,417) Successful CMO treatment was defined as a 
reduction in the increased central retinal thickness and/or return of the normal foveal 
configuration following the elimination or reduction of the intraretinal cysts on OCT (418). 
In cases where OCT was not available, we relied on case note documentation of resolving 
CMO on fundus examination and improvement in BCVA to pre relapse levels within three 
months following intervention.  
For both groups of patients with DM, the prevalence of DR was recorded based on the 
ETDRS definitions and the classification (186) into either no DR, mild and moderate 
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NPDR (background DR), severe NPDR (pre-proliferative), and PDR together with 
reporting the presence or absence of CSMO based on the criteria described in Chapter 2. 
Uveitis complications as well as complications associated with DR were documented. 
CMO secondary to uveitis was distinguished from that due to DM by the presence of 
associated vitritis or other signs of uveitis activity and/or the absence of other features 
suggestive of DR such as retinal haemorrhages, microaneurysms, hard exudates, venous 
beading and intraretinal microvascular abnormalities. Strategies for uveitis treatment using 
local corticosteroid injections, systemic corticosteroids and IMT were documented. 
 
3.3.3 Statistical analysis  
Detailed description of the statistical method used was presented earlier in chapter 2. 
Repeated measurements analysis of the BCVA measurement and its difference from 
baseline was done using a multivariate linear regression method obtained from GEE test. 
Kaplan-Meier survival analysis with Log-Rank (Mantel-Cox) test were applied together 
with survival curve graphs to compare the survival rates for the incidence of vision loss, 
uveitis following diagnosis of DM, as well as incidence of cataract surgery among diabetic 
patients with uveitis. The HR and 95% C.I for vision loss and uveitis complications were 
measured using Cox proportional hazards regression analysis.  
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3.4 Results  
 
Two groups of patients with uveitis and DM had been identified from the uveitis database. 
In addition, a control group of uveitis patients with no history of DM had been randomly 
selected from the uveitis cohort as illustrated in Figure 3.1 . 
 
 
Figure 3.1 Flow diagram illustrating the two groups of patients with uveitis and DM 
together with a selected control group. 
 
 
 
 
Case records of 
1169 patients with uveitis
Group 1
DM diagnosed with 
uveitis
64 patients
Group 2
Uveitis patients 
diagnosed with DM
52 patients
Remaining uveitis 
patients with no 
diagnosis of  DM
Selected Control Group 
Uveitis with no DM
100 patients
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3.4.1 Group 1 (diabetic patients diagnosed with uveitis) 
In this group, 64 diabetic patients (99 eyes) were subsequently diagnosed with uveitis, 
accounting for 5.4% of the 1169 uveitis cohort. They were compared to a control group of 
100 uveitis patients (170 eyes) who lacked the diagnosis of DM and were selected from 
uveitis database to match with the DM cases based on the uveitis classification, patient age 
and follow-up time. Comparison of the demographic and clinical characteristics of both 
case and control groups are presented in Table 3.1.  
Following first visit with uveitis, diabetic patients were observed for a mean (SE) follow-up 
period of 7.3 (0.48) years, ranging from 1.2 to 22 years. This was not significantly different 
from the control group who had a mean follow up period of 9 (0.6) years, ranging from 1.6 
to 35 years (p= 0.13, Mann-Whitney test). The diabetic patient group were older on average 
at time of uveitis diagnosis compared to the control group (55 versus 43 years, p<0.001). 
The distribution of the uveitis types among diabetic patient was not significantly different 
from those in the control group (p=0.67, Chi-square test).  
Retinal vasculitis was observed in 12 eyes (12.1%) of patients with diabetes. Idiopathic 
uveitis (56.5%) and sarcoidosis (15.2%) accounted for the majority of cases of uveitis in 
this cohort of diabetic patients. Among the 56 eyes with idiopathic uveitis, 22 eyes had AU, 
20 eyes had IU, four had PU, and ten eyes had PANU. Infectious diseases were associated 
with uveitis in ten eyes (10.0%) including TB hypersensitivity (four eyes), HSV related 
uveitis (three eyes), syphilis (two eyes), and toxoplasmosis chorioretinitis (one eye). 
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Table 3.1 Demographic and clinical characteristics of group 1 diabetic patients 
presenting with uveitis and the control group of uveitis patients without diabetes. 
Variables 
DM & uveitis 
(64 patients, 99 eyes) 
Control  
(100 patients, 170 
eyes) 
Mean (SE) age at uveitis diagnosis, years  55 (1), range 31-78 43(1), range 21-86 
Mean (SE) duration of uveitis, years 8 (0.5)                   
range 1.2 -28.4 
11.8 (0.7)        
range 1.6- 45.5 
Patients with bilateral uveitis, n (%) 40 (62.5) 70 (70) 
Female, n (%) 29 (45.3) 68 (68) 
Eyes with infectious uveitis, n (%) 10 (10.1) 21 (12.4) 
Site of uveitis eyes (%)   
 Anterior uveitis 32 (32.3) 64 (37.6) 
 Intermediate uveitis 33 (33.3) 52 (30.6) 
 Posterior uveitis 6 (6.1) 6 (3.5) 
 Panuveitis 28 (28.3) 48 (28.2) 
Aetiology of uveitis, no. eyes (%)   
 Idiopathic  56 (56.5) 90 (53.0) 
 Sarcoidosis 15 (15.2) 29 (17.0) 
 Tuberculosis  hypersensitivity  4 (4.0) 13 (7.5) 
 Behcet’s  syndrome 4 (4.0) 8 (4.7) 
 Rheumatoid arthritis 2 (2.0) 2 (1.2) 
 Syphilis 2 (2.0) 2 (1.2) 
 HLA-B27 related uveitis 5 (5.1) 9 (5.3) 
 Vogt Koyanagi Harada syndrome 4 (4.0) 10 (5.9) 
 Herpes Simplex virus 3 (3.0) 3 (1.8) 
 Serpiginous Choroiditis 2 (2.0) 2 (1.2) 
 Sympathetic Ophthalmitis 1 (1.0) 1 (0.6) 
 Toxoplasmosis chorioretinitis 1 (1.0) 1 (0.6) 
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The majority of the patients involved in this study had type 2 DM, with only six cases 
(9.4%) of type 1 DM. The median duration of diabetes until time of uveitis diagnosis was 
4.6 years (IQR 2 to 9 years). Figure 3.2 shows the survival curve for the incidence of 
uveitis from time of DM diagnosis according to the type of DM, with more than half of the 
eyes having their onset of uveitis within the first five years after diagnosis of DM. Uveitis 
was diagnosed in a median of 14.4 years (IQR 13.3 to 31.5 years) from onset of type I DM, 
and in a median of 4.2 years (IQR 1.8 to 8 years) from onset of type 2 DM. The delay in the 
onset of uveitis in patients with type 1 compared to type 2 DM was found to be statistically 
significant (p=0.001, Log Rank Mantel-Cox test). 
 
Figure 3.2 Kaplan-Meier survival curve for the incidence of uveitis following the 
diagnosis of type 1 and type 2 diabetes mellitus 
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In diabetic patients, the median BCVA at first visit was 0.18 LogMAR (IQR 0.0 to 0.60), 
which did not differ significantly from the median BCVA of 0.18 LogMAR (IQR 0.0 to 
0.48) measured at the last follow up visit (p=0.12, Wilcoxon signed ranks test).  The 
median baseline BCVA in the diabetic group was significantly different from the control 
group who had a median BCVA of 0.18 LogMAR (IQR 0.0 to 0.30) (p<0.002, Mann-
Whitney test). Over the follow-up period, there was an average improvement in BCVA of 
diabetic patients with uveitis up to 0.05 LogMAR over 10 years follow-up period. 
However, such change in the BCVA did not differ significantly from baseline vision at time 
of uveitis diagnosis nor there was a difference between diabetic cases compared to the 
control group with similar follow-up period as observed in Table 3.2.  This occurred despite 
a good study power of 0.91. 
Table 3.2 Change in best corrected visual acuity (LogMAR) over the follow-up period 
from baseline (time of uveitis diagnosis)  in group 1 diabetic patients presenting with 
uveitis and in comparison to the control group 
Follow up time 
No. eyes 
B 
Standard 
Error 
95% Confidence Interval P 
value* Lower Upper 
Baseline 99 0 . . . - 
1 year 99 -.057 .0550 -.164- .051 .302 
2 years 97 -.021 .0389 -.097- .055 .592 
3 years 89 -.044 .0641 -.170 .082 .493 
4 years 80 -.051 .0664 -.181 .079 .443 
5 years 64 -.042 .0618 -.163 .079 .500 
7 years 53 -.042 .0657 -.171 .087 .523 
10 years 29 -.056 .0659 -.185 .073 .397 
Final visit 99 -.015 .0720 -.156 .126 .831 
1 year * group 99/170 .02 .06 -.10 .15 .71 
5 years* group 64/114 -.09 .10 -.29 .11 .39 
10 years* group 29/46 -.006 .12 -.24 .23 .96 
*Repeated measurement analysis using generalised estimating equation. 
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Over the follow-up period, the most common ocular complication in this cohort of diabetic 
patients with uveitis was cataract (62.6%) followed by macular oedema (45.5%) and 
glaucoma (31.3%), all of which were significantly more prevalent in diabetic cases 
compared to the control group as presented in Table 3.3. The prevalence of CNVM and 
RPE atrophy were also significantly more observed in uveitis eyes of diabetic patients 
compared to control group while no significant difference was observed between both 
groups in terms of other uveitis complications.  By the final visit, vision loss occurred in 28 
eyes (28.2%) with equal distribution in the incidence of moderate and severe vision loss 
and was found to be significantly more common to occur compared to the control group 
(28.2% versus 8.2%, p<0.001). The most common causes for vision loss in diabetic patients 
were RPE atrophy, accounting for 35.7% of eyes with vision loss, and macular scar 
secondary to CNVM which was observed in 28.5% of cases with vision loss.  
Vision loss in diabetic patients occurred at a median interval of 1.16 years (IQR 0.03-5.9 
years), ranging from the time of uveitis diagnosis (in six eyes) up to 14 years following the 
onset of uveitis. There was a statistically significant difference in the incidence rate of 
vision loss between DM cases with uveitis compared to the control group (Log Rank 
Mantel-Cox test <0.001) (Figure 3.3).  
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Table 3.3 Ocular complications and causes of vision loss among diabetic patients 
presenting with uveitis and the control uveitis group. 
Complications Eyes; N (%) MVL  SVL  
 Case       Control p Case    Control Case Control 
Vision loss 28 (28.3) 14 (8.2) <0.001 - - - - 
Corneal clarity defect 3 (3.0) 3 (1.8) 0.38 -  1 - 
Cataract 62 (62.6) 38(22.4) <0.001 2 - - - 
Macular oedema 45 (45.5) * 31(18.2) <0.001 3 1 - - 
Retinal detachment 1 (1.0) 6 (3.5) 0.20 - - 1 1 
RPE atrophy 10 (10.1) 4 (2.4) 0.01 8 4 2 2 
CNVM 8 (8.1) 2 (1.2) 0.006 - - 8 1 
Epiretinal membrane 12 (12.1) 10 (5.9) 0.06 -  - - 
Optic neuropathy 7 (7.1) 4 (2.4) 0.06 - 1 1 3 
Macular ischaemia 1 (1.0) 0 (0) 0.20 1 - - - 
Glaucoma  31 (31.3) 12 (7.1) <0.001 - - 1 - 
Vitreous Haemorrhage 2 (2.0) 0 (0) 0.16 - - - - 
Retinal vein occlusion 3 (3.0) 0 (0) 0.15 - - - - 
Phthisis 0 (0) 1 (0.6) 0.20 - - - 1 
Postoperative 
inflammation 
2 (2.0) 0 (0) 0.16 - - - - 
Total    14(14) 6 (3.5) 14(14) 8 (4.7) 
N= Numbers; RPE= Retinal pigment epithelium; CNVM = Choroidal neovascular membrane; 
MVL=Moderate vision loss, SVL = Severe vision loss.  
* Five out of the 45 eyes with macular oedema had diffuse, clinically significant macular oedema associated 
with diabetic retinopathy. 
P value calculated using Chi-square test or Fisher’s exact test accordingly. 
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Figure 3.3 Kaplan-Meier survival curve for the incidence of vision loss (6/15 or worse) 
in group 1 (diabetic patients presenting with uveitis) and the control group, showing a 
higher rate of vision loss in the diabetic cases when compared to the control group 
(Log Rank test <0.001). 
 
 
 
 
Table 3.4 is mainly concerned with risk factors for vision loss among diabetic patients with 
uveitis. Macular scarring was associated with increased risk of vision loss with a HR of 6.7 
(C.I 2.9-15.6, p=<0.001) which persists even after adjusting for other potential risk factors 
for vision loss.  There was a significant increase in the risk of vision loss among patients 
with hypertension (HR 2.6, p=0.012) but this lost its significance when adjusted for other 
confounding risk factors. Uveitis complicated with ERM formation (HR 2.4, p=0.04) and 
RPE atrophy (HR 5.6, P<0.001) were both considered significant factors for vision loss. 
However, these factors also lost significance when adjusted for other factors. 
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Table 3.4 Risk factors for vision loss in diabetic patients presenting with uveitis 
Variables 
Crude risk 
         HR(C.I)             P value 
Adjusted risk 
      HR (C.I)       P value 
Male gender 0.62 (0.29-1.33) 0.22 - - 
Age at diagnosis of uveitis 1.07 (1.03 – 1.1) 0.001 1.05 (1.0 – 1.2 0.06 
Hypertension 2.64 (1.23-5.67) 0.01 2.6 (0.6-5.1) 0.05 
Type 2 DM 1.57 (0.37-6.7) 0.53 - - 
Diabetes control 1.91 (0.8-4.6) 0.14 1.7 (0.5-5.3) 0.35 
Diabetic retinopathy 1.48(0.59-3.6) 0.39 - - 
Non-Anterior uveitis 1.5 (0.65-3.6) 0.32 - - 
Infectious aetiology of uveitis 1.5 (0.52-4.3) 0.45 - - 
Use of systemic prednisolone 0.53 (0.25-1.12) 0.10 0.83 (0.2-5.4) 0.75 
IMT 2.8 (1.33-6.0) 0.013 1.2 (0.28-5.4) 0.77 
Cataract 1.9 (0.78-4.8) 0.14 - - 
Cataract surgery 0.61 (0.25-1.5) 0.29 - - 
Macular oedema 1.1 (0.55-2.5) 0.65 - - 
RPE atrophy 5.6 (2.4-13.0) <0.001 1.7 (0.44-7.2) 0.41 
Macular scarring 6.7 (2.9-15.6) <0.001 5.7 (1.4-22.1) 0.01 
Epiretinal membrane 2.4 (1.03-5.9) 0.04 2.3 (0.8-6.2) 0.10 
Optic neuropathy 1.2 (0.3-5.4) 0.74 - - 
Flare-up rate per eye-year 0.69 (0.28-1.6) 0.41 - - 
 
Meanwhile within the control group, RPE atrophy was the main risk factor for vision loss, 
increasing the risk by 5.8 times compared to eyes without RPE atrophy, and such factor 
remained significant even after adjusting for the presence of optic neuropathy. The 
remaining factors were not found to be significantly contributing to vision loss among 
control group of uveitis eyes without DM (Table 3.5). 
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Table 3.5 Risk factor for vision loss in the control group of uveitic eyes without 
Diabetes Mellitus 
Variables 
Crude risk 
         HR(C.I)             P value 
Adjusted risk 
      HR (C.I)       P value 
Male gender 0.7 (0.2-2.8) 0.67 - - 
Age at diagnosis of uveitis 1.01 (0.97-1.0) 0.37 - - 
Non-Anterior uveitis 6.7 (0.87-52.2) 0.06 - - 
Infectious aetiology of uveitis 0.7 (0.1-6.0) 0.80 - - 
Use of systemic prednisolone 2.1 (0.6-7.1) 0.21 - - 
IMT 0.95 (0.2-4.3) 0.95 - - 
Cataract 1.5 (0.4-5.1) 0.47 - - 
Macular oedema 0.8 (0.1-3.8) 0.82 - - 
RPE atrophy 19.3 (4.0-94.0) <0.001 5.8 (2.4 –13.6) <0.001 
Macular scarring 0.4 (0-413) 0.81 - - 
Epiretinal membrane 1.4 (1.9-11.3) 0.71 - - 
Optic neuropathy 40 (11-136) <0.001 1.5 (0.3 – 6.8) 0.53 
 
The risk of acquiring uveitis complications was compared between both the DM cases with 
uveitis and their control group in Table 3.6.  The risk of vision loss among uveitic eyes of 
DM patients was 4.6 times higher compared to the control group, and such risk was found 
to be statistically significant (<0.001) which persisted even after adjusting for other 
associated factors and for anatomical site of uveitis. In addition, the risk of acquiring uveitis 
complications including cataract, macular oedema, RPE atrophy, macular scarring and 
ERM formation were all found to be significantly more among uveitic eyes of DM patients 
compared to the control group. 
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Table 3.6 The risk of developing uveitis complications in diabetes patient with uveitis 
compared to their control group 
Variables 
Crude risk 
         HR(C.I)             P value 
Adjusted risk 
      HR (C.I)       P value 
Vision loss (6/15 or worse) 4.6 (2.3-9.2) < 0.001 6.2 (3.0-12.7) < 0.001 
Cataract 5.7 (3.6-9.0) < 0.001 5.7 (3.6-9.0) < 0.001 
Macular oedema 4.7 (2.8-7.7) < 0.001 4.4 (2.7 – 7.3) < 0.001 
RPE atrophy 6.6 (1.9-22.3) 0.002 6.0 (1.8-20.3) 0.003 
Macular scarring 13.7 (2.7-70) 0.002 10.8 (2.1 – 68) 0.004 
Epiretinal membrane 3.6 (1.4-9.0) 0.005 3.3 (1.3-8.3) 0.008 
Optic neuropathy 4.9 (1.2-19) 0.02 4.6 (1.2-19) 0.02 
Non anterior uveitis - - 2.0 (0.9 – 4.5) 0.06 
 
At the time of first visit of DM cases with uveitis, 42 patients (65.6%) were on one oral 
hypoglycaemic therapy at time of first visit with uveitis compared to two patients (3.1%) on 
two oral hypoglycaemic medications, six patients (9.3%) on diet control, and 14 patients 
(22.0%) on insulin therapy. All of the patients initially managed with diet control did 
eventually started on oral hypoglycaemic medication. The management of diabetes also 
changed in some cases over the follow-up period and by the last visit the use of insulin 
increased to 20 patients (31.3%), while 39 patients (60.9%) were on one oral 
hypoglycaemic therapy, and five patients (7.8%) were on two oral hypoglycaemic 
medications.  
 At time of uveitis diagnosis, the majority of cases had no DR and only 12 eyes of 8 
patients (12.1%) had variable grades of DR ranging from mild to moderate NPDR (7 eyes 
of 5 patients), NPDR with associated CSMO (3 eyes of 2 patients) and PDR (both eyes of 
one patient). Progression of DR occurred in 17 eyes of 12 patients (18.8%), of whom nine 
patients had no DR at the initial visit. By the time of the last follow up visit, 17 patients had 
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DR in the form of mild to moderate NPDR (16 eyes of 10 patients), severe NPDR 
associated with CSMO (5 eyes of 4 patients), and PDR (4 eyes of 3 patients). 
Hypertension was observed in 24 patients (37.5%) with diabetes. Repeated measurement of 
blood pressure (minimum of two measurements) was only available in 45 patients and the 
average levels of systolic and diastolic measurements over 7 years follow up are presented 
in Figure 3.4 and Figure 3.5 respectively. The mean systolic pressure at onset of uveitis 
(baseline) was 127 mmHg (SE 3). Although this was increased after six months with a MD 
of 3 mmHg (SE 4) from baseline, such difference was not statistically significant (p= 0.44, 
GEE). The mean systolic blood pressure also didn’t change significantly from baseline 
following one year (MD 0.5 mmHg, p=0.91), 2 years (-1.3 mmHg, p=0.8) and 3 years (MD 
1.4mmHg, p=0.80) following the diagnosis of uveitis.  The mean diastolic blood pressure at 
time of uveitis diagnosis was 76 mmHg (SE 1.6) which increased after six months by a MD 
of 2.8 mmHg (SE 2.1) from baseline, although it didn’t reach a statistical significance 
(p=0.18, GEE). The average diastolic blood pressure over the 7 years follow up period was 
not statistically significant from that measured at baseline.  
Random blood sugar level at time of uveitis diagnosis was available in 27 patients, 
measuring an average of 10.8 mmol/L (SE 0.74) and ranging from 3.1mmol/L to as high as 
22mmol/L, 13 patients (48.0%) had their random blood sugar ≥11mmol/L at the initial visit 
with uveitis. HbA1c levels at the time of uveitis diagnosis were only available in 6 patients 
(9.3%) with diabetes. Interestingly, 5 out of these 6 patients had their HbA1c levels above 
the upper normal levels (5.7%, 7%, 7.4%, 8.0%, 10.2% and 14.0%), with a total average of 
8.7%. 
138 
 
 
Figure 3.4 The mean and standard deviation of systolic blood pressure in diabetic 
patients at time of uveitis diagnosis (time zero) and onward up to seven years. N= 
number of patients  
 
 
Figure 3.5 The mean and standard deviation of diastolic blood pressure in diabetic 
patients at time of uveitis diagnosis (time zero) and onward up to seven years. N= 
number of patients  
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The average number of uveitis relapses is presented in Figure 3.6. The overall rate of 
uveitis flares up was 0.59 relapse per EY. During the first year following the diagnosis of 
uveitis, the mean number of uveitis relapse was 1.25 (SE 0.09), which reduced afterward 
into a mean of 0.5 relapse (SE 0.09) in the second year, 0.53 relapse (SE 0.09) in the third 
year, 0.27 relapse (SE 0.06) in the fourth year, and 0.4 relapse (SE 0.07) in the fifth year 
follow-up period.  
 
 
Figure 3.6 Average number of uveitis relapse in group 1 diabetic patients presented 
with uveitis. N= Number of eyes 
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The medical and surgical approaches in managing uveitis and its complication among the 
diabetic cohort are presented in Table 3.7. Almost half of the patients were on systemic 
corticosteroids at one point, whereas 23.0% of the eyes required further control of uveitis 
using a steroid sparing medication. About 24.0% of the eyes received periocular or 
intraocular steroid injections, while intravitreal anti-VEGF was given in 10.0% of the eyes 
for managing CNVM (eight eyes) NVI (one eye), and CSMO (one eye). Viterectomy was 
performed for ERM peeling (two eyes), and for managing nucleus drop into the vitreous 
during a complicated cataract surgery (one eye). CSMO was managed with macular grid 
laser (3 eyes), IVTA (one eye), and anti-VEGF (one eye). In one case, management of 
macular oedema with IVTA was complicated with sterile endophthalmitis post injection. 
 
Table 3.7 Management of uveitis and its complications in group 1 diabetes patients 
presenting with uveitis. 
Variables Eyes; N (%) 
Systemic prednisolone, n (%) 44 (44.4) 
Immunosuppressive therapy, n (%) 23 (23.2) 
Local ocular injection, n (%) 
- OFI 
- IVTA 
- Anti-VEGF 
 
11 (11.1) 
13 (13.1) 
10 (10.0) 
Laser photocoagulation 9 (9.0) 
Cataract surgery 29 (29.3)  
Glaucoma filtration surgery 8 (8.0) 
Viterectomy 3 (3.0)  
N= Number; OFI=Orbital Floor Injection; IVTA=Intravitreal Triamcinolone, VEGF=Vascular endothelial 
drive growth factor  
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Fourteen eyes were already pseudophakic at time of uveitis diagnosis, leaving 85 phakic 
eyes, of which one third required cataract surgery over the follow-up period of this study. 
Cataract surgery was performed at a median of 3.6 years (IQR 2.3 – 9.3 years) from the 
time of uveitis diagnosis. The risk of requiring cataract surgery in diabetic patients 
following the diagnosis of uveitis is illustrated in the survival analysis Figure 3.7. Those 
who had cataract surgery prior to the diagnosis of uveitis have been excluded (14 eyes). 
About 25.0% of the eyes at risk had undergone cataract surgery within the first 5 years 
following diagnosis of uveitis. In one eye, cataract surgery was associated with 
intraoperative complication in the form of ruptured posterior capsule and nucleus drop 
which required removal through vitrectomy and insertion of an anterior chamber IOL. 
 
Figure 3.7 Kaplan-Meier survival curve for the incidence of cataract surgery in group 
1 (diabetic patients presented with uveitis)  
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3.4.2 Group 2 (Uveitis patients diagnosed with diabetes) 
In this group, 96 eyes of 52 uveitis patients were subsequently diagnosed with DM, 
accounting for 4.4% of the 1169 uveitis patient cohort. The diagnosis of DM occurred 
within a mean of 8.4 years (SE 0.68) from time of diagnosis of uveitis. Thirty-eight patients 
(73%) were considered steroid-induced DM, accounting for 3.2% of the uveitis cohort 
versus 1.2% of the uveitis cases who were diagnosed with DM despite the lack of prior 
corticosteroid use.  
Following the diagnosis of DM, patients were subsequently monitored for an average 
follow-up period of 10.3 (0.2) years until last visit. The main demographic and clinical 
characteristics of the studied cohort are presented in Table 3.8.  Half of the uveitis eyes 
were idiopathic while sarcoidosis was the most common disease associated with uveitis in 
this group. Hypertension was observed in 17 patients (32.7%) with a median of 120mmHg 
(IQR 110-140) systolic blood pressure and 80mmHg (IQR 70-90) diastolic blood pressure 
at time of DM diagnosis.   
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Table 3.8 Demographic and clinical characteristics of 52 patients (96 eyes) with uveitis 
presenting with diabetes mellitus. 
Variables Results 
Mean age at uveitis diagnosis (SE), years  46.2 (1.1) 
Mean age at onset of DM (SE), years 54.6 (1.1) 
Female (%) 28(54.0) 
Visual acuity at first clinic visit  
 6/15 to 6/36, n (%) 25(26.0) 
 ≥ 6/60, n (%) 9 (9.3) 
Visual acuity at last follow up visit  
 6/15 to 6/36, n (%) 12 (12.5) 
 ≥ 6/60, n (%) 18 (18.8) 
Unilateral uveitis patients, n (%) 8(15.3) 
Site of uveitis eyes, n (%)  
 AU 29 (30.2) 
 IU 28 (29.2) 
 PU/PANU 39(40.6) 
Aetiological causes of uveitis eyes, n (%)  
 Idiopathic  48(50) 
 Sarcoidosis 13(13.5) 
 Multifocal choroiditis 8(8.3) 
 Behcet’s  syndrome 7 (7.3) 
 HLA-B27 related uveitis 4 (4.2) 
 Tuberculosis  hypersensitivity  4 (4.2) 
 Post ocular surgery 3 (3.1) 
 Posner Schlossman syndrome 2 (2.1) 
 Pars Planitis 2 (2.1) 
 Vogt Koyanagi Harada Syndrome 2 (2.1) 
 Acute retinal necrosis 2 (2.1) 
 Idiopathic retinal vasculitis 1 (1.0) 
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The median BCVA at first visit with uveitis was 0.18 LogMAR (IQR 0.00-0.48) which 
didn’t differ significantly when compared to the median vision of 0.18 LogMAR (IQR 
0.00-0.60) at final visit (p=023, Wilcoxon signed ranks test). An initial BCVA of ≥ 6/15 
was observed in 34 eyes (35.3%) during their first visit with uveitis compared to 30 eyes 
(31.3%) at final follow-up visit, including 13 eyes from first visit that progressed to vision 
loss. The distribution of eyes with vision loss was not different between the first and last 
visit when tested using McNemar test (p=0.58).   
The median (IQR) BCVA of uveitic eyes over 10 years follow-up before and after the 
diagnosis of DM is presented in Table 3.9 with a median BCVA of 0.18 LogMAR (IQR 
0.00-0.48) at time of diabetes diagnosis.  
Table 3.9 Median and interquartile range (IQR) of visual acuity in uveitic eyes before 
and after diagnosis of diabetes mellitus (time zero) 
Time 
(Years) 
No. 
eyes 
Median 
BCVA 
(Logmar) 
IQR 
Time 
(Years) 
No. 
eyes 
Median 
BCVA 
(Logmar) 
IQR 
0 96 0.18 0.00 to 0.48     
-1 96 0.18 0.00 to 0.30 +1 96 0.24 0.00 to 0.48 
-2 66 0.18 0.00 to 0.30 +2 88 0.18 0.00 to 0.48 
-3 62 0.09 0.00 to 0.48 +3 84 0.18 0.00 to 0.48 
-4 57 0.18 0.00 to 0.39 +4 71 0.18 0.00 to 0.48 
-5 41 0.18 0.00 to 0.54 +5 73 0.18 0.00 to 0.77 
-6 37 0.18 0.00 to 0.80 +6 63 0.30 0.00 to 0.6 
-7 35 0.00 0.00 to 0.48 +7 52 0.24 0.00 to 1.00 
-8 35 0.18 0.00 to 0.60 +8 39 0.30 0.00 to 1.00 
-9 30 0.00 0.00 to 0.48 +9 32 0.48 0.18 to 1.00 
-10 22 0.18 0.00 to 0.82 +10 22 0.39 0.00 to 1.00 
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The average BCVA was 0.31± 0.06 LogMAR at baseline (one year pre DM diagnosis) and 
0.44± 0.07 LogMAR at the time of DM diagnosis. Compared to baseline, 20 eyes (21.0%) 
lost one line of vision and 22 eyes (23.0%) lost two lines or more at time of DM diagnosis. 
After adjusting for the presence of CMO and cataract which required surgical removal, the 
BCVA at time of diagnosis of diabetes had a significant reduction from baseline by a MD 
of 0.11 LogMAR (p= 0.02, 95% CI 0.02-0.20, GEE). The significant reduction in BCVA 
was also observed at one year (MD 0.13 LogMAR, 95% CI 0.04-0.19, p=0.006), and two 
years (MD 0.10 LogMAR, 95% CI 0.01-0.20, p=0.03) post diagnosis of diabetes (Figure 
3.8). No significant reduction in BCVA was observed from baseline during the third, fourth 
and fifth years post diabetes diagnosis (p > 0.05) (Table 3.10). 
 
Figure 3.8 Average change in best corrected visual acuity (LogMAR) within five years 
post diagnosis of diabetes (Time zero) compared to the year before diagnosis 
(baseline) (* p<0.01) 
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Table 3.10  Changes in the best corrected visual acuity (LogMAR) of uveitic eyes 
following diabetes diagnosis compared to baseline (the year prior to diabetes 
diagnosis) 
Variables B 
Standard 
Error 
95% Confidence Interval 
P valuea 
Lower Upper 
Visits      
Baseline 0 - - - - 
               Time zero b 0.112 0.046 0.020 0.204 0.016 
               One year 0.127 0.046 0.036 0.218 0.006 
              Two years 0.101 0.046 0.010 0.191 0.028 
              Three years 0.088 0.047 -0.004 0.180 0.062 
              Four years 0.083 0.045 -0.005 0.173 0.066 
              Five years 0.105 0.054 -0.001 0.211 0.053 
Cataract 0.221 0.228 -0.226 0.668 0.332 
Cystoid macular oedema 0.097 0.081 -0.062 0.256 0.232 
a Correlation between eyes accounted for using the generalised estimating equation (GEE). 
b Time zero refers to the time of diabetes diagnosis 
 
At time of DM diagnosis, 30 eyes (31.2%) had BCVA of 6/15 or worse, which was not 
significantly different from the percentage of eyes with vision loss at time of final visit 
(p=0.45, McNemar test).  Among eyes with vision loss at time of DM diagnosis (time 
zero), cataract was the main cause and occurred in 12 eyes (12.5%) of 11 patients, 
including eight eyes (eight patients) that underwent cataract surgery within the first a year 
from the diagnosis of diabetes. The second most common cause of vision loss at time of 
DM diagnosis was new onset of CMO that occurred within three months prior to DM 
diagnosis in 11 eyes (11.4%) of seven patients.  
By the final visit, 30 eyes (31.2%) with uveitis had vision loss. Among these cases, 10 eye 
had their onset of vision loss prior to the diagnosis of DM which was secondary to macular 
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scar (2 eyes), phthisis bulbi (2 eyes), chronic CMO (2 eyes), RPE atrophy (1 eye), retinal 
detachment (1 eye), macular ischaemia (1 eye), and macular hole (1 eye). During the period 
following the diagnosis of DM, 20 eyes developed vision loss secondary to RPE atrophy (5 
eyes), chronic CMO (4 eyes), macular scar (3 eye), glaucoma (2 eyes), ERM (2 eyes), 
cataract (1 eye), previous retinal detachment (1 eye), phthisis bulbi (1 eye), and corneal 
decompensation (1 eye).  ERM formation was associated with 4 fold increase in the risk of 
vision loss in uveitic eyes following the diagnosis of DM (HR 4.0, 95% C.I 1.2-13.0, 
p=0.02) even when adjusting for other potential factors for vision loss. Meanwhile, CMO 
and glaucoma, although associated with about a two fold increase in the risk of vision loss, 
such risk didn’t reach a statistically significant level, nor did other factors like gender, 
steroid-induced DM, retinal detachment, cataract, and RPE atrophy (Table 3.11). 
Table 3.11 Risk factors for vision loss in uveitis eyes following the diagnosis of 
diabetes mellitus 
Variables 
Crude risk 
     HR (C.I)                P value 
Adjusted risk  
HR (C.I)          P value 
Female patients 0.87 (0.36-2.1) 0.77 - - 
Steroid induced diabetes 1.0 (0.38-2.9) 0.91 - - 
Cataract 1.6 (0.68-3.9) 0.26 - - 
Cystoid macular oedema 2.11 (0.8-5.1) 0.09 1.6 (0.6-4.3) 0.33 
Glaucoma 2.2 (0.94-5.4) 0.068 2.1 (0.8-5.6) 0.13 
Retinal pigment epithelium 
atrophy 
1.03 (0.13-7.8) 0.97 - - 
Retinal detachment 4.0 (0.91 – 17.7) 0.06 4.7 (0.8-26) 0.07 
Epiretinal membrane 3.7 (1.17-11.6) 0.02 4.0 (1.2-13) 0.02 
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During the year post DM diagnosis, the average daily dose of prednisolone was 
significantly lower compared to the year prior to diagnosis (14.7 mg /day versus 10.2 mg 
/day, p=0.03, Wilcoxon signed rank test). Twenty two patients (42.0%) were using 
systemic corticosteroids over the year prior to DM diagnosis which didn’t differ 
significantly when compared to 24 patients (46.0%) on corticosteroids over the year post 
DM diagnosed (p = 0.7, Mc Neemar test). Similarly, no statistically significant difference 
was observed in the proportion of patients using IMT therapy over the year pre DM 
diagnosis versus the year post DM diagnosis (17.0% versus 19.0% respectively, p = 0.95) 
nor in the proportion of eyes treated with OFI/IVTA (10.5% versus 10.5% respectively, 
p=0.95). 
The treatments used for uveitis relapses are presented in Table 2.10. There was a reduction 
in the proportion of relapses treated with systemic steroids from 97/138 (70.2%) pre 
diabetes to 50/90 (55.6%) post diabetes diagnosis. On the other hand, treatment of relapses 
with local steroid injection in combination with systemic steroid increased from 5 (3.6%) 
pre diabetes to 14 (15.5%) post diabetes. The difference in the use of systemic 
corticosteroids alone or combined with local corticosteroid injections pre and post DM was 
found to be statistically significant (p= 0.003, Chi square test). On three occasions, 
treatment had to be modified due to the presence of hyperglycaemia; one case had bilateral 
CMO treated using OFIs instead of increasing systemic prednisolone because of the 
patient’s poor glycaemic control. The other two cases were started on 40 mg rather than 60 
mg systemic prednisolone to treat uveitis flare up. There was no statistically significant 
difference in the success rate of relapse treatment using systemic steroid, OFI/IVTA, or 
combination of both when compared before and after the diagnosis of diabetes.   
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Table 3.12 Treatment of uveitis relapses before and after the diagnosis of diabetes in 
52 patients (96 eyes). 
Relapse 
treatment 
Pre DM 
relapses, 
n(%) 
Post DM 
relapses, 
n(%) 
P 
Valuea 
Pre DM 
Treatment 
success, n(%) 
Post DM 
Treatment 
success, n(%) 
P 
Valuea 
systemic 
steroids b 
97 (70.2) 50(55.6) 
 
0.003 
 
52/97 (53.6) 35/50 (70.0) 0.055 
OFI or IVTA 
with oral 
steroid 
5 (3.6) 14 (15.5) 3/5 (60.0) 10/14 (71.4) 0.60 c 
OFI or IVTA 
alone 
36 (26.2) 26 (28.9) 11/36 (30.5) 13/26 (50.0) 0.12 
Total relapses 138 (100) 90 (100)     
a Chi square test       b. systemic steroids alone or with IMT            c. Fisher exact test     
 
 
Of 96 eyes with uveitis and DM, seven eyes (7.3%) of six patients developed mild to 
moderate NPDR, which occurred at a median of six years (range 2-11years) following the 
diagnosis of DM, all of which occurred while patients were on oral hypoglycaemic 
medications. CSMO occurred in one patient with idiopathic panuveitis three years after 
being diagnosed with DM, requiring grid laser treatment. 
3.5 Discussion 
This chapter looked at the interaction between DM and uveitis through two studied groups; 
the first group looked specifically at the characteristics and clinical outcome of new uveitis 
diagnosis among DM patients while the second group looked at the influence of new 
diagnosis of DM on the clinical course and management of uveitis patients. 
The incidence of steroid-induced DM was 3.2% of the uveitis cohort whereas non-steroid 
induced DM was observed in 1.2% of the uveitis cases. This was slightly more than the 
reported risk of developing DM in the SITE study, which showed an incidence of steroid- 
induced DM to be 1.2% and an incidence among those without prior intake of 
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corticosteroids to be 0.19% (413). This can be attributed to the method of DM diagnosis in 
the SITE study which depended on history of initiating hypoglycaemic medications in the 
uveitis patients whereas the diagnosis of DM in our cohort were additionally based on 
abnormal blood glucose levels observed during regular follow up visits at the uveitis clinic. 
The onset of uveitis was significantly delayed in patients with type 1 DM (median 14.4 
years) when compared to type 2 DM (median 4.2 years).  This could be attributed to the 
time when type 1 DM is typically diagnosed at a younger age (mean 6.5 years of age) when 
compared to type 2 DM (419). 
In both groups of diabetic patients, idiopathic uveitis and sarcoidosis were the most 
common aetiological classifications of uveitis types. While most of the studies on diabetic 
patients presenting with idiopathic uveitis are AU (396–398), only 40.0% of our of diabetic 
cohort with idiopathic uveitis were AU.  Within the first group of diabetic patients, 10.0% 
of the uveitic eyes had an infectious aetiology, which was similar to another study on 
diabetic patients among which 12.5% were presented with an infectious aetiology (403). 
We reported the time from diabetes diagnosis to onset of uveitis as median of 4.2 years, 
using median as the data was not normally distributed.  However, for the purpose of 
comparison, the mean duration between time of DM diagnosis and the first presentation 
with uveitis in this study was 6.9 years (SD 6.4) which was almost identical to the mean 
duration of 6.8 years (SD 8.3) reported by Oswal et al (403).  
The first group did not have a significant difference in the repeated measurement of their 
BCVA when compared to their vision at time of uveitis onset. This is unlike the second 
group of uveitis cases which, when compared to the year preceding the diagnosis of uveitis, 
showed a significant reduction in BCVA at time of diabetes diagnosis and for up to two 
years afterwards. The visual acuity, however, gradually returned to its prediabetic level 
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over the 3rd, 4th and 5th years post diabetes diagnosis. This reduction in BCVA soon after 
the onset of DM was most likely attributable to new onset CMO or accelerated progression 
of cataract, both associated with the diagnosis of DM. Both DM and uveitis have been 
associated with breakdown of BRB leading to increased vascular permeability with 
subsequent fluid retention and formation of CMO (256). Uveitis and DM combined would 
have a synergistic effect on the development of CMO and cataract, increasing the chance of 
visual loss from these complications. Alternatively, the drop in vision at the time of DM 
diagnosis occurred secondary to uveitis relapse or CMO formation requiring the use of high 
dose of systemic corticosteroids, which in turn triggered the onset of DM.   
In this study, vision loss occurred in 28.2% of group 1 diabetic patients who subsequently 
developed uveitis, which was similar to the results of a study by Oswal et al who reported a 
final BCVA of 6/18 or worse in one third of the eyes from 36 diabetic patients presented 
with uveitis (407). The risk of vision loss among uveitic eyes of DM patients was 4.6 times 
higher when compared to the control group, mainly because the former group had also a 
significantly higher risk of uveitis complications which included cataract, macular oedema, 
RPE atrophy, all of which are also known ocular complications of DM as well. The cause 
of vision loss in our group 1 cohort was mainly secondary to RPE atrophy and CNVM 
associated macular scarring. This was different from the Oswal et al study which mainly 
attributed the vision loss to be secondary to new and chronic CMO, cataract and glaucoma. 
The mechanism of CNVM and RPE atrophy in our diabetic patients is not clear. While this 
finding could be coincidental, other explanations could be related to the increased 
expression of COX-2 and VEGF observed in diabetic patients leading to an increased risk 
of CNVM formation within uveitis associated retinal atrophy or scars. The pathogenesis of 
CNVM is multifactorial, but there is increasing evidence to suggest that COX enzymes can 
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contribute to its formation. COX-2 can be found in the RPE cells and is mainly upregulated 
by proinflammatory cytokines. Studies on diabetic rats found COX-2 to play an important 
role in the production of PGE2 and VEGF in the retina (204,205) which could eventually 
lead to BRB discruption, mediate leukocyte migration and promote CNVM formation 
(420). The role of COX-2 in the formation of CNVM has also been supported by the 
positive expression of COX-2 within CNVM of human eyes (421).  
Management of CMO due to uveitis in diabetic patients can be challenging. Bilateral CMO 
in patients with non-infectious uveitis would ideally be treated with high dose systemic 
corticosteroid. However, in the presence of uncontrolled hyperglycaemia this treatment 
option carries an increased risk of inducing diabetic ketoacidosis and thus may be replaced 
with local administration of corticosteroid or using a lower starting dose of systemic 
corticosteroid and more rapid tapering. In our second group cohort, uveitis relapses that 
occurred during the period post DM diagnosis were significantly more likely to be managed 
by adding OFI/IVTA rather than increasing the dose of systemic corticosteroid. In addition, 
the mean dose of systemic prednisolone was significantly reduced in the year post DM 
diagnosis when compared to the previous year.  
Among DM patients who had blood tests at time of presenting with uveitis, most cases 
showed poor hypoglycaemic control with an average blood glucose level of 10.8mmol/L 
and 48% had a random blood sugar ≥11mmol/L together with an average HbA1c level of 
8.7%. These results were comparable to the diabetic group in the study of Oswal et al who 
measured an average blood glucose level of 13.6 mmols/L, and mean HbA1c level of 8.7% 
at time of the first presentation with uveitis (403). It is difficult in this study to address 
whether there is an association between poor glycaemic control and the onset of uveitis 
based on the limited number of patients who had blood test results at time of uveitis 
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presentation. However, the Oswal et al group who as well lacked blood test results for most 
of their patients did not find a significant association between uveitis activity at first 
presentation and glycaemic control (403). It is recommended to check the blood glucose 
level in patients with DM presenting with their first onset of uveitis, regardless of the 
aetiology of uveitis or severity of inflammation to detect cases with poor glycaemic control 
and to allow for its management in collaboration with their health care provider. 
Within the first group of diabetic patients, new onset or progression of DR occurred in 18% 
of the eyes during the follow-up period following the diagnosis of uveitis, including two 
eyes (2.0%) that progressed to PDR, while in the second group, 7.3% of the eyes 
progressed from no DR to develop mild NPDR.  A recent study on the progression of DR 
among diabetic patients in UK found that within 10 years, 16.4% developed 
preproliferative DR, 1.2% had sight threatening maculopathy, and 1.5% developed 
proliferative DR(422). We do acknowledge that this is a descriptive analysis obtained from 
our study cohort and that no conclusions can be drawn regarding the impact of uveitis on 
the progression of DR due to the lack of comparison with a parallel control group of 
diabetic patients without uveitis. The study of Oswal et al reported more cases who had 
progression of DR into PDR following onset of uveitis when compared to our studied 
group [7 eyes (14.5%) versus 2 eyes (2%); respectively]. However, this might be attributed 
to the fact that Oswal et al studied group had larger proportion of patients who had DR at 
time of uveitis diagnosis when compared to our group (65.5% versus 12%, respectively) 
(407). Whether uveitis can accelerate the development of DR is still unclear but the 
possibility has been suggested by previous published papers who observed an increase in 
the progression of DR following endophthalmitis (423), ARN, and toxoplasmosis 
chorioretinitis (404). On the other hand, one author proposed a protective effect of uveitis 
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on the development of DR after reporting a case with progression to proliferative DR only 
in the eye not affected by FHC (424). Progression of DR in patients with uveitis might be 
related to the effects of inflammatory mediators on the retinal vasculature. There is more 
evidence now supporting the role of inflammatory cells, cytokines and other inflammatory 
products in the development of DR (199). The aim of treating uveitis in diabetic patients is 
to preserve vision and prevent or treat ocular complications while maintaining good 
glycaemic control. For this purpose, close collaboration with the primary care physician is 
important to achieve glycaemic control, especially in uveitis patients requiring high doses 
of systemic corticosteroids with or without IMT. It is also recommended that some IMT 
used in the treatment of uveitis, such as cyclosporine, should be either avoided or used with 
caution due to their hyperglycaemic effect (425).   
In conclusion, our study is of interest as it attempts to complete our understanding of the 
synergistic effect of uveitis and diabetes by examining the effect of newly diagnosed 
diabetes on eyes with pre existing uveitis and the effect of diabetes on the uveitis treatment 
strategies used. This was done using, to the best of our knowledge, the largest cohort of 
diabetic patients with uveitis as a whole, and within each of the two studied groups. We 
have concluded that incidence of DM in uveitis patients is associated with a significant 
reduction in visual acuity within the first two years post diagnosis that soon returns to the 
pre diabetic visual acuity by five years.  Diabetic patients diagnosed with uveitis have a 
higher risk of vision loss compare to eyes with uveitis alone, and thus a good control of the 
DM and uveitis complications is required to maintain a stable vision in these patients. 
Reduction in systemic corticosteroid therapy and increased usage of local therapy implies 
that clinicians are adjusting their treatment protocols following DM diagnosis, and this has 
not change the ability to control the uveitis relapses. Given the association between DM, 
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corticosteroids and some second-line IMT used in treating uveitis, it is important to 
optimise treatment protocols for these conditions when they occur concurrently. 
 
 
3.6 Publications and poster presentations 
 Poster presentation at the UCL graduate poster event 2012 
 Talat L, Tompkin-Netzer O, Taylor SRJ, MD Din S, Barr A, Isa H, and Lightman S. 
"The influence of diabetes mellitus on the management and visual outcome of 
patients with uveitis". Acta Ophthalmol. 2014 Jun;92(4):329-30  
 Poster presentation "The influence of diabetes mellitus on the management and 
visual outcome of patients with uveitis" at RCOphth annual meeting 2013 
 Poster presentation "The influence of diabetes mellitus on the management and 
visual outcome of patients with uveitis" at WOC Tokyo 2014. 
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4 CHAPTER FOUR: COMPARISON OF VISUAL 
OUTCOME IN UVEITIS WITH AND WITHOUT 
RETINAL VASCULITIS AND PREDICTORS FOR 
PROGNOSIS OF ISCHAEMIC RETINAL VASCULITIS  
 
4.1 Introduction 
Retinal vasculitis is a clinical finding in 6-15% of eyes with uveitis (263). Its incidence has 
been reported in the United States as 1 to 2 cases per 100,000 population, including isolated 
retinal vasculitis or in association with systemic diseases (426). It can present as 
intermediate or posterior uveitis in association with an underlying systemic disease such as 
BD, sarcoidosis, MS, and collagen-vascular diseases (264,265), or as an isolated ocular 
disease. Rosenbaum et al after reviewing 1390 patients with uveitis identified 15% with 
retinal vasculitis (263). Retinal vasculitis presents clinically as a spectrum varying from 
mild venous sheathing to severe obstructive vascular occlusion. Vascular damage can result 
in loss of vessel wall integrity, leakage of blood constituents into the retinal extracellular 
space and CMO, a significant factor contributing to vision loss (427). In the presence of 
occlusive retinal vasculitis, vision loss can occur as a consequence to CMO, or secondary to 
NVD or NVE which can bleed resulting in VH or cause fibrovascular traction and 
subsequently tractional retinal detachment and vision loss. NVI can also occur leading to 
neovascular glaucoma and permanent vision loss (427). Irreversible vision loss can be 
inevitable when the area of ischaemia is involving the posterior pole resulting in macular 
ischaemia (16).   
In a retrospective study of 113 eyes with retinal vasculitis in eastern India, capillary 
nonperfusion was the most common FFA finding seen in retinal vasculitis, found in 40% of 
the cases, followed by collateral vessels, seen in 19.5% of eyes with vasculitis (428). 
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Different causes of retinal vasculitis carry variable risks of developing retinal ischaemia 
ranging from being common in presumed TB related retinal vasculitis and BD to a more 
rare association in sarcoidosis and MS (265,269). 
Graham et al identified 150 patients with retinal vasculitis from a single uveitis clinic in 
UK after excluding ischaemia and neoplastic cases. Out of these cases, 67 patients had 
idiopathic vasculitis without associated systemic disease, among which peripheral vascular 
sheathing was observed in 64%, periphlebitis in 15%, RVO in 9% and CMO in 60% of 
cases. Retinal NV was observed in 16% of the patients with isolated retinal vasculitis, and 
less than half of patients with NV had associated retinal ischaemia. Capillary closure on 
FFA was more commonly observed in patients with retinal vasculitis associated with BD 
(14 patients, 48%) compared to idiopathic vasculitis (14 patients, 23%) and sarcoidosis 
with retinal vasculitis (two patients, 14%) (429). 
Ku et al (430) examined the visual outcome and prognostic factors in 114 patients (203 
eyes) with vasculitis obtained from a cohort of 1390 patients with uveitis as a continuation 
of the work initially reported by Rosenbaum et al (263). They found the mean change in 
BCVA from first visit was 0.01 LogMAR per year of follow-up. Improvement in BCVA 
from first visit by at least two Snellen lines during the follow up occurred in 33.6%. 
Improvement in visual acuity from first visit was more likely in non-white subjects, and in 
eyes with infectious uveitis or worse vision at first presentation (430). 
Ocular involvement in BD is associated with a high risk of visual loss, mainly secondary to 
complications associated with retinal vasculitis (277,431). The contribution of BD to the 
overall incidence of retinal vasculitis can vary based on the population at risk. A review of 
1390 uveitis cases on the west coast of the United States found 207 patients with evidence 
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of retinal vasculitis; of these cases, only 14 patients had BD (263). On the other hand, 
retinal vasculitis is common among patients with ocular BD. In one multicentre study, 22% 
of eyes with ocular BD had retinal vasculitis (277). In a retrospective study of 107 patients 
with ocular BD, the 10 year risk of developing severe visual loss of 6/60 or worse was 13% 
and ischaemic maculopathy secondary to BRVO was attributed to half the cases of 
irreversible severe visual loss (275). Eyes with ocular sarcoidosis mainly present with non-
ischaemic retinal vasculitis. In a study including 75 eyes of patients with sarcoid related 
uveitis, 37% had retinal vasculitis, three of which had ischaemic vasculitis associated with 
NV (432).  In another study involving 68 patients with posterior uveitis related to 
sarcoidosis, NVD and VH were reported in 4% of cases, with an increased incidence of VH 
up to 16% in the young age group (433). BRVO, although very rare, has been previously 
reported in sarcoidosis associated uveitis especially among young age group in the presence 
(434) or absence (435) of iridocyclitis. 
Despite the potential risks of retinal vasculitis in causing vision loss, only limited numbers 
of studies related to the outcome of this condition have been published, especially for eyes 
with ischaemic retinal vasculitis. So far, only two papers addressed some aspects of the 
clinical features and visual outcome of ischaemic vasculitis in comparison to non-ischaemic 
vasculitis. One paper by Palmer et al in 1996 examined 53 patients with idiopathic retinal 
vasculitis (20 ischaemic and 33 non ischaemic) and found no significant difference in the 
median number of relapses per year between both groups (0.29 relapse per year for 
ischaemic versus 0.36 per year in non ischaemic retinal vasculitis) and found visual loss to 
be more common  in eyes with ischaemic vasculitis (34%) compared to the non-ischaemic 
group (6%) (436). In the second more recent retrospective study by Ali et al, 56 patients 
with 101 eyes affected with non-infectious vasculitis with a minimum one year follow up 
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period were selected. Vasculitis was defined based on documented clinical ocular 
examination for the presence of different clinical findings of vasculitis, such as perivascular 
sheathing, intraretinal haemorrhage, or cotton wool spots while only 39 eyes had FFA 
available to document additional findings of vasculitis such as vascular leakage or 
occlusion. Only six eyes (5.9%) with occlusive vasculitis were available to compare with 
non-occlusive retinal vasculitis and found no change in BCVA from time of diagnosis until 
the last follow up period (258). Both studies have not included all aetiological forms of 
ischaemic vasculitis and the numbers of eyes with ischaemic vasculitis were considerably 
small. No study so far had addressed the outcome of NV management in the setting of 
ischaemic vasculitis and the rate of its recurrence following initial laser treatment.  
Treatment of retinal vasculitis depends on the underlying cause, extent of vessel 
involvement, effect on visual acuity and presence of retinal complications, such as retinal 
ischaemia and NV. In cases when treatment is warranted this may include use of 
corticosteroids with the addition of immunosuppressant drugs when required, together with 
anti-microbial agents in cases of suspected infectious aetiology. When NV has occurred 
laser photocoagulation is the mainstay in management.  However, the role of retinal laser 
and anti-inflammatory medications in preventing further NV formation and ischaemia 
progression has not been fully addressed.  
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4.2 Aims and objectives 
1) Describe the demographic and clinical characteristics of eyes with  retinal vasculitis 
2) Describe the demographic and clinical characteristics of eyes with  ischaemic retinal 
vasculitis 
3) Assess visual outcome and risk factors for vision loss in eyes with retinal vasculitis 
in comparison to eyes with no vasculitis.  
4) Assess visual outcome and risk factors of vision loss in eyes with ischaemic retinal 
vasculitis and in comparison to eyes with non-ischaemic vasculitis.  
5) Examine the treatment strategies used in the management of ischaemic retinal 
vasculitis and the rate of uveitis relapse and ischaemia progression following 
initiation of anti-inflammatory medications and retinal laser photocoagulation, 
respectively.  
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4.3 Materials and method 
4.3.1 Patient selection 
The clinical settings and ethical approval for this longitudinal, case note based, study has 
been previously described in Chapter 2. For the purpose of this study, eyes with 
intermediate, posterior and panuveitis were included and divided initially into two groups 
based on the presence or absence of retinal vasculitis. Patients were considered to have 
retinal vasculitis according to the SUN description, which considered perivascular 
sheathing and vascular leakage or occlusion on FFA as evidence of retinal vascular 
disease(19).  For this purpose, all uveitis patients attending the uveitis clinic over the study 
period had their notes reviewed for any documentation during clinical examination of cells 
in the anterior chamber and/or vitreous associated with perivascular sheathing or exudates 
or intraretinal haemorrhage or identified from the FFA findings, if performed, for the 
presence of vascular fluorescein leakage or occlusion which supports the diagnosis of 
vasculitis (263) (Figure 4.1).  All uveitic patients with high suspicion of vasculitis 
secondary to ocular BD, sarcoidosis, ANCA positive, MS and TB associated uveitis had 
their FFA reviewed regardless of documentation in the clinical notes. Patients with retinal 
vasculitis were further sub-divided into ischaemic retinal vasculitis (IRV) and non-
ischaemic retinal vasculitis (non-IRV). Retinal ischaemia was defined as an area of 
hypofluorescence on FFA of at least one disc diameter representing retinal non-perfusion or 
capillary dropout(437). Exclusion criteria for eyes with vasculitis included missing or poor 
quality FFA images, the presence of concomitant diabetes mellitus, sickle cell disease, 
ocular tumour/vasoproliferative lesion, or the presence of an area of chorioretinal scarring 
prior to the diagnosis of retinal ischaemia that was larger than five disc diameters.  
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Figure 4.1 Fundus Fluoresceine angiography of the right eye with vasculitis showing 
perivascular fluorescein leakage (white arrow) suggestive of active inflammation 
associated with parafoveal fluorescein staining secondary to macular oedema (black 
arrow). 
 
4.3.2 Data collection  
Data was gathered at the time of patient inclusion as presented in Appendix 1 and included 
demographic information, anatomical and aetiological type of uveitis, and BCVA at 
baseline and final visit. Baseline was defined as the time of the first visit with a diagnosis 
of uveitis or, for the IRV group, time of diagnosis of retinal ischaemia. Further information 
was gathered regarding treatment of vasculitis including the use of systemic or local 
corticosteroids and steroid sparing drugs. In eyes with IRV, the incidence of NV formation 
requiring retinal laser photocoagulation was documented. In addition, we measured the rate 
of progression of ischaemia defined as evidence of NV formation in new areas requiring 
further laser photocoagulation or the presence of new areas of capillary non-perfusion. 
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4.3.3 Fundus fluorescein angiography image analysis 
FFA images were either taken using a digital retinal camera system (Topcon TRC 50IX; 
Topcon Medical Systems Inc, Paramus, NJ) or the ultra-widefield imaging (Optos PLC, 
Dunfermline, Scotland). For images taken through the Topcon camera system, an 
automated mosaic software program [i2k Retina (DualAlign LLC, Clifton Park, NY)] was 
used to combine together overlapping retinal fundus photographs and construct a single, 
easy to review, composite image which helps to evaluate the presence of NVD, NVE, NVI, 
macular ischaemia, and angiographic CMO (438) (Figure 4.2). Macular ischaemia was 
defined as a foveal avascular zone (FAZ) ≥ 1,000 µm at its widest diameter, or broken 
perifoveal capillary rings at the border of the FAZ (186). In addition to reporting CMO 
based on the OCT findings defined in Chapter 2, angiographic CMO was also described, 
and was defined as macular leakage at 5-10 minutes post fluorescein sodium injection.  
For the purpose of quantifying the area of retinal nonperfusion, only eyes with ultra-
widefield FFA were included to calculate the ischaemic index using previously described 
methodology (439–441). In this method, the total area of capillary nonperfusion seen in 
arteriovenous phase image was measured and expressed as a percentage of the total image 
area in pixels. This was done using the manual area measurement function in ImageJ 
software (ImageJ 1.44p, National Institutes of Health, Bethesda, MD, USA) as in the 
example shown in Error! Reference source not found.. The central FFA images were 
used to measure the total image area for calculating the ischaemic index, thus avoiding 
areas of peripheral distortion of the wide-field image owing to the spherical curvature of the 
eye. However, peripherally steered FFA images were used to determine the extent and 
boundaries of the peripheral nonperfusion. Disc areas (DA) of nonperfusion were also 
quantified. One disc area was defined for each eye as the number of pixels composing the 
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optic disc (442) and hence the outlined area of capillary nonperfusion was divided over one 
DA to give the area of retinal ischaemia measured in DA. 
 
4.3.4 Statistical analysis 
Detailed description of the statistical method used was presented earlier in Chapter 2. 
Repeated measurements analysis of the BCVA and its difference from baseline was done 
using a multivariate linear regression method obtained from GEE test. Kaplan-Meier 
survival analysis with Log-Rank (Mantel-Cox) test were applied together with survival 
curve graphs to compare the survival rates for the incidence of vision loss, ischaemia 
following diagnosis of uveitis, as well as incidence of NV or initiation of first laser and its 
relapse. The HR and 95% C.I for vision loss, CMO and NV relapse were measured using 
Cox proportional hazards regression analysis.  
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Figure 4.2 Montage of combined fundus fluorescein angiography images of the right eye using 
i2k retina software program. The image shows inferotemporal retinal hypoperfusion and a 
single hyperfluorescent area representing new vessels formation (black arrow). 
 
 
Figure 4.3 Images of merged fundus fluorescein angiography images analysed using 
ImageJ software to measure disc area (area 1) in pixel (short arrow) as well as area of 
retinal ischaemia (area 2) in pixels (long arrow). Then the area 2 is divided over area 1 
to obtain the measured area of retinal ischaemia in disc areas.  
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4.4 Results 
The process of patient selection for this study is illustrated in Figure 4.4. In this study, 1169 
case records of patients with uveitis were reviewed among which retinal vasculitis was 
observed in 163 cases (14.0%). Patients with AU were excluded from the non-vasculitis 
group and 21 patients with vasculitis were excluded based on the exclusion criteria. 
Eventually, we compared the outcome of 142 patients (236 eyes) with retinal vasculitis to 
584 non-AU patients (1022 eyes) with no vasculitis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case records of  
1169 patients with uveitis 
163 with retinal vasculitis 
21 patients No/poor quality FFA 
and other exclusion criteria 
142 with vasculitis 
54 patients No evidence of 
retinal vasoocclusion 
1006 patients (no vasculitis).  
No documentation in clinical notes of signs of 
vasculitis on fundus examination and/or FFA 
88 patients with 
vasoocclusion 
11 patients  
Non ischaemic vasoocclusion 
77 patients with ischaemic retinal 
vasculitis 
Figure 4.4 Flow diagram showing the process of selecting patients with ischaemic 
retinal vasculitis 
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4.4.1 Visual and clinical outcome of retinal vasculitis versus non-
vasculitis 
Baseline demographic and clinical characteristics of the retinal vasculitis group as well as 
the non-vasculitis group are presented in Table 4.1. There was no significant difference 
between both groups regarding the mean age of patients, the follow-up period, baseline 
BCVA and vision at final visit. However, male were more predominant among the 
vasculitis group (56.3%) compared to the non-vasculitis group (44.0%). The vasculitis 
cases were also more observed as part of eyes described as PU and PANU compared to 
non-vasculitis cases. 
Table 4.1 Demographic and clinical comparison of eyes with retinal vasculitis versus 
non-vasculitis 
Variables 
Non-vasculitis 
group 
 584 patients,  
1022 eyes 
Vasculitis group 
142 patients, 
 236 eyes 
P value* 
Age, years;  mean (SE), range 42.5 (0.50), 18-72 40.0 (1.13), 19-87 0.18 
Follow up, years; mean (SE), range 7.8 (0.20), 1-21 7.9 (0.58), 1-23 0.80 
Male; n (%) 261 (44.0) 80 ( 56.3) 0.014 
Bilateral; n (%) 438 (43.0) 94 (66.2) 0.04 
Uveitis classification; n eyes (%)    
 IU 490 (48.0) 83 (35.2)  
 PU 148 (14.5) 48 (20.3) <0.001 
 PANU 384 (37.5) 105 (44.5)  
BCVA at time of diagnosis; Median 
(IQR), LogMAR 
0.18 (0.00-0.48) 0.18 (0.00-0.48) 0.52 
BCVA at last follow up visit; 
Median (IQR), LogMAR 
0.18 (0.00-0.30) 0.18(0.00-0.48) 0.056 
N= number; SE= Standard Error; IQR = Interquantile range; LogMAR = Logarithm of the 
minimum angle of resolution; IU= Intermediate uveitis; PU= Posterior uveitis; PANU= Panuveitis.  
* p value calculated using Mann-Whitney test for continuous variables and Pearson Chi-square test 
for categorical variables 
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Among non-vasculitis eyes, the BCVA significantly improved from baseline to five year 
(0.03±0.01, p=0.04) and ten year (0.06±0.02, p=0.002) follow-up. This is unlike patients 
with retinal vasculitis where changes in BCVA from baseline remained non-significant 
throughout the follow-up period with a calculated power of 0.62 (Table 4.2). Vision loss 
was noted in 202 eyes (20.0%) of the non-vasculitis patients compared to 57 eyes (24.2%) 
with vasculitis (Figure 4.5). The risk of vision loss was significantly more in eyes with 
retinal vasculitis compared to those with no vasculitis [HR 1.67 (1.24 - 2.25), p=0.001], 
with the risk persisting even after adjusting for the presence of CMO [HR 1.44 (1.06 – 
1.96), p=0.018], but lost significance when adjusted for the presence of macular ischaemia 
[HR 1.33 (0.95 – 1.85), p=0.08].  
Table 4.2  Mean changes and standard error in best corrected visual acuity in eyes 
with uveitis, vasculitis and ischaemic /non ischaemic retinal vasculitis 
    0 - 1 year 0 - 5 year 0 - 10 years 
VA change 
(LogMAR) 
MD, SE  
(C.I) 
P* MD, SE  
(C.I) 
P  MD,  SE  
(C.I) 
P  
Non-vasculitis 
-0.01, 0.01 
(-0.03 - 0.01) 
0.36 
0.03, 0.01 
(0.00 - 0.06) 
0.04 
0.06, 0.02 
(0.02 - 0.10) 
0.002 
Vasculitis 
-0.08, 0.03 
(-0.15 - 0.00) 
0.05 
-0.07, 0.04     
(-0.15 - 0.00) 
0.06 
-0.10, 0.05 
(-0.21 - 0.00) 
0.05 
IRV 
-0.13, 0.03  
(-0.20, -0.05) 
<0.001 
-0.14, 0.04 
(-0.22, -0.05) 
0.001 
-0.16, 0.04     
(-0.25, -0.08) 
0.001 
Non-IRV 
-0.02, 0.07 
(-0.16 - 0.12) 
0.78 
-0.004, 0.07 
(-0.14 - 0.13) 
0.95 
-0.05, 0.09 
(-0.24 - 0.14) 
0.61 
VA difference 
vasculitis versus 
non-vasculitis 
0.08, 0.04 
(-0.01 - 0.17) 
0.10 
0.06, 0.05 
(-0.04 – 0.16) 
0.22 
0.03, 0.05 
(-0.77 - 0.15) 
0.53 
VA difference 
IRV versus non-
IRV 
-0.10, 0.08 
(-0.27 - 0.05) 
0.18 
-0.13, 0.08 
(-0.29 - 0.02) 
0.10 
-0.11, 0.10 
(-0.32 – 0.09) 
0.27 
 
IRV= Ischaemic retinal vasculitis; VA= Visual acuity; LogMAR: Logarithm of the minimum angle 
of resolution; MD= Mean difference; SE= Standard Error; CI= Confidence Interval 
* P value based on generalised estimating equation analysis adjusted for the baseline value. 
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Figure 4.5 Kaplan-Meier Survival analysis graph showing the incidence of vision loss 
over the follow up time following diagnosis of uveitis among both groups of retinal 
vasculitis and non-vasculitis 
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Risk factors contributing to vision loss among both non-vasculitis and vasculitis groups are 
listed in Table 4.3.  In non-vasculitis eyes, the risk of vision loss was three times more 
likely to occur in eyes with macular scarring (HR 3.7, C.I 2.3-6.0, p=<0.001), optic 
neuropathy (HR 3.4, C.I. 2.0-5.7, p=<0.001) and retinal detachment (HR 3.6, C.I. 2.1-6.2, 
p=<0.001). In eyes with retinal vasculitis, macular ischaemia remained a significant factor 
that increased the risk of vision loss by more than four times even after adjusting for other 
associated complications (HR 4.4, C.I 2.0-9.6, p<0.001) (Table 4.3).  
CMO was reported in 103 eyes (43.6%) with retinal vasculitis compared to 197 eyes 
(19.3%) among the non-vasculitis group. Eyes with retinal vasculitis had more than twice 
the risk of developing CMO compared to non-vasculitis eyes (HR 2.2, C.I 1.6-2.5, 
p=<0.001).  Cataract was more prevalent in non-vasculitis eyes (21.4%) compared to 
vasculitis eyes (11.5%) with a significantly increased risk of developing cataract in the non-
vasculitis group (HR 1.9, C.I. 1.3-2.8, p=0.006). No significant difference was observed 
between vasculitis cases compared to non-vasculitis when looking at other complications 
such as retinal detachment (2.1% versus 2.3%, respectively, p=0.72), retinal pigment 
epithelial atrophy (1.7% versus 3.9%, p= 0.18), ERM formation (11.4% versus 10.0%, p= 
0.38) and optic neuropathy (2.5% versus 3.5%, p=0.53).   
Systemic prednisolone was used in the management of 168 eyes (71.2%) with vasculitis 
compared to 640 eyes (63.0%) without vasculitis with no significant difference between the 
two groups (HR 1.06, C.I. 0.8-1.2, p=0.49). IMTs were used in the management of 69 eyes 
(29.2%) with retinal vasculitis compared to 144 eyes (14.2%) with no vasculitis. Eyes with 
retinal vasculitis were twice more likely to require IMT as part of their management when 
compared to non-vasculitis eyes (HR 2.0, C.I. 1.5-2.7, p=<0.001). 
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Table 4.3 Risk factors for vision loss in eyes with vasculitis compared to non-vasculitis 
 
ERM = Epiretinal membrane; RPE= Retinal pigment epithelium; CI= Confidence interval;   HR= Hazard ratio 
 
 
 
 
 
 
 
Factors 
Non-Vasculitis 
Crude                     Adjusted 
Vasculitis 
Crude             Adjusted 
HR 
(CI) 
P 
value 
HR 
(CI) 
P 
value 
HR 
(CI) 
P 
value 
HR 
(CI) 
P 
value 
Male gender 
1.26 
(0.9-1.6) 
0.10 - - 
2.6 
(0.9-7.5) 
0.07 - - 
Age 
1.02 
(1.01-0.03) 
<0.001 
1.02 
(1.01-1.03) 
<0.001 
1.05 
(1.01-1.10) 
0.03 
1.06 
(0.9-1.1) 
0.06 
Corneal opacity 
1.33 
(0.4- 4.1) 
0.62 
- 
 
- 
 
- - - - 
Cataract 
1.2 
(0.9-1.6) 
0.21 - - 
1.1 
(0.50-2.4) 
0.38 - - 
Macular oedema 
1.39 
(1.01-1.9) 
0.04 
1.17 
(0.8-1.6) 
0.38 
1.42 
(0.6 – 3.0) 
0.36 - - 
Macular RPE 
Atrophy 
1.66 
(1.02-2.7) 
0.04 
1.06 
(0.63-1.8) 
0.82 
1.4 
(0.3 – 5.7) 
0.64 - - 
Macular scar 
3.1 
(2.0-4.8) 
<0.001 
3.7 
(2.3-6.0) 
<0.001 
2.0 
(0.2-15.1) 
0.47 - - 
Macular ischaemia 
- 
 
- - - 
7.7 
(3.5-16.9) 
<0.001 
4.4 
(2.0-9.6) 
<0.001 
ERM 
1.44 
(0.004-2.0) 
0.048 
1.04 
(0.68-1.6) 
0.82 
0.5 
(0.2-1.3) 
0.20 - - 
Optic neuropathy 
3.0 
(1.8-4.9) 
<0.001 
3.4 
(2.0-5.7) 
<0.001 
4.2 
(1.7-10.0) 
0.001 
2.28 
(0.8-6.2) 
0.10 
Retinal detachment 
2.92 
(1.7 – 4.8) 
<0.001 
3.6 
(2.1-6.2) 
<0.001 
4.9 
(1.5-15.9) 
0.008 
2.4 
(0.7-8.3) 
0.16 
Use of systemic 
prednisolone 
1.05 
(0.77-1.42) 
0.73 - - 
0.36 
(0.15-0.82) 
0.01 
0.18 
(0.05-0.6 
0.005 
Use of 
Immunomodulatory 
medications 
1.73 
(1.15-2.60) 
0.008 
1.53 
(1.00-2.30) 
0.05 
1.10 
(0.51-2.37) 
0.80 - - 
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4.4.2 Ischaemic compared to non-ischaemic retinal vasculitis 
Among the 142 patients (236 eyes) with retinal vasculitis, 65 patients (115 eyes) had non-
IRV, while 77 patients (121 eyes, 42.5%) had IRV. There were no differences in baseline 
characteristics between the two groups apart from baseline BCVA (0.18 versus 0.18 
LogMAR, p=0.02), uveitis type distribution and the mean follow-up time which was longer 
for the non-IRV group (7.7 versus 4.4 years, p=<0.001) (Table 4.4). 
Table 4.4 Demographic and clinical characteristics of 142 patients with retinal vasculitis  
Variables Ischaemic vasculitis 
 77 patients, 121 eyes 
Non Ischaemic  
65 patients, 115 eyes 
P 
value* 
Age, years; median (IQR) 37.7 (29 - 48) 40.5 (28 - 52) 0.82 
Follow up, years; median (IQR) 4.4 (1.4 – 8.9) 7.7 (3.8 - 11.7) <0.001 
Male; n (%) 47 (61.0) 33 (55.8) 0.23 
BCVA at baseline    
 Median (IQR), LogMAR 0.18 (0.00-0.60) 0.18 (0.00-0.48) 0.28 
 6/15 – 6/36; n (%) 22 (18.2) 14 (12.2) 
0.39 
 ≤ 6/60, n (%) 19 (15.7) 17(14.8) 
BCVA at last follow up visit    
 Median (IQR), LogMAR 0.18 (0.00-0.30) 0.18 (0.00-0.48) 0.52 
Uveitis classification; n eyes (%)    
 IU 31 (25.6) 52 (45.2) 
<0.001  PU 
 PANU 
38 (31.4) 
52 (43.0) 
10 (8.7) 
53 (46.1) 
Aetiology of uveitis; n eyes (%)   - 
 Idiopathic  44 (38.0) 59 (51.0)  
 Tuberculosis hypersensitivity  22 (19.0) 17 (15.0)  
 SLE 11(9.0) -  
 Behcet’s  syndrome 15 (13.0) 17 (15.0)  
 Sarcoidosis 8 (7.0) 12 (10.0)  
 ANCA positive  3 (2.4) 3 (2.0)  
 Antiphospholipid syndrome  2 (2.0) -  
 Multiple sclerosis 2 (2.0) 4 (3.0)  
 Leukocytoclastic vasculitis 2 (2.0) -  
 Dermatomyositis  2 (2.0) -  
 Takayasu arteritis 2 (2.0) 1 (1.0)  
 Syphilis/VZV 1 (0.8) 2 (2.0)  
 Rheumatoid arthritis  1 (0.8) 1 (1.0)  
N= number; IQR = Interquantile range; LogMAR = Logarithm of the minimum angle of resolution; IU= Intermediate uveitis; PU= Posterior uveitis; PANU= 
Panuveitis; ANCA= Antinuclear cytoplasmic antibodies. SLE=Systemic Lupus Erythematosis, VZV= Varicella zoster virus.* p value calculated using 
Mann-Whitney test for continuous variables and Pearson Chi-square test for categorical variables. 
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Changes in the BCVA from baseline in eyes IRV were statistically significant over one, 
five and ten years follow-up period unlike eyes with non-IRV in which the change in their 
BCVA overtime were not significantly different from baseline and there was no different 
between the two groups at each follow up interval (Table 4.2). Vision loss occurred in 29 
(23.0%) eyes with IRV and 29 (25.2%) of eyes with non-IRV. Over time the risk of vision 
loss was slightly more significant in eyes with IRV versus non-IRV [HR 1.84 (1.07 – 3.17), 
p=0.027].  
Figure 4.6 shows a lower probability of survival against vision loss in eyes with IRV 
compared to non-IRV, although it didn’t reach a statistical significance (p= 0.37, Log Rank 
Mantel-Cox). The onset of vision loss in most cases of IRV occurred early following the 
diagnosis of retinal ischaemia. The median time for the onset of vision loss in eyes with 
ischaemia was 0.2 years (IQR 0 to 2.7 years) compared to non-IRV which had a median 
onset of vision loss of 1 year (IQR 0 to 5.5 years). The most common causes of vision loss 
in eyes with vasculitis were macular ischaemia (15 IRV), chronic CMO (7 IRV, 9 non-
IRV), macular RPE atrophy or scarring (2 IRV, 8 non-IRV), retinal detachment (2 IRV, 1 
non-IRV), glaucoma (2 non-IRV), optic neuropathy (3 non-IRV), or formation of an ERM 
(3 IRV, 3 non-IRV) and phthisis (3 non-IRV). CMO was observed in 57 eyes (47.1%) with 
IRV and 46 eyes (40.0%) with non-IRV, with the risk of developing CMO significantly 
greater among eyes with IRV (HR 2.0, C.I 1.3-3.1, p<0.001).  
 
174 
 
 
Figure 4.6 Kaplan-Meier survival analysis curve showing the incidence of vision loss 
over the follow-up time since the diagnosis of ischaemia in eyes with ischaemic retinal 
vasculitis (IRV) and since the diagnosis of uveitis in eyes with non-ischaemic retinal 
vasculitis (non-IRV).  
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The risk factors contributing to vision loss in eyes with IRV and non-IRV are presented in 
Table 4.5. CMO in eyes with IRV had 2.5 times more risk of vision loss after adjusting for 
the presence of macular ischaemia and use of systemic prednisolone [HR 2.5, C.I 1.8-5.7, 
p=0.03). Macular ischaemia was observed in 19 eyes (15.7%) with IRV, all of which were 
diagnosed at the initial presentation with ischaemic vasculitis with no incidence during the 
follow-up period. Macular ischaemia increased the risk of visual loss by 9.2 times 
(p<0.001). The use of systemic corticosteroids had a protective effect in preventing visual 
loss even after adjusting for the presence of macular ischaemia and CMO (HR 0.33, C.I 
0.14 – 0.77, p=0.01). 
Table 4.5 Risk factors for vision loss in ischaemic and non-ischaemic vasculitis 
 
IRV= Ischaemic retinal vasculitis; HR= Hazard ratio; CI= Confidence Interval. NV= 
Neovascularisation. IMT = Immunomodulatory therapy 
 
Factors 
IRV  
       Crude                    Adjusted 
Non-IRV  
      Crude                 Adjusted 
HR (CI) P  HR (CI) P  HR (CI) P  HR (CI) P  
Cataract 
1.45 
(0.5-4.1) 
0.47 - - 
1.38 
(0.6-3.2) 
0.46 - - 
Macular oedema 
1.40 
(0.6 – 3.0) 
0.38 
2.5 
(1.08-5.7) 
0.03 
1.67 
(0.8-3.5) 
0.18 
1.64 
(0.6-4.0) 
0.27 
Retinal 
detachment 
2.0 
(0.26-15.1) 
0.49 - - 
6.8 
(1.5-29.5) 
0.01 - - 
Non-infectious  
0.22 
(0.06-0.75) 
0.01 
0.5 
(0.1-1.9) 
0.34 
4.76 
(1.8-12.1) 
0.001 
2.72 
(0.9-7.9) 
0.06 
Disc areas of 
ischaemia 
0.99 
(0.99-1.00) 
0.80 - - - - - - 
Ischaemic Index 1.01(0.9-1.0) 0.50 - - - - - - 
Macular 
ischaemia 
7.8 
(3.6 – 17.1) 
<0.001 
9.2 
(3.9-21.6) 
<0.001 - - - - 
Vitreous 
haemorrhage 
1.51 
(0.6 – 3.3) 
0.30 - - - - - - 
NV 
0.95 
(0.4 – 2.3) 
0.91 - - - - - - 
Systemic 
prednisolone 
0.35 
(0.15 – 0.80) 
0.01 
0.33 
(0.14-0.77) 
0.01 
0.26 
(0.1-0.7) 
0.01 
0.19 
(0.04-0.8) 
0.02 
Use of IMT 
1.05 
(0.5 – 2.2) 
0.89 - - 
1.01 
(0.40-2.5) 
0.98 - - 
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4.4.3 Characteristics of retinal ischaemia  
Retinal ischaemia was already established during first visit with uveitis in 70 eyes (57.8%). 
In the remaining 51 eyes, ischaemia occurred at a median of 7 years (IQR 2.0 – 9.3 years). 
The area of ischaemia was localised to the peripheral area in 45 eyes (37.2%), extended to 
the midperipheral area in 45 eyes (37.2%), and was either confined to the posterior pole or 
was extended to involve this area in 31 eyes (25.6%).  The area of ischaemia involved one 
quadrant in 41 eyes (33.9%), two in 42 eyes (34.7%), three in 13 eyes (10.7%), and all four 
quadrants in 25 eyes (20.7%).  
The area of retinal ischaemia was measured in 63 eyes with ultra-widefield FFA. The 
median area of ischemia was 99 DA (IQR 48 – 169 DA) with 52 eyes (82.5%) had an area 
of ischaemia at diagnosis ≥30 DA. When measuring the ischaemic index, the median area 
of ischaemia was 25.8% (IQR 10.2 – 46%) with 17 eyes (27%) had an ischaemic index > 
50%.   
 Established complications of retinal ischaemia included VH in 26 eyes (21.5%), NVD in 
18 (14.9%), NVE in 75 (62.0%), and NVI in 4 eyes (3.3%). Retinal laser photocoagulation 
was administered in 75 eyes (62.0%), out of which 29 eyes (38.1%) had NV relapse and 
required an additional laser treatment (14 for treating NV at a new location and 15 for NV 
that failed to respond to the initial laser therapy). The first retinal laser photocoagulation 
was given at a median of 5 months (IQR 1-12) from baseline, ranging from 0 to 179 
months post diagnosis of ischaemia. The additional laser given for NV relapse was given at 
a median of 10.5 months (IQR 7.75 – 23.5) from the initial laser, ranging from 5 to 76 
months.  
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Ischaemia involving ≥2 quadrants was associated with an increased risk of NV formation 
(HR 2.7, C.I. 1.3-5.5, p=0.003) but was not significantly associated with risk of NV relapse. 
No significant correlation was observed between the incidence of NV formation and its 
relapse with the presence of infectious vasculitis. The uveitis activity or the uses of 
maintenance cover of systemic anti-inflammatory medications were also not significantly 
correlated with the incidence of NV relapse.  No significant correlation was observed 
between the relapse of NV formation and the ischaemic index (Table 4.6). 
 
Table 4.6 Risk of neovascularisation following diagnosis of retinal ischaemia and the 
risk of neovascularisation relapse following initial retinal laser photocoagulation. 
 
Variables 
Neovascularisation requiring 
first laser photocoagulation 
Relapse requiring second 
laser photocoagulation 
HR (CI) P value HR (CI) P value 
Infectious versus 
non-infectious uveitis 
1.4 (0.86 – 2.53) 0.15 1.54(0.54-4.5) 0.40 
Area of retinal ischaemia 
(number of disc areas)* 
0.99 (0.99-1.003) 0.60 1.007 (0.99-1.01) 0.19 
Area of retinal ischaemia 
 ≥ 30 disc areas* 
1.07 (0.62-1.86) 0.78 1.35(0.40-4.49) 0.62 
Ischaemic index* 0.99 ( 0.98 – 1.01) 0.78 1.01 (0.98 – 1.04) 0.26 
Peripheral ischaemia versus 
- Midperipheral 
- Posterior pole 
 
0.98 (0.40 – 2.3) 
1.34 (0.44 – 4.1) 
 
0.96 
0.59 
 
1.7 (0.33-9.2) 
1.03 (0.27 – 3.8) 
 
0.49 
0.96 
Ischaemia involving ≥2 
quadrants 
2.70 (1.3 – 5.5) 0.003 0.81 (0.27 – 2.39) 0.7 
Active uveitis at time of 
neovascularisation diagnosis 
1.42 (0.83-2.41) 0.19 0.80 (0.26 – 2.47) 0.70 
On systemic                         
anti-inflammatory medications 
at time of neovascularisation 
diagnosis 
1.13 (0.67-1.91) 0.62 1.56 (0.48 – 4.99) 0.43 
HR= Hazard ratio; CI= Confidence Interval 
* Done for 63 eyes with Fluorescein angiography done with ultra-widefield Optos imaging 
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4.5 Discussion 
In this study, we examined the impact of retinal vasculitis on vision loss, as well as the 
progression of IRV and the effect of treatment. We found that (1) vasculitis eyes were more 
likely to develop vision loss than eyes without vasculitis, mainly secondary to macular 
ischemia. (2) Eyes with retinal vasculitis had more than twice the risk of developing CMO 
compared to non-vasculitis. 3) Eyes with IRV carried more risk of vision loss than eyes 
with non-IRV. (3) The greatest risk factors related to vision loss in eyes with IRV were 
macular ischaemia and chronic CMO. (4) Systemic corticosteroids were an important 
protective factor, reducing the risk of vision loss in both IRV and non-IRV eyes. (5) Retinal 
ischaemia involving two or more quadrants of the retina is significantly correlated with the 
initial NV formation.  
The prevalence of retinal vasculitis among our uveitis cohort was 14.0%. This is 
comparable to the study by Rosenbaum et al on1390 patients with uveitis out of which 15% 
had retinal vasculitis (263). Meanwhile, the prevalence of retinal ischaemia in our vasculitis 
cohort was 51.2%, which was much higher than that reported by Ali et al, which described 
occlusive vasculitis in only six eyes (5.9%) out of 101 eyes with vasculitis (258). The low 
prevalence of ischaemic vasculitis in their study could be attributed to the lack of FFA 
images in most of their cases, as it was only available in 39 eyes making it difficult to 
identify areas of capillary non-perfusion and thus underestimating the prevalence of 
occlusive vasculitis in their study. Furthermore, ultra-wide field FFA images were not 
employed unlike our cohort group in which about half of the eyes had their FFA undertaken 
using Ultra-widefield imaging. Previous studies had shown that utilisation of  ultra-
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widefield angiography increases the ability to detect peripheral retinal ischaemia and 
NV(443). 
Unlike the non-vasculitis eyes which showed an average improvement in vision from 
baseline to five and ten year follow-up, the average visual acuity was not significantly 
different for eyes with vasculitis. While our cohort of eyes with vasculitis had significantly 
worse visual outcome compared to the non-vasculitis eyes, this difference was less 
significant once both groups were adjusted for the presence of macular ischaemia, 
emphasizing the role of macular ischaemia in determining the visual outcome of eyes with 
vasculitis.  A study examining 53 patients with idiopathic retinal vasculitis observed severe 
visual loss more often in eyes with ischaemic vasculitis (34%) compared to the non-
ischaemic group (6%) (436). Ku et al (430) examined the visual outcome and predictors for 
its prognosis in 114 patients (203 eyes) with vasculitis and found the mean change in 
BCVA from first visit was 0.01 LogMAR per year of follow up, with 33.6% of the eyes 
having an improvement in BCVA by ≥ 2 lines in 33.6%. Improvement in vision over the 
follow-up time was more predominant non-white patients, infectious uveitis, and those with 
worse vision at first presentation (430). 
In this studied cohort, macular ischaemia and CMO were related to vision loss, suggesting 
a direct involvement in ocular morbidity among eyes with vasculitis. This finding was 
consistent with the results observed in a recent study on 82 eyes with vasculitis in which 
poor VA was independently associated with central macular thickness and the size of FAZ 
(444).  The increased risk of CMO in the IRV compared to the non-IRV group in our study 
was also observed in previous study by Ali et al (258) which suggests that additional 
factors apart from inflammation are involved in producing CMO in eyes with IRV and that 
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areas of nonperfusion may also promote the release of elevated levels of VEGF leading to 
increased vascular permeability and development of CMO, as is found in cases of DR and 
retinal vein occlusion (439). In a study of DR it was noted that retinal ischaemia increased 
the risk of developing DMO by 3.75 times when compared with non-ischaemic DR (437). 
Thus, tight control of the underlying disease with the aim of preserving the macula region 
should be the paramount objective and guide treatment decisions.  We should also consider 
the additional risk of PRP itself in inducing CMO and thus increasing its prevalence among 
eyes with IRV compared to non-IRV (445).   
Most of the eyes with retinal ischaemia received their initial laser treatment within the first 
year following the diagnosis of ischaemia, suggesting the need to closely observe the 
ischaemic retina during this period for the development of NV. Among eyes with IRV that 
underwent initial laser treatment, 38.1% required more than one session of laser 
photocoagulation.  The rate of receiving additional laser therapy in our cohort was similar 
to that observed in a study on Eales’ disease in which 47% of eyes that underwent laser 
therapy required additional retinal laser photocoagulation(446). The need for additional 
laser therapy in our study did not reflect an increased risk of vision loss.  
Systemic corticosteroids were used in the management of 71.2% of the eyes with vasculitis, 
which was not different from the non-vasculitis eyes group of which 63.0% were treated 
with systemic corticosteroids at one point. A study on eyes with retinal vasculitis also 
reported the use of systemic prednisolone in the management of about two third of their 
patients (258). While some patients with retinal vasculitis might experience sight 
threatening complications that require the use of high dose corticosteroids with or without 
IMT, a considerable number of cases are presented with low grade uveitis and vascular 
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leakage confined to the fundus periphery with no direct risk to vision, requiring only 
observation or treatment with local corticosteroids.  
In our cohort, the use of corticosteroids was associated with a reduced risk of vision loss, 
including eyes with IRV and non-IRV.  The use of corticosteroids and other anti-
inflammatory medications in managing vasculitis and some of its associated complications, 
such as CMO, contributes to their role in preventing vision loss (447). Interestingly, 
macular ischaemia developed early in the diagnosis of IRV, with no incidence observed 
over the rest of the follow up period; thus the role of anti-inflammatory medications in 
preventing macular ischaemia is something to be addressed in future studies. On the other 
hand, the study did not find a significant role for anti-inflammatory medications in 
preventing ischaemic relapse and NV formation.  
While the ischaemic index and area of ischaemia measured in DA in relation to NV 
formation did not reach a statistically significant level, the study found that retinal 
ischaemia involving ≥2 quadrants can significantly increase the risk of NV formation. This 
is similar to a study on IRVAN cases  which suggested using laser photocoagulation in eyes 
with retinal ischaemia even before NV is formed when there is more than two quadrants 
affected with capillary non-perfusion (361).  
The study has a number of limitations related to its retrospective nature and the selection of 
patients from heterogeneous pathologies. However, the common clinical presentation of 
retinal vasculitis and its functional consequences suggest that the outcome of these 
conditions can be collated and examined together. Furthermore, retinal ischaemia is an 
uncommon occurrence in conditions associated with retinal vasculitis and this study 
represents a unique opportunity to examine the long-term visual outcome of eyes with 
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ischaemic vasculitis and the rate of progression of NV formation following laser therapy 
and immunosuppressive treatment.  Another limitation was associated with the use of 
Optos FFA images in measuring the peripheral area of ischaemia. Due to the spherical 
curvature of the eye, ultra-widefield images commonly associated with blurred areas within 
the far periphery when the central portion of the image is in focus. When we excluded these 
blurred far peripheral areas, the total area measured is slightly smaller than the 200 degree 
achieved by the ellipsoidal mirror within the Optos imaging system.  
In conclusion, the long term visual outcome in eyes with retinal vasculitis is worse when 
compared to eyes without vasculitis, mainly due to the risk of macular ischaemia. In 
addition to the management algorithm of retinal vasculitis presented in Figure 1.10, the 
control of vasculitis with the use of systemic immunosuppressant and specifically 
corticosteroids is essential part in vasculitis management as it provides long-term protection 
by preventing further deterioration in visual function, although in this study the anti-
inflammatory medication by itself did not prevent further NV formation. It is also 
recommended to apply laser photocoagulation when ≥ 2 quadrants of retina are affected by 
capillary non-perfusion as this group carries a higher risk of NV formation.  
4.6 Publications and Poster presentations 
 Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its 
management. J Ophthalmol. 2014;2014:197675  
 Poster presentation “Visual outcome and treatment strategies among patients with 
ischaemic retinal vasculitis.” RCOphth Annual Meeting 2014.  
 Poster presentation “Ischaemic retinal vasculitis management and visual outcome” 
Submitted for participation at the coming Faculty of Brain Sciences Annual Post-
Graduate Research Poster and Presentation Symposium 2013-2014. 
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5 CHAPTER FIVE: THE INFLUENCE OF CATARACT 
SURGERY IN UVEITIS ON THE VISUAL OUTCOME 
AND RATE OF INFLAMMATION RELAPSE AND 
MANAGEMENT  
5.1 Introduction 
Cataract is one of the leading causes of vision loss worldwide, accounting for 33% of cases 
of blindness and 18% of cases with moderate to server vision loss during 2010 (448). 
Cataract is one of the most common complications associated with uveitis and the leading 
cause of vision loss in uveitis as general (147,449). Cataract may be seen in up to 50-78% 
of patients with uveitis depending on the type of uveitis, being more common in chronic 
anterior uveitis such as FHC and JIA as well as IU (156,450).  
The incidence of cataract in uveitis can vary according to the anatomical and aetiological 
type of uveitis, severity of inflammation, use of topical or local steroid therapy, and 
duration of uveitis with reported average of 7.5 years from time of uveitis diagnosis until 
the eye require cataract surgery (147). One large cohort study involving 3000 patients with 
uveitis, 35% complicated with cataract formation among which 80% required cataract 
surgery (38). Within the same study, FHC was the most common aetiology, accounting for 
23% of cataract cases among the uveitis cohort and was associated with the highest 
incidence of cataract, reported in 70 - 78% of FHC cases (38,450). In children, cataract 
formation is the most frequently observed complication in JIA related uveitis, with an 
estimated incidence rate of 0.04 per EY and a prevalence rate that varies from 9% to 80% 
of uveitis cases (451).  
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Cataract in uveitis may develop as a result of the intraocular inflammation itself or due to 
the chronic corticosteroid treatment with the risk of cataract formation varying based on the 
duration, dose, frequency and application mode of corticosteroid therapy (452,453).   
Cataract in uveitis may develop as a result of the intraocular inflammation itself due to the 
effect of multiple factors such as free oxygen radicals, lysosomal enzymes, immune 
complex deposition on lens capsule, hypoxia, and altered composition or flow of the 
aqueous humor. Chronic corticosteroid usage, whether topical, local or systemic 
administration can also contribute to the loss of lens transparency in uveitic eyes and this 
risk varies based on the duration, dose, frequency and  application mode of corticosteroid 
treatment (84,454). In JIA associated uveitis, several retrospective series have described 
risk factors for cataract, which include presence of posterior synechiae at initial 
presentation with uveitis, the use of systemic corticosteroids, the use of topical 
corticosteroids more than 3 times per day, and persistent active inflammation. Thorne and 
his co-workers studied the incidence of cataract and its risk factors in 75 children with JIA 
associated uveitis. Cataract was already present at initial presentation in 25% of the eyes, 
and cataract surgery was needed in 23% of the eyes with JIA uveitis. In this study, the 
presence of posterior synechiae at initial presentation with uveitis, the use of systemic 
corticosteroids, the use of topical corticosteroids more than 3 times per day, and persistent 
active inflammation were all considered risk factors for the development of cataract in 
these patients. Meanwhile, the use of topical corticosteroids less than 3 times per day, was 
associated with 68% reduced risk of cataract formation, although such association was not 
independent from associated risk factors for cataract development (84,454). The risk of 
cataract development in JIA uveitis can also extend into adulthood, especially in the 
absence of early and prompt control of uveitis in these cases. A case series on 30 eyes of 
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adults with active JIA uveitis that extended into adulthood period found 53% who had a 
new incidence of cataract requiring surgery. These patients had a mean age of uveitis onset 
at 11.5 years and never been started on IMT agents during childhood.  Systemic 
corticosteroid can also be cataractogenic but its role in cataract formation is of less 
significance when compared to topical or local routes of steroid administration (38). 
While most uveitis complications can be addressed with medical therapies as an option, 
surgical removal of the cataract is the only treatment option available for this specific 
uveitis complication. In a study involving 1799 eyes with uveitis, 474 (26%) required 
cataract surgery within an average of 7.5 years from the time of uveitis diagnosis (147).  
Whether cataract removal in uveitis eyes can alter the long term visual outcome and uveitis 
complications has been the aim of variable published studies which has been recently 
addressed in a systematic review and meta-analysis study (376). The review’s aggregate 
outcome of 24 studies on uveitic cataract with heterogeneous aetiology found 70% of cases 
achieved a postoperative vision of 6/12 or better. According to the type of surgery, the 
review included 13 articles that studied phacoemulsification with IOL implantation among 
uveitic eyes with variable aetiologies and sample numbers ranging from 32 eyes to a 
maximum of 140 eyes (369,455–466). Phacoemulsification with IOL implantation achieved 
good visual outcome in 68% while 73% did so following extracapsular cataract extraction. 
According to the insertion of IOL post cataract removal, those with IOL implantation 
achieved a postoperative vision of 6/12 or better in 70% of cases compared to only 54% of 
uveitic eyes had cataract removal without IOL implantation, suggesting that on average, the 
uveitic eyes which undergoing cataract removal with IOL implantation can have a 
significantly better visual outcome when compared to eyes with cataract removal without 
IOL implantation (376).  
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FHC has been one of the most widely studied cases of uveitis and its outcome following 
cataract surgery. It also has one of the best visual outcomes following cataract surgery 
compared to other causes of uveitis. In the meta-analysis research, 22 studies evaluating 
cataract surgery outcome in eyes with FHC found a cumulative 85% of the eyes to have a 
postoperative BCVA of 6/12 or more (376).  Meanwhile, cataract surgery in JIA associated 
uveitis have in general worse visual outcome and more chance of developing sight 
threatening complications compared to cataract surgery outcome in children with idiopathic 
or non-JIA related uveitis (467). The prognosis in cataract surgery for JIA associated 
uveitis is strongly based on the degree of uveitis activity control prior to cataract surgery. In 
the meta-analysis study, JIA associated uveitis was reported to achieve good visual 
outcome in 65% of cases following cataract surgery, this can increase to 71% among eyes 
with controlled uveitis (376) compared to only 22% of the eyes undergoing cataract surgery 
with preoperative active uveitis (371).  
In most eyes with chorioretinal inflammation, the visual outcome post cataract surgery is 
less favourable compared to those with mixed uveitis aetiology and in eyes with AU and IU 
possibly due to pre-existing maculopathy in eyes with PU and PANU that guard the vision 
prognosis post surgery. Eyes with IU undergoing cataract surgery can achieve a 
postoperative vision of 6/12 or better in 70% of cases, making it very similar to that of a 
mixed uveitis cohort, whereas ocular BD did worse, achieving a good postoperative vision 
in only 36% of the eyes. The same goes for sympathetic ophthalmitis in which the 
postoperative vision of 6/12 or better is only achieved in 40% of cases VKH associated 
uveitis can have a postoperative visual outcome of 6/12 or better in only half of the cases 
following cataract surgery (376).   
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A study reviewed the long-term follow-up of cataract surgery in 61 uveitic patients (72 
eyes) and found that after a minimum of 5 years follow-up, 82% of eyes maintained a 
visual improvement of at least 2 Snellen lines from preoperative vision, with 74% having a 
visual acuity of 6/9 or better. Postoperative CMO was observed in one third of the cases 
and 15% required subsequent glaucoma drainage surgery (468). It was noted though that 
more than half of the cataract surgery (41 eyes) were performed using extracapsular 
cataract extraction. The majority of eyes included in the study were chronic anterior uveitis 
(55 eyes including 33 FHC) and only two eyes with IU and 13 with PU; this may explain 
the relatively good vision maintained during the follow up period. Elgohary et al. 
retrospectively analysed the outcomes of 101 eyes undergoing cataract surgery in the 
setting of uveitis, but excluding patients with JIA. This group found that approximately 
71% of patients had visual improvement of more than 2 Snellen lines by final follow-up 
and the probability of losing one line of vision after 6 years of follow-up was 52%. 
However, reactivation of uveitis and CMO was only documented within the first 3 months 
post cataract surgery during which 14% had reactivation of their uveitis, 21% developed 
postoperative CMO, and 39% developed PCO (463).  
The vision loss in uveitic eyes following cataract surgery can be attributed to many 
preoperative factors as well as complications that occur during the surgery or afterwards. 
Some of the uveitis complications may already exist prior to cataract surgery, leading to 
poor vision gain post surgery such as pre-existing amblyopia, or maculopathy, including 
RPE atrophy or macular ischaemia, or secondary to optic neuropathy due to neuritis, 
ischaemia or advanced glaucoma. Eyes with chronic may also present with variable pre-
existing complications such as anterior and posterior synechiae which requires further 
manipulation of the iris and prolongs the duration of surgery. This would increase the risk 
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of postoperative complications or exaggerate postoperative inflammation leading to a poor 
visual outcome.  
Recurrence of uveitis had been previously reported in one study to occur in 51.3% out of 38 
eyes with uveitis following extra capsular cataract extraction with IOL implantation (378). 
Sight threatening postoperative complications that can occur in uveitic eyes following 
cataract surgery with variable risk based on anatomical classification of the uveitis as well 
as the degree of inflammation control prior to the surgery and the use of prophylactic 
therapy. CMO in uveitic eyes is reported to occur in 33% to 56% of cases post 
extracapsular cataract extraction (378,379) compared to 10% to 59%  (with an incidence of 
0.02 per EY) following cataract removal using phacoemulsification (380,469).  PCO is also 
one of the common complications, reported in a study among 27% to 48% of eyes post 
cataract surgery with an incidence of 0.07 per EY with FHC and chronic AU have a high 
risk of developing PCO following phacoemulsification surgery.(380,449) Other reported 
complications include ERM (378,379), increased IOP and hypotony/phthisis. A reported 
study on the outcome of phacoemulsification following a minimum of three years follow up 
in adult patients with uveitis reported hypotony to occur in 5% of cases with an incidence 
of 0.02 per EY associated with postoperative chronic inflammation. The same study 
reported elevated IOP to occur in 10.2% of cases with an incidence of 0.04 per EY, mainly 
in eyes with anterior uveitis and regardless of the degree of postoperative 
inflammation(380). 
While there have been variable studies looking at the visual outcome of uveitic eyes 
following cataract surgery, limited studies have looked at the influence of cataract surgery 
on the uveitis activity parameters including rate of uveitis relapse and the use of topical and 
systemic prednisolone compared to the period prior to surgery. 
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5.2 Aims and objectives 
1) Assess changes in the best corrected visual acuity over the follow up period post 
cataract surgery in uveitic eyes compared to the baseline vision during the first 
postoperative week. 
2) Examine risk factors for vision loss following cataract surgery in uveitic eyes. 
3) Examine the incidence of intraoperative and postoperative complications of cataract 
surgery as well as the incidence of uveitis complications over the follow-up period. 
4) Study the influence of cataract surgery on the uveitis activity through comparing the 
rate of uveitis relapse following cataract surgery compared to the rate prior to the 
surgery. In addition, the rate of using topical and systemic steroids and the use of 
ocular steroid injections and steroid-sparing treatment following cataract surgery 
were compared to the preoperative period.   
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5.3 Materials and method 
The study settings and its ethical approval as well as the definition of the general data 
related to uveitis characteristics and measurement of visual acuity were previously 
described in Chapter 2. Clinical and demographic data of interest were collected using the 
designed data collection form in Appendix 2. 
In this study, uveitis patients with pseudophakia were compared to a randomly selected 
control group of uveitis patients with phakic eyes at time of uveitis database collection. 
Pseudophakic eyes were included if they had a minimum follow up period of one year prior 
to and after undergoing cataract surgery in the form of phacoemulsification with IOL 
implantation. Exclusion criteria include infectious retinitis or choroiditis, aphakia, and 
history of vitrectomy and retinal detachment prior to cataract surgery. The date of diagnosis 
of uveitis was recorded together with the date of diagnosis of cataract defined as the first 
ophthalmologist visit confirming the diagnosis of lens opacity on clinical examination 
associated with at least 2 Snellen line drop in vision. The type of cataract was classified as 
either nuclear, cortical or posterior subcapsular cataract (389). Time of cataract surgery was 
documented together with the use of prophylactic steroid cover in eyes with previous 
history of CMO or PANU. When indicated, prophylaxis treatment was given in the form of 
oral prednisolone at a dose of 40mg per day given two weeks prior to surgery and then 
taper down postoperatively according to the inflammation status postoperatively. In cases 
where there was a high risk associated with high dose systemic prednisolone, an alternative 
prophylaxis method was used in the form of IVTA, mainly for eyes not known to be steroid 
responders or at risk of increased IOP.  
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The BCVA was recorded preoperatively (within 2 months prior to surgery) and then 
postoperatively at 1 week. The change in BCVA from the baseline (1st week postoperative 
vision) was measured during 1 month, 3 months, 6 months, and 12 months postoperatively 
and then annually afterward until last visit together with the incidence of vision loss (6/15 
or worse).  
OCT images of the macular area were obtained from the Topcon OCT system (3D OCT-
1000; Topcon Corp, Tokyo) and Spectralis HRA OCT (Heidelberg Engineering, 
Heidelberg, Germany) subject to the availability of the images taken during the follow-up 
visits. A preoperative OCT image within three months prior to surgery was required to be 
available together with a minimum of one OCT image postoperatively in order to measure 
change in the retinal thickness over the postoperative period compared to the preoperative 
image. The central foveal thickness (CFT) in the central circle with 1mm diameter were 
measured automatically as micrometer (μm) through the program software and presented in 
the output report (470). Uveitis relapses were evaluated during the preoperative and 
postoperative period through counting the number of the relapses per eye per year (EY) 
divided, respectively, for the preoperative and postoperative follow-up time (380). The use 
of topical steroid drops, local and systemic steroids and IMT was also compared over the 
period prior and post surgery. The rate of using topical steroid drops (>3 times/day versus 
≤3 times/day) and the use of systemic prednisolone (>7.5mg/day versus ≤ 7.5mg/day) was 
measured as number of months being on the medication per EY. The use of the cut-off of  
≤3 times /day for the topical drops and  ≤ 7.5mg/day  for systemic prednisolone as they had 
shown to be associated with the minimum risk of side effects (83,84). Intraoperative 
complications such as posterior capsule rupture and the need for anterior vitrectomy were 
documented if present. Postoperative complications and the time of onset were also noted 
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including CMO, PCO and the date of capsulotomy if done, hypotony, elevated IOP and 
date of glaucoma filtration surgery if done, and any other sight threatening complications.  
5.3.1 Statistical analysis  
Detailed description of the statistical method used was presented earlier in Chapter 2. 
Repeated measurements analysis of the BCVA and its difference from preoperative vision 
(baseline) was done using a multivariate linear regression method obtained from GEE test. 
Kaplan-Meier survival analysis with Log-Rank (Mantel-Cox) test was applied together with 
survival curve graphs to compare the survival rates for the incidence of vision loss and 
postoperative CMO. The HR and 95% C.I for vision loss and postoperative CMO was 
measured using Cox proportional hazards regression analysis.  
The incidence rates (EY) and 95% C.I for uveitis relapse and use of topical and systemic 
corticosteroids over the period before and after cataract surgery were calculated using 
negative binominal regression with log link model. 
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5.4 Results 
Among the total 1907 eyes with uveitis, 619 eyes (32.5%) underwent cataract surgery. 
There were 246 eyes falling under the exclusion criteria as well as 32 patients whom their 
clinical notes were inaccessible. Eventually, a total of 309 eyes from 217 patients were 
eventually included in the study. A control group of 300 phakic eyes (210 patients) were 
also selected from the uveitis cohort for comparison with the pseudophakic group (Figure 
5.1). 
 
  
 
 
 
 
 
 
 
 
 
 
Case records of  
1907 eyes with uveitis 
619 eyes (35.2%) had 
cataract surgery 
Exclusion criteria (246 
eyes) 
No data prior to surgery (97) 
PPV prior to surgery (47) 
Postop uveitis (19) 
Surgery outside hospital (18) 
Posterior infectious uveitis (14) 
Aphakia (14) 
ECCE (13) 
Paediatric age at time of surgery (14) 
Poor VA potential (7) 
309 eyes (217 patients) with 
uveitis underwent cataract 
surgery  
Selective Control group 
phakic eyes 
 300 eyes (210 patients) 
32 patients’ files 
on loan/recall 
Figure 5.1 Flow diagram showing the process of selecting uveitis patients 
underwent cataract surgery and their control group from the uveitis database 
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The clinical and demographic data of both case and control groups were presented in Table 
5.1.  The overall follow-up time with uveitis was significantly longer in the eyes who 
underwent cataract surgery at one point compared to the control group (p<0.001). However, 
the median follow-up time for pseudophakic eyes post surgery was 6.7 years or 2249 eye-
year (EY) which was of no difference to the control group (p=0.052). No significant 
difference in the gender distribution between the two groups was observed. Eyes underwent 
cataract surgery were most commonly in the form of IU (43.4%) and were an idiopathic 
uveitis (47.6%) while the most common aetiological diagnosis of the uveitis cases was 
secondary to sarcoidosis (14.2%) and HLA-B27 associated uveitis (11.3%). The median 
time from uveitis diagnosis until cataract formation was 3 years (IQR 1.2-8.6 years), mainly 
in the form of posterior subcapsular cataract (84.1%) and half of the eyes had been 
identified to have cataract within the first three years following the diagnosis of uveitis. The 
median time from uveitis diagnosis to cataract surgery was 6 years (IQR 3.2-13.3) with half 
of the eyes had surgery within 5.8 years following onset of uveitis.  
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Table 5.1 Demographic and clinical characteristics of pseudophakic uveitic eyes and 
their phakic control group 
Variables 
Cases group  
309 eyes, 217patients 
Control group 
300eyes, 210patients 
 
P value* 
Follow-up time with uveitis, 
Median (IQR), Years 
12.4 (8.6-17.9) 5.8 (3.0-10.0) 
<0.001 
Follow-up time post surgery, 
Median (IQR), Years 
6.7 (3.9-10.6) 5.8 (3.0- 10.0) 
    0.052 
Female; n patients (%) 136 (62.7) 127 (60.5) 0.35 
BCVA LogMAR first visit, 
Median (IQR) 
0.18 (0.00-0.48) 0.00 (0.00-0.30) 
<0.001 
BCVA LogMAR last visit, 
Median (IQR) 
0.18 (0.00-0.30) 0.00 (0.00-0.18) 
<0.001 
Classification of uveitis; n 
eyes (%) 
 
 
 
 
 Anterior uveitis 96 (31) 114 (38)  
 Intermediate uveitis 134(43.4) 92 (30.6) 0.23 
 Panuveitis 79 (25.6) 94 (31.4)  
Aetiological causes of uveitis; 
n eyes (%) 
   
 Idiopathic  147 (47.6) 220 (73.3)  
 Sarcoidosis  44 (14.2) 25 (8.3)  
 HLA-B27  35 (11.3) 15 (5)  
 Tuberculosis 
hypersensitivity 
14 (4.5) 14 (4.7) 
 
 Behcet’s disease  11 (3.6) 7 (2.3)  
 Fuchs’ heterochromic 
iridocylitis  
13 (4.2) 0 (0) 
 
 Multifocal choroiditis 12 (3.9) 0(0)  
 Herpes virus 9(2.9) 6 (2)  
 ANCA positive 6 (1.9) 2 (0.7)  
 Multiple sclerosis 8 (2.6) 0(0)  
 Rheumatoid arthritis 5 (1.6) 2 (0.7)  
 Vogt Koyanagi Harada 
syndrome 
5 (1.6) 9 (3) 
 
N= number; SE= Standard error; IQR= Interquantile range; ANCA= Antinuclear cytoplasmic antibodies. 
*p value tested using Mann-Whitney U test for continuous data, and Chi-square test for categorical data 
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The median BCVA within two months prior to cataract surgery was 0.60 LogMAR (IQR 
0.30-1.00). This was improved significantly post surgery at which the median BCVA 
measured one week after surgery was 0.18 LogMAR (IQR 0.18 – 0.30, p<0.001, GEE). 
The change in the BCVA from the 1st week postoperatively (baseline) up to 10 years follow 
up period is presented in Error! Reference source not found.. The average change in BCVA 
continued to improve significantly postoperatively up to 10 years follow-up period 
compared to vision obtained during first week following surgery (Table 5.2). This was 
associated with a good power level of 0.96. 
 
Figure 5.2 Mean changes (and standard error) in the best corrected visual acuity 
following cataract surgery from baseline (first postoperative week) in uveitic eyes 
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The presence of CMO was significantly associated with reduced vision from baseline by an 
average of 0.1 LogMAR (p=0.03). In addition, eyes with PCO had significantly worse 
vision compared to those without history of PCO (MD 0.13±0.04, p=0.004). Patient gender 
was not significantly associated with the difference in BCVA from baseline (Table 5.2).  
Table 5.2 The mean change in the best corrected visual acuity from baseline (first 
postoperative week) among uveitic eyes following cataract surgery 
Variables 
No. of 
eyes B 
Standard 
Error 
95% Confidence 
Interval P value 
Lower Upper 
Postoperative time       
- Baseline (1 week) 309 0 . . . . 
- 1 month 309 -0.05 0.015 -0.08 -0.02 0.001 
- 3 months 309 -0.08 0.018 -0.12 -0.04 <0.001 
- 6 months 309 -0.07 0.022 -0.11 -0.03 0.001 
- 1 year 309 -0.10 0.024 -0.15 -0.06 <0.001 
- 2 years 286 -0.13 0.029 -0.19 -0.07 <0.001 
- 3 years 258 -0.12 0.030 -0.18 -0.06 <0.001 
- 4 years 235 -0.10 0.031 -0.15 -0.03 0.003 
- 5 years 194 -0.11 0.031 -0.17 -0.05 <0.001 
- 6 years 163 -0.12 0.034 -0.18 -0.05 0.001 
      -    7 years 145 -0.10 0.030 -0.16 -0.04 0.001 
      -    10 years 115 -0.09 0.028 -0.15 -0.04 0.001 
Female gender - -0.08 0.06 -0.21 0.05 0.23 
Macular oedema - 0.10 0.03 0.02 0.16 0.01 
Capsule opacity - 0.13 0.04 0.04 0.21 0.004 
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Majority of the eyes managed to achieve more than 2 Snellen line (>0.3 LogMAR) 
improvement in BCVA following cataract surgery when compared to the preoperative 
vision. However, 22 eyes (7%) didn’t manage to achieve similar improvement in vision 
postoperatively; half of these cases were eyes with PANU (Figure 5.3). Compared to the 
preoperative vision, the maximum improvement in the BCVA post cataract surgery was 
mainly achieved during the 1st week (126 eyes; 41.0%) and the 1st month (59 eyes; 19.0%) 
postoperatively. The remaining eyes achieved their maximum improvement in vision 
during the 3rd month (14.0%), 6th month (9.0%), 12th month (10.2%) and 24th month (4.3%) 
postoperatively.  
 
Figure 5.3 Kaplan-Meier survival analysis for the incidence of vision loss post cataract 
surgery in eyes with anterior uveitis (AU), intermediate uveitis (IU) and panuveitis 
(PANU). 
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By the end of the follow-up period, the median BCVA in pseudophakic eyes was 0.18 
LogMAR (IQR 0.00 – 0.30) which was significantly worse than the final median BCVA of 
0.00 LogMAR (IQR 0.00-0.18) in the control group (Table 5.1).  The incidence rate of 
vision loss post cataract surgery was 0.02/EY and occurred in 58 pseudophakic eyes 
(18.8%) compared to 22 phakic eyes (7.4%) from the control group. The difference 
between both groups was found to be statistically significant (p<0.001, Chi-Square test).  
Vision loss in pseudophakic group was mainly secondary to chronic CMO (23 eyes), RPE 
atrophy (22 eyes), optic neuropathy (9 eyes), glaucomatous optic neuropathy (5 eyes), 
ERM (7 eyes), retinal detachment (5 eyes), corneal scar (3eyes), CRVO (1 eye), macular 
hole (1 eye), macular scar (1 eye) and hypotony (1 eye). Uveitic eyes that experienced 
CMO post cataract surgery demonstrate a significantly more chance of vision loss 
compared to eyes that haven’t exhibit similar complication (p=0.002, Log Rank Mentel-
Cox) as presented in Figure 5.4.  Similarly, eyes that had an incidence of increased IOP 
>30mmHg had more chance of vision loss compared to the other group with no similar 
increase in the IOP (p=0.009, Log Rank Mantel-Cox) (Figure 5.5). 
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Figure 5.4 Kaplan-Meier survival analysis for the incidence of vision loss post cataract 
surgery according to the presence of macular oedema. 
 
 
Figure 5.5 Kaplan-Meier Survival analysis for the incidence of vision loss post cataract 
surgery according to the presence of high intraocular pressure more than 30mmHg. 
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The multivariate Cox regression analysis showed that uveitic eyes underwent cataract 
surgery had a higher risk of vision loss compared to the control group (HR 2.4, C.I 1.4- 4.0; 
p<0.001) and such difference remained significant even after adjusting for the incidence of 
CMO in both groups (HR 2.0, C.I 1.2- 3.4; p 0.007). In addition, the risk of CMO post 
cataract surgery was found to be twice more common than the control group (HR 2.2, C.I. 
1.4 – 3.4, P<0.001). 
CMO post cataract surgery was associated with two folds increase in the risk of vision loss 
in pseudophakic eyes compared to eyes without incidence of CMO post surgery and such 
risk persisted even after adjusting for the presence of other risk factors for vision loss (HR 
2.1, C.I 1.1- 3.9, p = 0.01). Meanwhile, history of CMO did not show to be a significant 
factor in the risk of vision loss among the control group (HR 2.1, C.I. 0.70 – 6.5, p=0.17). 
Initially, history of CMO prior to cataract surgery was associated with 1.90 fold increase in 
the risk of vision loss post surgery. However, such factor lost its significance in the 
presence of other associated risk factors.  
Uveitic eyes with incidence of increased IOP>30mmHg following cataract surgery were 
associated with significant increase in the risk of vision loss that persisted even after 
adjusting for other possible risk factors (HR 1.7, C.I. 1.0- 3.1, p= 0.045). The role of 
systemic prednisolone in association with vision loss had lost its significance after 
adjusting for other risk factors. This is unlike IMT which show a significant association 
with vision loss (HR 2.8, C.I 1.08-7.4, p=0.03). Other factors such as patient gender, uveitis 
type and type of prophylaxis treatment and postoperative PCO did not exhibit a significant 
risk on the incidence of vision loss in uveitic eyes following cataract surgery (Table 5.3). 
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Table 5.3 Risk factors for vision loss post cataract surgery in eyes with uveitis 
Variables 
Crude  
HR (C.I) 
P value* 
Adjusted  
HR (C.I) 
P value* 
Female  0.94 (0.5-1.6) 0.85 - - 
Uveitis type 
- Anterior uveitis 
- Intermediate uveitis 
- Panuveitis 
 
- 
1.0 (0.50-1.9) 
1.3 (0.69-2.6) 
 
- 
0.52 
0.08 
 
- 
- 
- 
 
- 
- 
- 
Prophylaxis treatment 
- None 
- Systemic steroids 
- IVTA 
 
- 
0.73 (0.37 – 1.4) 
0.83 (0.5 – 1.73) 
 
- 
0.36 
0.83 
 
- 
- 
- 
 
- 
- 
- 
Macular Oedema pre surgery 1.90 (1.12 – 3.2) 0.01 1.5 (0.92-2.7) 0.09 
Macular Oedema post surgery 2.4 (1.36-4.5) 0.003 2.1 (1.1- 3.9) 0.016 
IOP>30mmHg pre surgery 1.59 (0.93-2.7) 0.05 1.6 (0.94-2.8) 0.07 
IOP>30mmHg post surgery 2.0 (1.18– 3.5) 0.01 1.7 (1.0- 3.1) 0.045 
Posterior capsular Opacity 0.79 (0.46- 1.3) 0.39 - - 
Systemic steroids post surgery 1.8 (1.08-3.2) 0.02 0.88 (0.4-1.8) 0.74 
IMT use post surgery 2.7 (1.2-6.1) 0.01 2.8 (1.08-7.4) 0.03 
C.I.= Confidence Interval; IVTA= Intravitreal Triamcinolone acetonide; IOP = Intraocular pressure; IMT= 
Immunomodulatory therapy 
* Hypothesis tested using Cox regression analysis.  
 
There were 70 eyes with uveitis that had an OCT scan with CFT measurement done within 
3 months prior to cataract surgery and with at least one OCT scan postoperatively. The 
mean CFT preoperatively was 258μm (SE 6.2μm), which didn’t differ significantly during 
the first week postoperatively with a mean CFT of 260 μm (SE 11.6μm), but it was 
significantly increased during 1 month (354, SE 25μm), 3 months (329, SE 15μm), one 
year and two years postoperative follow-up period (Table 5.4). This is unlike the control 
group of contralateral phakic eye from same patient which showed no significant change in 
the CFT over same follow-up period compare to baseline (Figure 5.6). 
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Table 5.4 Changes in central foveal thickness from baseline (within three months 
preoperatively) among eyes with uveitis undergoing cataract surgery 
Variables 
Number 
of eyes 
Mean 
CFT 
(μm) 
B 
Standard 
Error 
95% Confidence 
Interval P value 
Lower Upper 
- Baseline* 70 258 0 . . . . 
- 1 week 22 260 7.0 10.0 -12.9 26.5 0.48 
- 1 month 26 354 78.8 25.0 29.8 127.8 0.002 
- 3 months 30 329 51.1 13.4 24.7 77.6 <0.001 
- 6 months 31 295 6.7 20.8 -16.2 29.7 0.56 
- 1 year 43 308 42.0 11.7 14.7 69.0 0.002 
- 2 years 39 299 33.5 13.8 5.3 61.7 0.02 
- 3 years 36 276 14.0 14.3 -6.6 34.6 0.18 
- 4 years 26 260 -12.1 14.0 -40.2 16.0 0.39 
- 5 years 14 272 -2.7 18.1 -38.3 32.7 0.87 
*Baseline= Preoperative period (within three months prior to surgery); CFT= Central Foveal 
Thickness; B=Delta change in CFT from baseline 
 
Figure 5.6 Change in central foveal thickness (CFT) over follow-up time compare to 
preoperative baseline measurement. The pseudophakic eyes had a significant increase 
in CFT over the first month, 3rd month, and first two years postoperatively, unlike 
the contralateral phakic eye (control) which did not experience significant change in 
CFT over follow-up time from baseline. 
204 
 
Figure 5.7 shows a decreasing trend in the average number of uveitis relapse up to eight 
years following cataract surgery when compared to the period preceding the surgery. The 
median number of relapses within the first year following cataract surgery was 0 relapse 
(IQR 0.0 – 1.0) compared to a median of 0.0 relapse (IQR 0.0 – 1.0) prior to the surgery, 
with no significant difference in the rate of uveitis relapse between both time periods (-
0.01, 95% C.I -0.3 – 1.2, p= 0.50, Poisson loglinear model). This changed when looking at 
the annual rate of relapses over 5 years follow up period [median 0.4 relapse/EY (IQR 0.0 – 
1.0) pre surgery versus 0.2 relapse/EY (0.0 – 0.6) post surgery] with a significant reduction 
in the annual number of relapses/EY following surgery (-1.2, 95% C.I -2.0 to -0.2, 
p=0.012).  
 
Figure 5.7 The mean and standard error bars of uveitis relapse over 10 years before 
and after cataract surgery. 
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The annual rate of using topical steroid drops did not vary significantly in the year 
following cataract surgery compared to the year preceding it. The lack of significant change 
persisted for the annual rate of using the drops over 5 years follow up period. Meanwhile, 
the annual rate of using systemic steroids at a dose > 7.5mg/day had significantly decreased 
over five years post cataract surgery compared to the same period pre surgery (rate 
difference -1.1 months/EY, 95% C.I -2.0 to -0.3, p=0.007). This was associated with a 
concomitant increase in the annual rate of using systemic steroids ≤ 7.5 mg/day over 1 year 
(0.25 months/EY, 95% C.I 0.02 to 0.4, p=0.02) and five years (0.6 months/ EY, 95% C.I 
0.2 to 0.9, p=0.002) post surgery (Table 5.5). 
Table 5.5 Changes in the rate of using topical and systemic steroids after cataract 
surgery in eyes with uveitis 
Treatment Time  
No. 
Eye 
The mean (SE) rates of medication 
use (no. months/EY) 
Preoperative   Postoperative 
Rate 
Difference*  
(95% C.I) 
P† 
Steroid drops 
>3 times/day  
1 year 
5 years 
309 
130 
1.0 (0.1) 
0.6 (0.1) 
1.0 (0.1) 
0.5 (0.06) 
0.08 (-0.12 -0.23) 
- 0.84 (-1.7-0.05) 
0.53 
0.06 
Steroid drops 
≤3 times/day 
1 year 
5 years 
309 
130 
5.8 (0.3) 
5.0 (0.4) 
5.7 (0.3) 
5.0 (0.3) 
0.04 (-0.15 - 0.24) 
0.11 (-0.3 - 0.55) 
0.64 
0.61 
Prednisolone 
>7.5mg/day  
1 year 
5 years 
309 
130 
1.1 (0.2) 
0.4 (0.1) 
1.0 (0.2) 
0.6 (0.1) 
-0.13 (-0.38-0.12) 
-1.1 (-2.0 - -0.3) 
0.31 
0.007 
Prednisolone 
≤7.5mg /day 
1 year 
5 years 
309 
130 
1.7 (0.3) 
1.3 (0.3) 
2.2 (0.3) 
2.1 (0.3) 
0.25 (0.02-0.47) 
0.59 (0.21-0.97) 
0.02 
0.002 
* After versus before surgery 
† A negative binominal regression with log link model was used when the data did not fit the Poisson model 
satisfactorily  
EY = Eye per year. C.I = Confidence Interval, SE= Standard error 
 
Prophylactic steroid cover prior or during cataract surgery was administered in 195 eyes 
(63.5%) in the form of systemic prednisolone (39.4%) or IVTA (24.1%). Systemic steroids 
at high dose were initiated in 170 eyes (40.0%) over the follow up period prior to cataract 
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surgery. This was significantly decreased into 107 eyes (21.7%) following cataract surgery 
(p=0.007, McNemar test). Likewise, immunomodulatory agents were initiated in 46 eyes 
(14.9%) prior to cataract surgery compared to only 18 eyes (5.8%) who initiated the 
medication following surgery (p<0.001, McNemar test). Periocular/intraocular steroids 
were given into 97 eyes (31.3%) for managing uveitis activity prior to cataract surgery (34 
eyes had one injection, 22 eyes had two injections, and 41 eyes had three injections or 
more). This was reduced into 50 eyes (17.0%) who had ocular steroids injection after 
cataract surgery (23 eyes had one injection, 10 eyes had two injections, and 19 eyes had 
three injections or more). 
The prevalence of increased IOP >30mmHg was significantly less within the period 
following cataract surgery (23.0% versus 36.4%, p= 0.002, McNemar test), with 29 eyes 
had their first onset of increased IOP >30mmHg after cataract surgery without prior 
incidence before that. The incidence rate of high IOP>30mmHg was 0.01/EY.  PCO 
occurred in 104 eyes (33.7%) at a median of 8 months (IQR 4.8 – 38 months) post cataract 
surgery and required capsulotomy within a median of 15 months (IQR 5.5 to 54 months) 
post cataract surgery. Other intraoperative and postoperative complications include IOL 
sublaxation/dislocation in four eyes (1.3%), hypotony in two eyes (0.6%), sterile 
endophthalmitis with intraoperative IVTA use in two eyes (0.6%), corneal decompensation 
in one eye (0.3%), intraoperative rupture of posterior capsule with nucleus drop in one eye 
(0.3%), and retinal detachment in one eye (0.4%). 
The prevalence of CMO formation following cataract surgery was significantly more than 
the control group [80 eyes (26.9%) versus 31 eyes (10.3%), p<0.001) and occurred at a 
median of 5.3 months (IQR 1.4 – 21.7 months) postoperatively with 10.4% had CMO 
within the first three months postoperatively. The incidence rate of CMO postoperatively 
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was 0.03/EY and is illustrated as a whole and according to the anatomical classification of 
uveitis in Figure 5.8 and Figure 5.9, respectively. During the period following cataract 
surgery, CMO occurred in 22 eyes (22.9%) with AU compared to 38 eyes (28.4%) with IU 
and 20 eyes (25.9%) with PANU with no significant difference between the groups 
(p=0.64, Pearson Chi-square). CMO was significantly less prevalent following cataract 
surgery compared to the period before (26.8% versus 41.2% respectively, p=<0.001, 
McNemar test). New onset of CMO occurred in 24 eyes (10.5%) after cataract surgery with 
no history of CMO prior to the surgery. Previous history of CMO prior to surgery was 
associated with two and half increased risk of developing CMO post surgery (95% C.I 1.4- 
3.7, p<0.001). Other factors such as gender, type of uveitis and route of prophylaxis steroid 
used did not have a statistically significant impact on the risk of CMO development post 
cataract surgery (Table 5.6) 
 
Table 5.6 Risk factors for macular oedema post cataract surgery in eyes with uveitis 
Variables HR C.I P value* 
Female  1.1 0.68 – 1.8 0.6 
History of CMO presurgery 2.3 1.49 – 3.7 <0.001 
Prophylaxis treatment 
- None 
- Systemic steroids 
- Intravitreal triamcinolone 
 
- 
0.90 
1.7 
 
- 
0.53 – 1.5 
0.95 – 3.0 
 
 
0.72 
0.07 
Uveitis type 
- Anterior uveitis 
- Intermediate Uveitis 
- Posterior/panuveitis 
 
- 
1.1 
0.76 
 
- 
0.67 – 1.9 
0.41 – 1.4 
 
 
0.59 
0.76 
* Hypothesis test using Cox regression analysis 
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Figure 5.8 Kaplan-Meier Survival analysis for the incidence of macular oedema 
following cataract surgery in 309 eyes with uveitis  
 
 
Figure 5.9 Kaplan-Meier Survival analysis for the incidence of macular oedema post 
cataract surgery in eyes with anterior uveitis (AU), intermediate uveitis (IU) and 
panuveitis (PANU). 
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5.5 Discussion 
This study examined the influence of cataract surgery on the visual outcome and incidence 
of sight threatening complications, as well as the uveitis activity and treatment required 
post surgery. The results showed that 1) the best visual outcome following cataract surgery 
is achieved during the first postoperative week and continues to improve postoperatively. 2) 
Uveitic eyes underwent phacoemulsification had a higher risk of vision loss and CMO 
formation compared to the control phakic group. 3) Eyes with CMO and PCO had worse 
vision over the follow-up time compared to the vision achieved during the first week 
postoperatively. 4) Postoperative CMO and high IOP >30mmHg increase the risk of vision 
loss in uveitic eyes following cataract surgery. 5) Cataract surgery was associated with a 
lower uveitis relapse rate over the five years following cataract surgery when compared to 
the rate over the same period prior to surgery. 6) A previous history of CMO prior to 
cataract surgery was associated with increased risk of developing CMO post surgery. 7) 
And finally, while there was no significant difference in the rate of using topical steroid 
drops following surgery compared to the preoperative period, there was a significant 
reduction in the rate of using systemic steroids at a dose >7.5 mg/day over the period of 
five years post surgery when compared to the same period pre surgery. 
The majority of uveitic eyes achieved a postoperative vision improvement of > 0.3 
LogMAR from the preoperative vision in 93% of cases. This is better than the results 
reported in a study by Ram et al on 108 eyes with uveitis which had a postoperative 
improvement of ≥ 0.3 LogMAR in 71.3% of the patients (464). The high rate of significant 
postoperative improvement in BCVA in our studied cohort could have partly be influence 
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by the study exclusion criteria which excluded cases with preoperative macular scar which 
could have affected the postoperative vision improvement anticipated early following 
cataract surgery. However, there were still cases who failed to achieve an improvement in 
vision by a minimum of two Snellen line postoperatively. This could be attributed to a few 
cases where the cataract was too dense making it difficult to have a good view of the 
macula by fundus examination as well as using OCT imaging. Therefore, there might be 
macula oedema or atrophy that pre-existed preoperatively and its influence on the 
postoperative vision has only become apparent after the removal of the dense cataract.  
Our study showed that majority of the eyes did achieve a final visual acuity of 6/12 or 
better in 81.2% following cataract surgery. This was slightly better than the outcome of a 
recent systematic review and meta-analysis of 24 studies on uveitic eyes with 70% of cases 
following cataract surgery (68% following phacoemulsification) which achieved a 
postoperative vision of 6/12 or better by the end of the follow up period (376). In another 
study by Abbouda et al , 74.5 % of uveitic eyes had a final BCVA better than 6/18 
following a minimum of three years follow up period post cataract surgery (380). SVL 
occurred in 8.3% of our uveitis cohort following cataract surgery, which is slightly more 
than what is observed in a study by Ram et al which reported severe vision loss of 5.5% at 
the final follow up visit of uveitic eyes underwent cataract removal. This can possibly be 
attributed to the longer postoperative follow-up in our study (median 78 months compared 
to a mean of 22 months follow up) and the difference in the uveitis aetiology of the cohorts 
and preoperative complications (464).  
The risk of vision loss post cataract surgery in our uveitis cohort was strongly associated 
with the presence of CMO as well as high IOP >30mmHg over the postoperative period. In 
this study, the rate of CMO post cataract surgery was 26.9%, including 28.4% of eyes with 
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IU had CMO postoperatively. This falls within previous reports on the rate of CMO 
following cataract surgery in eyes with parsplanitis which has been reported to range from 
12 to 59% (469). The incidence of CMO postoperatively among AU patients in our studied 
cohort (22.9%) was noted to be more when compared to a recent study on the outcome of 
phacoemulsification in 55 eyes with cataract secondary to AU which had a CMO incidence 
of 12.7% postoperatively.(471) The higher rate of postoperative CMO among our AU cases 
might be attributed to the higher portion of HLA-B27 associated AU in our cohort which 
has the tendency to develop more severe postoperative inflammation and CMO (93). 
Our study found the incidence of CMO post cataract surgery in eyes with no prior history 
of CMO preoperatively was 10.5%, which is almost identical to another study looking at 
long term outcome of at least three years post cataract surgery which detected new onset 
CMO in 10.2% of the uveitic eyes without a prior history of CMO before surgery (380). 
CMO following cataract surgery or Irvine-Gass syndrome, usually occurs in the 4th to 6th 
week postoperatively and has been reported to occur in 5% of nonuveitic eyes following 
uncomplicated phacoemulsification (470). In our study, the incidence of CMO within the 
first three months postoperatively was 10.3%, slightly more than that observed in 
nonuveitic eyes from the above study. Furthermore, the incidence of CMO in our 
pseudophakic group was significantly more than the control phakic group. Postoperative 
CMO has inflammatory mediators as key players in the pathogenesis but the risk is still 
more in eyes with history of uveitis and that cataract surgery may be associated with other 
factors that lead to increase inflammation and capillary permeability in the retinal layer 
which has already been compromised by inflammatory episodes prior to surgery. The role 
of inflammation and breakdown of the BRB in the pathogenesis of postoperative CMO was 
also supported by previous studies which showed patients with clinically significant CMO 
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postoperatively have higher aqueous flare values than pseudophakic and phakic eyes 
without CMO, especially in the first postoperative day before it declines thereafter (472). A 
recent study did show eyes with chronic postoperative inflammation were significantly 
associated with higher risk of developing postoperative CMO and that eyes with more than 
one postoperative uveitis relapse per year were associated with a seven fold increase in the 
risk of developing CMO following cataract surgery (380). We also found that a previous 
history of CMO preoperatively in eyes with uveitis can be associated with a 2.5 fold 
increase in the risk of CMO postoperatively. This conclusion has been similarly drawn by 
Agrawal et al. who suggested an increased risk of developing CMO postoperatively in eyes 
with previous episodes prior to surgery (372). 
The incidence of endophthalmitis in this study was 0.6% which were two cases of 
suspected to be sterile endophthalmitis that occurred following intraoperative prophylactic 
injection of IVTA, given to reduce the risk of postoperative CMO, and with no growth of 
microorganisms observed from the intravitreal sample. Nevertheless, it was still treated as 
possible bacterial endophthalmitis. Sterile endophthalmitis can occur post IVTA injection 
with an incidence report ranging from none(97) to 0.21% (105), while the incidence of 
endophthalmitis among eyes in general following cataract surgery had been reported to 
occur in 0.12% (383). It was difficult to compare the incidence of endophthalmitis among 
our uveitis cohort to other studies due to limited reports available on the actual incidence of 
endophthalmitis among uveitic eyes following cataract surgery. This is possibly due to the 
relatively small sample size included in the published reports making it difficult to draw a 
close estimate for the incidence of a rare complication as endophthalmitis in these cases.   
In this study, cataract surgery on uveitic eyes was not associated with an increased uveitis 
relapse rate, as there was a significantly lower relapse rate over the follow-up period post 
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cataract surgery when compared to the preoperative period. This was also reflected in the 
rate of using systemic prednisolone at a dose >7.5mg/day which was significantly less in 
the postoperative period compared to preoperative period and there was no increase in the 
rate of using topical steroid drops postoperatively compared to preoperative period. To our 
knowledge there have not been previous studies looking at the rate of using systemic and 
topical steroids over the time period prior versus post surgery to compare our results with. 
However, the reduced relapse rate following cataract surgery was observed in a study in 
Taiwan on 62 eyes with recurrent uveitis after excluding eyes with chronic uveitis in their 
analysis. They found the relapse rate of 0.48 relapses per year postoperatively to be 
significantly less when compared to the preoperative relapse rate of 1.32 relapses per year 
(473). The lower relapse rate post cataract surgery as compared to the period prior to 
surgery might reflect the natural trend of reduced uveitis activity over time. Our results 
however suggest that cataract surgery with IOL implantation in uveitic eyes, with good 
preoperative inflammation control and under prophylactic steroid cover when indicated, 
does not on a long term basis increase the overall rate of uveitis relapse or the rate of using 
topical or systemic steroid therapy. Postoperative relapse rate can vary widely according to 
the aetiological and anatomical type of uveitis and the studied group, leading to a wide 
range of postoperative uveitis relapse reported in the literature which can vary from as low 
as 5% of eyes post cataract surgery with intraoperative IVTA reported by Okravi et al (474) 
to 41% in another study by Estafanous et al (455).   
The adequate control of inflammation prior to cataract surgery and slow tapering of topical 
and oral prednisolone, if used, is crucial in preventing recurrence of uveitis postoperatively 
and the associated risk of poor visual outcome in uveitic eyes following cataract surgery. 
The use of either systemic prednisolone or intraoperative steroid injection as a prophylactic 
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measure against postoperative inflammation in our studied group had a similar effect on the 
visual outcome and the incidence of CMO postoperatively.  This finding complements the 
study findings of Roesel et al which found a similar effect of a single intraoperative OFI of 
steroids to that of postoperative oral prednisolone in terms of the visual outcome 
postoperatively and the ability to control postoperative inflammation and CMO(475). A 
conclusion that was similarly drawn in another study looking at intraoperative IVTA 
injection in comparison to postoperative oral prednisolone (476). 
In conclusion, our study demonstrates an overall good visual outcome following 
phacoemulsification with IOL implantation in our uveitis cohort, with the vision continuing 
to improve from the 1st week postoperative vision onwards over the first three years 
postoperatively. Vision loss occurred in 18.2% of the eyes postoperatively, with CMO and 
high IOP >30mmHg as major risk factors. The lower relapse rate over the follow-up period 
post cataract surgery compared to the preoperative period together with a lower rate of 
using systemic prednisolone at high dose >7.5mg/day postoperatively compared to 
preoperative period suggests that cataract surgery on uveitic eyes is not associated with 
worsening of uveitis control nor does it increase the need for using topical or systemic 
steroids over the long term.  
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6 CHAPTER SIX: SUMMARY OF THE RESEARCH 
CONCLUSIONS AND RECOMMENDATIONS 
 
In this thesis, the main aim was to address the influence of a group of systemic and ocular 
factors on the outcome of uveitic eyes and its management. The increasing incidence of 
DM worldwidely has had a tremendous impact on the health and wellbeing of all 
population groups. The first study focused on the interaction between DM and uveitis 
through two studied groups; the first group addressed the characteristics and clinical 
outcome of new onset of uveitis among known diabetic patients while the second group 
looked at the influence of new onset of diabetes on the clinical course and management of 
uveitis patients. The overall incidence of DM among our uveitis cohort was 4.4%. In both 
groups of diabetic patients, idiopathic uveitis and sarcoidosis were the most common 
aetiological classification of uveitis. While the general view is that AU is the main form of 
uveitis seen in diabetes (396–398), only 40% of our cohort of diabetic patients with 
idiopathic uveitis had AU.  Within the first group of diabetic patients, 10% of the uveitic 
eyes had an infectious aetiology. The onset of uveitis was significantly delayed in patients 
with type 1 DM compared to type 2 DM, reflecting the time when type 1 DM is typically 
diagnosed at a younger age (mean 6.5 years of age) compared to type 2 DM (419).  
In diabetic patients presenting with uveitis, the vision remained mostly stable over the 
follow-up time when compared to the first visit with uveitis. The prevalence of vision loss 
was significantly more in the diabetic group presented with uveitis compared to non-
diabetic control group, mainly secondary to RPE atrophy and CNVM associated macular 
scarring. The prevalence of RPE atrophy and CNVM formation in these patients, while it 
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could be coincidental finding, it can also be explained by the presence of proinflammatory 
cytokines which mediates the expression of COX-2 enzyme as the latter has been detected 
in the RPE cells of diabetic rats. There is increasing evidence that the COX-2 enzyme, 
which mediates the formation of PGs and VEGF, plays a role in the formation of CNVM 
formation and has been expressed within the CNVM of human eyes with age related 
macular degeneration. Whether similar mechanism is contributing to the CNVM formation 
in uveitic eyes of diabetic patients is a question of interest to be addressed in future studies. 
 Within group 2, the incidence of DM in uveitis patients was associated with a significant 
reduction in visual acuity within the first two years post diagnosis but returned to the 
average pre diabetic vision afterward.  Reductions in systemic corticosteroid therapy and 
increased usage of local therapy imply that clinicians are adjusting their treatment protocols 
following DM diagnosis, without changing the ability to control uveitis relapse.  Given the 
association between DM, corticosteroids and some second-line IMT used in treating 
uveitis, it is important to optimise treatment protocols for these conditions when they occur 
concurrently. The management of uveitis and its complications should take into 
consideration keeing the patients within the accepted diabetes control level agreed by his 
physician. When possible, it is more preferred to provide the anti-inflammatory 
medications locally rather than systemic medications which can compromise the diabetes 
control in these patients.   
Management of CMO due to uveitis in diabetic patients can be challenging. Bilateral CMO 
in patients with non-infectious uveitis would ideally be treated with high dose systemic 
corticosteroid. However, in the presence of uncontrolled hyperglycaemia this treatment 
option carries an increased risk of side effects and thus can be replaced with local 
administration of corticosteroid or using a lower starting dose of systemic corticosteroid 
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and more rapid tapering. In our second group cohort, uveitis relapses that occurred 
following the diagnosis of DM tend to be managed by adding OFI/IVTA rather than 
increasing the dose of systemic corticosteroid. In addition, the mean dose of systemic 
prednisolone was significantly reduced in the year post DM when compared to the previous 
year. While these changes in the use of systemic corticosteroid may reduce the risk of 
hyperglycaemia, they carry the risk of uveitis relapses and increase the chance of visual 
loss.  
Most of the diabetic patients presented with uveitis within the first group and had an 
available blood test showed poor hypoglycaemic control at time of uveitis diagnosis. It was 
difficult in this study to address whether there is an association between poor glycaemic 
control and the onset of uveitis due to the limited number of patients with blood test results 
at the onset of uveitis. It is recommended to check the blood glucose level of patients with 
DM presenting with their first onset of uveitis, regardless of the aetiology of uveitis or 
severity of inflammation to detect cases with poor glycaemic control and allow for its 
management in collaboration with their health care provider. 
Within the first group, new onset or progression of DR occurred in 18% of the eyes of 
diabetic patients during the follow-up period following the diagnosis of uveitis, including 
2% that progressed to PDR, while in the second group, 7.3% of the eyes progressed from 
no DR to develop mild, non-proliferative DR.  We do acknowledge that this is a descriptive 
analysis of our study cohort and that no conclusions can be drawn regarding the impact of 
uveitis on the progression of DR due to the lack of comparison with a control group. 
Whether uveitis can accelerate the development of DR is still unclear and it would require 
prospective controlled clinical trials to establish an answer to this question. In theory, 
progression of DR in patients with uveitis might be related to the synergistic effect of 
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inflammatory mediators on the retinal vasculature which has already been compromised in 
diabetic patients. In conclusion, this study expands our understanding of the cumulative 
effect of uveitis and diabetes using, to the best of our knowledge, the largest cohort of 
diabetic patients with uveitis.  
The aim of treating uveitis in diabetic patients is to preserve vision and prevent or treat 
ocular complications while maintaining good glycaemic control in diabetic patients. In 
managing diabetic patients with uveitis, it is recommended to have a close collaboration 
with the primary care physician to achieve glycaemic control, especially in uveitis patients 
requiring high doses of systemic corticosteroids with or without IMT. 
In the second study, the prevalence of retinal vasculitis among our uveitis cohort was 
14.0% which was similar to the prevalence observed in other large cohort studies. The long 
term visual outcome was worse in eyes with retinal vasculitis compared to eyes without 
vasculitis, mainly due to the risk of macular ischaemia. However, the risk of vision loss did 
not differ between eyes with IRV and non-IRV cases when adjusting for the presence of 
macular ischaemia.  
In both subgroups of eyes with no-vasculitis and vasculitis, older age groups at time of 
uveitis diagnosis were significantly associated with increase in the risk of vision loss per 
year, respectively. Capillary non-perfusion involving ≥ quadrants of the retina is a 
significant risk factor for NV formation and thus laser photocoagulation may be considered 
at an early stage in these cases. Most of the eyes with retinal ischaemia received their initial 
laser treatment within the first year following the diagnosis of ischaemia, suggesting the 
need to closely observe eyes with retinal ischaemia during this period for the development 
of NV. 
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 Control of vasculitis with systemic anti-inflammatory medications, as well as the 
application of retinal laser photocoagulation for managing NV formation can result in long-
term stabilisation of the disease and prevent further deterioration in visual function, 
although in this study the use of anti-inflammatory medications did not result in preventing 
further NV formation as 38.1% had a relapse with further NV formation requiring more 
retinal laser photocoagulation.  
In eyes with vasculitis, macular ischaemia and CMO were related to vision loss, suggesting 
a direct involvement in ocular morbidity. CMO in eyes with IRV had 2.5 times more risk of 
vision loss while macular ischaemia, which occurred in 15.7% of eyes with IRV, increased 
the risk of visual loss by 9.2 times. This finding was consistent with the results observed in 
a recent study on eyes with ischaemic retinal vasculitis in which a significant correlation 
was observed between poor visual acuity and increased central macular thickness and 
foveal avascular zone even when adjusted for neovascularisation and peripheral ischaemia 
indexes. Thus, tight control of the underlying disease with the aim of preserving the 
macular region should be paramount objectives and guide treatment decisions.  In this 
study, the use of corticosteroids was associated with a reduced risk of vision loss in both 
IRV and non-IRV.  The use of corticosteroids and other anti-inflammatory medications in 
managing vasculitis and some of its associated complications, such as CMO, contributes to 
their role in preventing vision loss. Interestingly, macular ischaemia occurred early in the 
diagnosis of IRV, with no incidence observed over the rest of the follow up period; thus the 
role of anti-inflammatory medications in preventing macular ischaemia is something to be 
addressed in future studies. On the other hand, the study did not find a significant role for 
anti-inflammatory medications in preventing ischaemic relapse and NV formation. 
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In the third study, cataract surgery removal using phacoemulsification with IOL 
implantation was associated with improving vision from the 1st week postoperative onward 
over the first 3 years postoperatively.  The incidence rate of vision loss was 0.02/EY and 
occurred in 18.8% of cases which was significantly worse than control group of phakic 
eyes, mainly related to the incidence of CMO and high IOP >30mmHg during the 
postoperative period. The adequate control of uveitis activity prior to undergoing cataract 
surgery together with the improving techniques and technology in cataract surgery have 
been the main factor contributing to the visual outcome observed in this uveitis cohort and 
in preventing significant worsening of uveitis activity post surgery. This was also supported 
by the finding of a lower relapse rate over the follow-up period postoperatively compared 
to the preoperative period together with a lower rate of using systemic prednisolone at a 
high dose >7.5mg per day postoperatively compared to preoperative period suggested that 
cataract surgery on uveitic eyes did not cause worsening of uveitis control nor did it 
increase the need for topical or systemic steroids over a long period of time following 
cataract surgery. These findings may also suggest that cataract formation in this uveitis 
cohort was not essentially associated with more severe disease as the cataract surgery was 
not associated with more severe postoperative inflammation. The administration of 
prophylactic cortiocsteroids together with proper inflammation control for a considerable 
period prior to surgery and with slow tapering of topical and systemic corticosteroids 
postoperatively are all key elements in maintaining a good postoperative outcome in uveitis 
patients. 
As a conclusion, this thesis was able to address the influence of three factors on the visual 
outcome and inflammation activity and management. Newly diagnosed DM in uveitic eyes 
require careful management plans that can address the significant increase risk of reversible 
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vision loss mainly secondary to CMO and cataract and afterward take the risk of 
hyperglycaemia into consideration when planning for long term uveitis control. We have 
also shown that the adequate management of retinal vasculitis in this cohort has been able 
to maintain good visual outcome and prevent the occurrence of irreversible vision loss in 
most of the cases although the relapse of NV formation in ischaemic area remains an issue 
that can occur independently from the uveitis activity. And finally, with the use of current 
standards of good inflammation control around the time of cataract surgery, uveitic eyes are 
able to maintain a good visual outcome postoperatively with no increase in the rate of 
uveitis activity and treatment over a long period of time.  
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8 APPENDICES 
8.1 Appendix 1.  Ischaemic retinal vasculitis data collection form 
 
 
 Gender:     Male          Female   
 Year of diagnosis.............. 
 Side of uveitis      Right    Left                    Bilateral   
 Anatomical diagnosis of uveitis   IU     PU    PANU   
 Systemic disease  Behçet’s disease   Sarcoidosis   MS   SLE  TB    Other.......date DX 
 Quantiferon TB Gold test Titre..................ACE titre...........ANA titre............. 
 Date of first visit ............... VA RE....... LE.........    BCVA 
RE............when.............LE.........When........ 
 Date of onset of ischaemia     RE...........          LE.......... 
o VA    RE............. LE.............. 
o IOP    RE .............LE 
o AC cells    RE............. LE.............. 
o Vitreous cells    RE............. LE.............. 
o Vitreous Haze     RE............. LE.............. 
o VH     RE         LE     
o OCT finding:    
 RE CRT............NFL Thickness........MO:  cystic     focal thickeningdiffuse thick. 
 LE CRT............NFL Thickness...........MO:  cystic     focal thickeningdiffuse thick. 
 Treatment         topical    PO prednisolone        IMM:             Laser 
Right eye FA Finding at onset of ischaemia Left eye 
 Date  
mild  moderate  severe Severity of vascular leaking mild  moderate  severe 
 yes       No   Macular ischaemia**  yes       No   
Grade 1 Grade 2 Grade 3 Grade 4 Angiographic CMO† Grade 1 Grade 2 Grade 3 Grade 4 
 yes       No   NVD  yes       No   
 No       Single foci  Multiple    NVE  No       Single foci  Multiple    
 post pole    mid    peripheral Area of ischaemia  post pole    mid    peripheral     
 1     2    3      4 Area of Ischaemia (quadrant)  1     2    3      4 
 Area of ischaemia (Disc area)  
PO TR  No.  PRP  Relapse VA RE Follow up VA LE Relapse No.  PRP PO TR 
    1 YEAR     
    2 YEAR     
    3 YEARS     
    4 YEARS     
    5 YEARS     
Last visit date................. VA    RE...........  LE.............. 
DATE RE  VA <6/12............ Cause......................... ≤6/60........... Cause.................. 
 DATE LE VA <6/12 .............Cause........................ ≤ 6/60........... Cause..................  
 
Case No.................. 
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8.2 Appendix 2.  Cataract surgery in uveitis data collection form  
 
 
 Year of birth: ...............   
 Gender:     Male          Female   
 Date of uveitis diagnosis............. 
 Side of uveitis      Right    Left                    Bilateral   
 Anatomical diagnosis of uveitis   AU    IU     PU    PANU   
 Cause  ............................ 
 Date of first visit ...............   
 
 
 VA at first visit......................     VA at first visit.................... 
 AC cells at first visit  0  +0.5  +1  +2  ≥+3  AC cells first visit   0  +0.5 +1  +2  ≥+3 
 AC Flare at first visit     0    ≥+1    AC Flare at first visit      0   ≥+1 
  Vitreous cells/Haze  0  +1  +2  ≥+3   Vitreous cells/Haze  0  +1  +2  ≥+3 
 CMO First visit     No       yes    CMO First visit     No       yes  
 Other uveitis features at onset.................   Other uveitis features at onset................. 
 Steroid responder  No       yes    Steroid responder  No       yes 
 Pre surgery IOP≥ 30 mmHg No yes; when..............  Pre surgery IOP ≥ 30 mmHg No yes 
when....  
 Pre surgery OFI   No       yes,  #....... when............  Pre surgery OFI No     yes,  #......... 
when....... 
 Pre surgery IVTA No       yes,   # ........when............  Pre surgery IVTA No   yes, #........when........ 
 
  +1 NS    +1 Cortical   +1  PSCC   When ........          +1 NS    +1 Cortical   +1  PSCC   When........ 
 Date of CATSX......................                   Date of CATSX......................  
 CATSX prophylaxis  None    PO Steroids  IVTA            CATSX prophylaxis None    PO Steroids  IVTA  
 Date Post op drops 3 /day +quiet eye...........              Date Post op drops  3/day +quiet eye........... 
 Date Post op steroid drops stopped...................       Date Post op steroid drops stopped................... 
 Date drops restarted/increased postop................       Date drops restarted /increased postop..........
   
   Post op OFI No       yes,   when....................  Post op OFI No       yes,   when.................... 
 Post op IVTA No       yes,   when....................  Post op IVTA No       yes,   when.................... 
 
 Dates High dose PO steroid started /increased......................./............../................../................. 
 Dates PO steroid down to ≤7.5 mg            ....................... /.............../.................../................... 
 Dates PO steroid stopped                             ......................./............../.............../..................... 
 IMS use  No       yes,   when............................ 
 
 Last visit date.................       BCVA    RE...........       LE.............. 
 DATE RE  VA >6/12............    Cause......................... ≥6/60...........       Cause.................. 
 DATE LE VA >6/12 .............   Cause........................ ≥ 6/60...........       Cause..................  
 
 
Case No.................. 
OD OS 
258 
 
  RIGHT EYE  LEFT EYE   
#mo  
PNL 
≤7.5 
# 
mo 
PNL 
>7.5 
# mo 
Drop 
<3/d 
# mo 
Drop 
>3/d 
CRT #Flare BCVA  F/U BCVA  #Flare CRT # mo 
Drop 
>3/d 
# mo 
Drop 
<3/d 
#mo 
PNL 
>7.5 
#mo  
PNL 
≤7.5 
       -8 yr        
       -7 yr        
       -6 yr        
       -5 yr        
       -4 yr        
       -3 yr        
       -2 yr        
        - 1yr        
       Preop*        
       SX        
       1 wk        
       1 mo        
       2 mo        
       3 mo        
       6 mo        
       1 yr        
       2 yr        
       3 yr        
       4 yr        
       5 yr        
       6 yr        
       7 yr        
       8 yr        
Preop* period = within two months prior to CATSX 
 Post op complications 
 
 High IOP≥ 30 mmHg; when..............                      High IOP ≥ 30 mmHg ; when..............  
 Glaucoma, when.............., SX when........        Glaucoma, when............ SX when........  
 PCO; when.............    Capsulotomy when.......                       PCO; when............. Capsulotomy when....... 
 CMO; when.............                         CMO; when.............  
 Hypotony, when..........         Hypotony, when.............. 
 RD ; when..............                          RD ; when.............. 
 Endophthalmitis, when.................        Endophthalmitis, when................. 
 Others ........................., when.................        Others ........................., when................. 
OD OS 
